"alt_sample_name"	"unique_patient_ID"	"sample_type"	"histological_type"	"primarysite"	"arrayedsite"	"summarygrade"	"summarystage"	"tumorstage"	"substage"	"grade"	"age_at_initial_pathologic_diagnosis"	"pltx"	"tax"	"neo"	"days_to_tumor_recurrence"	"recurrence_status"	"days_to_death"	"vital_status"	"os_binary"	"relapse_binary"	"site_of_tumor_first_recurrence"	"primary_therapy_outcome_success"	"debulking"	"percent_normal_cells"	"percent_stromal_cells"	"percent_tumor_cells"	"batch"	"uncurated_author_metadata"
"TCGA.04.1331"	"TCGA-04-1331-01A-01T-0438-07"	"TCGA-04-1331"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	78	"y"	"y"	"n"	1224	"norecurrence"	1336	"deceased"	NA	NA	NA	"completeresponse"	"optimal"	0	42	54	NA	"age_at_initial_pathologic_diagnosis: 78///anatomic_organ_subdivision: NA///bcr_patient_uuid: 6d10d4ee-6331-4bba-93bc-a7b64cc0b22a///days_to_birth: -28848///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1331///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 301b373d-8abe-471e-8805-51bcf72a4fc2///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1336///days_to_last_followup: 1224///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 459///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Spiral CT///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1331-01A-01T-0438-07///unique_patient_id: TCGA-04-1331"
"TCGA.04.1332"	"TCGA-04-1332-01A-01T-0438-07"	"TCGA-04-1332"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	70	"y"	"y"	"n"	395	"recurrence"	1247	"deceased"	NA	NA	"metastasis"	NA	"optimal"	0	70	24	NA	"age_at_initial_pathologic_diagnosis: 70///anatomic_organ_subdivision: NA///bcr_patient_uuid: b46263ab-c3ca-4fda-a895-74c7e6e6fe22///days_to_birth: -25785///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1332///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 10d96c4f-798d-4db3-95ce-0ba9beacfc5f///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1247///days_to_last_followup: 1247///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 395///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular marker- CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1332-01A-01T-0438-07///unique_patient_id: TCGA-04-1332"
"TCGA.04.1335"	"TCGA-04-1335-01A-01T-0438-07"	"TCGA-04-1335"	"tumor"	"ser"	"ov"	NA	"low"	"early"	1	"b"	2	60	NA	NA	NA	55	"norecurrence"	55	"deceased"	NA	NA	NA	NA	NA	0	18	66	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: NA///bcr_patient_uuid: ab3dbbbe-eed6-4a35-a505-1815225e86c9///days_to_birth: -21963///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1335///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3b638854-eea9-42f7-a790-93ea3d17bd9d///chemo_therapy: NO///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 55///days_to_last_followup: 55///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1335-01A-01T-0438-07///unique_patient_id: TCGA-04-1335"
"TCGA.04.1336"	"TCGA-04-1336-01A-01T-0438-07"	"TCGA-04-1336"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	55	"y"	"n"	"n"	1495	"norecurrence"	1495	"living"	NA	NA	NA	"completeresponse"	"optimal"	8	2	88	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: NA///bcr_patient_uuid: 538acb2a-c4ca-4656-a91c-841a42dbf15f///days_to_birth: -20270///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1336///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 12a042d9-c0ed-4d91-bdd8-41e8aefd19ee///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1495///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1336-01A-01T-0438-07///unique_patient_id: TCGA-04-1336"
"TCGA.04.1337"	"TCGA-04-1337-01A-01T-0438-07"	"TCGA-04-1337"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	78	NA	NA	NA	61	"norecurrence"	61	"deceased"	NA	NA	NA	NA	"optimal"	0	36	64	NA	"age_at_initial_pathologic_diagnosis: 78///anatomic_organ_subdivision: NA///bcr_patient_uuid: d1e974e7-dd68-40cc-ad06-2b57d964e5a1///days_to_birth: -28625///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1337///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 08769910-7006-46f3-a58f-3c6a4c34bf1f///chemo_therapy: NO///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 61///days_to_last_followup: 61///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1337-01A-01T-0438-07///unique_patient_id: TCGA-04-1337"
"TCGA.04.1338"	"TCGA-04-1338-01A-01T-0438-07"	"TCGA-04-1338"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	78	"y"	"y"	"n"	380	"recurrence"	1418	"living"	NA	NA	"metastasis"	NA	"optimal"	NA	35	50	NA	"age_at_initial_pathologic_diagnosis: 78///anatomic_organ_subdivision: NA///bcr_patient_uuid: 31872f6a-d225-4f91-b38d-4505d19e406c///days_to_birth: -28788///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1338///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a1d5c870-53e2-4dcf-91b7-2edaf75e8168///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1418///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 380///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1338-01A-01T-0438-07///unique_patient_id: TCGA-04-1338"
"TCGA.04.1341"	"TCGA-04-1341-01A-01T-0438-07"	"TCGA-04-1341"	"tumor"	"ser"	"ov"	NA	"high"	NA	NA	NA	3	85	NA	NA	NA	NA	"norecurrence"	NA	"living"	NA	NA	NA	NA	NA	NA	25	65	NA	"age_at_initial_pathologic_diagnosis: 85///anatomic_organ_subdivision: NA///bcr_patient_uuid: 92badeb5-a50e-4a62-a67e-6a8a59c948ab///days_to_birth: -31214///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1341///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: NA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 081a449e-6733-4d5e-9dd0-b22add890b42///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1341-01A-01T-0438-07///unique_patient_id: TCGA-04-1341"
"TCGA.04.1342"	"TCGA-04-1342-01A-01T-0438-07"	"TCGA-04-1342"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	80	"y"	"y"	"n"	563	"norecurrence"	563	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	0	10	88	NA	"age_at_initial_pathologic_diagnosis: 80///anatomic_organ_subdivision: NA///bcr_patient_uuid: 8727855e-120a-4216-a803-8cc6cd1159be///days_to_birth: -29500///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1342///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6e216144-e4b9-40a2-a542-ca6a7d037eae///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 563///days_to_last_followup: 563///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 2///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1342-01A-01T-0438-07///unique_patient_id: TCGA-04-1342"
"TCGA.04.1343"	"TCGA-04-1343-01A-01T-0438-07"	"TCGA-04-1343"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	72	"y"	"y"	"n"	361	"norecurrence"	361	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	0	10	88	NA	"age_at_initial_pathologic_diagnosis: 72///anatomic_organ_subdivision: NA///bcr_patient_uuid: b7715ff6-57a6-4513-9447-aa8bc93f16d4///days_to_birth: -26428///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1343///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4e21e399-0648-4940-99e9-5e7eb3bd9c68///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 361///days_to_last_followup: 361///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 3///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1343-01A-01T-0438-07///unique_patient_id: TCGA-04-1343"
"TCGA.04.1346"	"TCGA-04-1346-01A-01T-0438-07"	"TCGA-04-1346"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	73	NA	NA	NA	1992	"norecurrence"	1992	"living"	NA	NA	NA	"completeresponse"	NA	0	30	68	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: NA///bcr_patient_uuid: 25a0a9e6-4f5b-45d8-8f34-abfd31d5ff1b///days_to_birth: -26865///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 1346///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: da328292-e520-498b-aaaa-60337d841505///chemo_therapy: NO///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1992///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 100///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1346-01A-01T-0438-07///unique_patient_id: TCGA-04-1346"
"TCGA.04.1347"	"TCGA-04-1347-01A-01T-0438-07"	"TCGA-04-1347"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	81	"y"	"y"	"n"	1918	"norecurrence"	1918	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	22	74	NA	"age_at_initial_pathologic_diagnosis: 81///anatomic_organ_subdivision: NA///bcr_patient_uuid: f0c353fd-947c-41e2-b643-3ecc0d69796c///days_to_birth: -29695///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1347///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 930a5b42-2e0e-4912-901d-b712de302d38///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1918///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 100///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1347-01A-01T-0438-07///unique_patient_id: TCGA-04-1347"
"TCGA.04.1348"	"TCGA-04-1348-01A-01T-0455-07"	"TCGA-04-1348"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	44	"y"	"y"	"n"	574	"recurrence"	1483	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	2	92	NA	"age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: NA///bcr_patient_uuid: f7752d6e-f9cd-4dc9-ab01-3ab87acb21e4///days_to_birth: -16236///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1348///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 4bd91396-4007-4ff3-9673-58e37b089fe6///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1483///days_to_last_followup: 1483///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 574///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1348-01A-01T-0455-07///unique_patient_id: TCGA-04-1348"
"TCGA.04.1349"	"TCGA-04-1349-01A-01T-0455-07"	"TCGA-04-1349"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	69	"y"	"y"	"n"	425	"recurrence"	656	"deceased"	NA	NA	"metastasis"	"completeresponse"	NA	0	15	84	NA	"age_at_initial_pathologic_diagnosis: 69///anatomic_organ_subdivision: NA///bcr_patient_uuid: 4b930a10-4b12-4428-84f9-3255b4a3bc4f///days_to_birth: -25212///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1349///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 989bb706-37f0-4425-9e52-384c66da23cb///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 656///days_to_last_followup: 656///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 425///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT A/P; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1349-01A-01T-0455-07///unique_patient_id: TCGA-04-1349"
"TCGA.04.1350"	"TCGA-04-1350-01A-01T-0455-07"	"TCGA-04-1350"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	46	"y"	"y"	"n"	111	"recurrence"	1946	"deceased"	NA	NA	"metastasis"	"stabledisease"	"suboptimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0f4a4ad1-e394-45c4-9aa9-aadf2bff0628///days_to_birth: -16941///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1350///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7b044c52-3464-4207-bbec-d65b1cc081f0///chemo_therapy: NO///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1946///days_to_last_followup: 1946///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 111///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1350-01A-01T-0455-07///unique_patient_id: TCGA-04-1350"
"TCGA.04.1351"	"TCGA-04-1351-01A-01T-0455-07"	"TCGA-04-1351"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	76	NA	NA	NA	1658	"recurrence"	1991	"living"	NA	NA	"metastasis"	"completeresponse"	NA	0	35	48	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: NA///bcr_patient_uuid: 12b032ed-ff92-4bfe-b980-eb273ae8ae17///days_to_birth: -28045///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1351///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 32e5fadb-7231-48fb-b1fe-54e0acf09411///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1991///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1658///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 100///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: PET/CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1351-01A-01T-0455-07///unique_patient_id: TCGA-04-1351"
"TCGA.04.1356"	"TCGA-04-1356-01A-01T-0455-07"	"TCGA-04-1356"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	62	"y"	"y"	"n"	156	"recurrence"	1499	"deceased"	NA	NA	"metastasis"	"progressivedisease"	NA	0	8	85	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: NA///bcr_patient_uuid: 8652ddee-98f4-4584-b450-e6f2f5c9d7ec///days_to_birth: -22854///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1356///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5860debc-e1f5-4cbf-a327-55eaada5452e///chemo_therapy: NO///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1499///days_to_last_followup: 1499///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 156///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study- CT Scan of abdomen and pelvis; Other- Biopsy///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1356-01A-01T-0455-07///unique_patient_id: TCGA-04-1356"
"TCGA.04.1357"	"TCGA-04-1357-01A-01T-0455-07"	"TCGA-04-1357"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	52	NA	NA	NA	NA	"norecurrence"	NA	"living"	NA	NA	NA	NA	NA	0	35	64	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: NA///bcr_patient_uuid: feda41d8-ca56-425d-b149-4d5485328107///days_to_birth: -18998///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1357///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 111f374e-4892-4400-8dd3-60c2e3d4f213///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1357-01A-01T-0455-07///unique_patient_id: TCGA-04-1357"
"TCGA.04.1360"	"TCGA-04-1360-01A-01T-0455-07"	"TCGA-04-1360"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	65	NA	NA	NA	NA	"norecurrence"	NA	"living"	NA	NA	NA	NA	NA	0	30	69	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: NA///bcr_patient_uuid: e0502c47-3234-4609-a8d5-730a9e6eb5b8///days_to_birth: -23993///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1360///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5f8f3a39-d1e6-4a2c-9f74-9c4eb792fa5f///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1360-01A-01T-0455-07///unique_patient_id: TCGA-04-1360"
"TCGA.04.1361"	"TCGA-04-1361-01A-01T-0455-07"	"TCGA-04-1361"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	57	"y"	"y"	"n"	989	"norecurrence"	989	"living"	NA	NA	NA	"stabledisease"	"optimal"	0	30	69	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: NA///bcr_patient_uuid: a6aad7f9-8444-4c2f-8e4b-b19fd453544f///days_to_birth: -20860///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1361///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 015f5756-302f-4344-b865-61515b2151b8///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 989///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 926///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: PET Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1361-01A-01T-0455-07///unique_patient_id: TCGA-04-1361"
"TCGA.04.1362"	"TCGA-04-1362-01A-01T-0455-07"	"TCGA-04-1362"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	59	"y"	"y"	"n"	223	"recurrence"	1348	"deceased"	NA	NA	"metastasis"	NA	"optimal"	0	12	86	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: NA///bcr_patient_uuid: 1d192835-524e-429d-bf74-3c4727acb446///days_to_birth: -21745///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1362///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f6d3414e-afc6-44a6-a4e2-0e59c5b2a796///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1348///days_to_last_followup: 1348///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 223///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1362-01A-01T-0455-07///unique_patient_id: TCGA-04-1362"
"TCGA.04.1364"	"TCGA-04-1364-01A-01T-0455-07"	"TCGA-04-1364"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	"y"	"y"	"n"	288	"recurrence"	1024	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"optimal"	0	5	93	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: NA///bcr_patient_uuid: 80f85c54-e12f-4afa-8fa5-5f3e083b6f95///days_to_birth: -22294///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1364///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4a04d83d-7ae1-45e0-81a1-55960afdf90b///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1024///days_to_last_followup: 1024///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 288///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1364-01A-01T-0455-07///unique_patient_id: TCGA-04-1364"
"TCGA.04.1365"	"TCGA-04-1365-01A-01T-0455-07"	"TCGA-04-1365"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	87	"y"	"n"	"n"	1328	"recurrence"	2328	"living"	NA	NA	"metastasis"	"completeresponse"	NA	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 87///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0484a929-7a7f-4926-8d25-470ddab082ec///days_to_birth: -31925///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1365///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5342e1bf-6201-45cf-8499-dc41206e4420///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2328///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1328///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1365-01A-01T-0455-07///unique_patient_id: TCGA-04-1365"
"TCGA.04.1367"	"TCGA-04-1367-01A-01T-0455-07"	"TCGA-04-1367"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	2174	"norecurrence"	2174	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	89	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: NA///bcr_patient_uuid: 30b8f4cd-9245-4496-a8a8-c3e59093bc0a///days_to_birth: -18576///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1367///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 88ca4e8a-5a13-4da2-909f-cffd1961f4ed///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2174///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 100///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1367-01A-01T-0455-07///unique_patient_id: TCGA-04-1367"
"TCGA.04.1369"	"TCGA-04-1369-01A-02T-1051-07"	"TCGA-04-1369"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	53	"y"	"y"	"n"	NA	"recurrence"	642	"deceased"	NA	NA	"metastasis"	NA	"optimal"	0	8	88	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6c43727d-631a-40fb-b1a1-242a12889eaa///days_to_birth: -19570///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1369///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 590a9f8c-922d-4d99-92b9-f7ed95f172b5///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 642///days_to_last_followup: 642///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 315///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-04-1369-01A-02T-1051-07///unique_patient_id: TCGA-04-1369"
"TCGA.04.1371"	"TCGA-04-1371-01A-01T-0455-07"	"TCGA-04-1371"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	2505	"norecurrence"	2505	"living"	NA	NA	NA	NA	"optimal"	0	20	77	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: NA///bcr_patient_uuid: bff84539-7862-45b2-b5fc-e77291fcca8b///days_to_birth: -21243///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1371///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5ec41cd6-f520-4e24-99eb-0885ce8ff21b///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2505///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1371-01A-01T-0455-07///unique_patient_id: TCGA-04-1371"
"TCGA.04.1514"	"TCGA-04-1514-01A-01T-0505-07"	"TCGA-04-1514"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	45	"y"	"y"	"n"	1221	"recurrence"	1720	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	10	85	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e9483296-cb91-497a-b955-39a3c3289dac///days_to_birth: -16724///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1514///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 5d6ed657-10c2-447e-bd5e-9a72631507ab///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1284///days_to_death: 1720///days_to_last_followup: 1720///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1221///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1514-01A-01T-0505-07///unique_patient_id: TCGA-04-1514"
"TCGA.04.1516"	"TCGA-04-1516-01A-01T-1051-07"	"TCGA-04-1516"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	48	"y"	"y"	"n"	1265	"norecurrence"	1265	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Left///bcr_patient_uuid: 1c86e4e5-ecc9-4f6d-a557-77bf396a653b///days_to_birth: -17767///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1516///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 315cef90-6683-4c74-ae71-9888cc51cc33///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1265///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-04-1516-01A-01T-1051-07///unique_patient_id: TCGA-04-1516"
"TCGA.04.1517"	"TCGA-04-1517-01A-01T-0541-07"	"TCGA-04-1517"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	79	"y"	"n"	"n"	349	"recurrence"	608	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	5	90	NA	"age_at_initial_pathologic_diagnosis: 79///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 35916942-e7aa-45db-ad27-03cba67d4d5b///days_to_birth: -29044///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1517///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b75fd0b7-9f36-44b6-81e4-69d7cddd5ec3///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 608///days_to_last_followup: 608///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 349///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker-CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1517-01A-01T-0541-07///unique_patient_id: TCGA-04-1517"
"TCGA.04.1519"	"TCGA-04-1519-01A-01T-0541-07"	"TCGA-04-1519"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	48	NA	NA	NA	NA	"norecurrence"	NA	NA	NA	NA	NA	NA	NA	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: e9b5336e-d724-4e7d-8c81-1147abd0a80d///days_to_birth: -17670///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1519///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: NA///chemo_therapy: NA///day_of_form_completion: NA///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: NA///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: NA///year_of_form_completion: NA///Extract.Name: TCGA-04-1519-01A-01T-0541-07///unique_patient_id: TCGA-04-1519"
"TCGA.04.1525"	"TCGA-04-1525-01A-01T-0541-07"	"TCGA-04-1525"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	47	"y"	"n"	"n"	212	"recurrence"	1167	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	38	62	NA	"age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2bb96e1e-6992-434d-83e5-2f03713b3911///days_to_birth: -17469///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1525///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 375c3a71-0dc9-475a-bf5d-bea64f332b78///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1167///days_to_last_followup: 1167///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 212///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Spiral Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1525-01A-01T-0541-07///unique_patient_id: TCGA-04-1525"
"TCGA.04.1530"	"TCGA-04-1530-01A-02T-0505-07"	"TCGA-04-1530"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	68	"y"	"y"	"n"	350	"recurrence"	3622	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	30	0	58	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 42b3dfa3-152f-4ab7-ac9f-988c7f473bea///days_to_birth: -25013///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1530///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ad540bc7-095f-4f96-ad41-0981da3fcb0e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 350///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 3622///days_to_last_followup: 3622///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 350///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1530-01A-02T-0505-07///unique_patient_id: TCGA-04-1530"
"TCGA.04.1542"	"TCGA-04-1542-01A-01T-0505-07"	"TCGA-04-1542"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	52	"y"	"y"	"n"	1035	"recurrence"	2561	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	21	10	71	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0c1a2e7d-e7e4-481e-a012-ef214c444497///days_to_birth: -19263///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1542///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6c66cb68-4c55-4a8a-9241-99a2f36bc6fd///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2561///days_to_last_followup: 2561///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1035///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular marker- CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1542-01A-01T-0505-07///unique_patient_id: TCGA-04-1542"
"TCGA.04.1638"	"TCGA-04-1638-01A-01T-0585-07"	"TCGA-04-1638"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	57	"y"	"y"	"n"	298	"recurrence"	1685	"deceased"	NA	NA	"metastasis"	NA	"optimal"	0	4	92	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: NA///bcr_patient_uuid: c75c915f-ef4b-4c19-8ace-995e6c6015fd///days_to_birth: -20987///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1638///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9dd72b20-6a99-48af-bd9b-a8890dd66dfd///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1685///days_to_last_followup: 1685///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 298///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Biopsy///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1638-01A-01T-0585-07///unique_patient_id: TCGA-04-1638"
"TCGA.04.1644"	"TCGA-04-1644-01B-01T-1051-07"	"TCGA-04-1644"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	48	"y"	"y"	"n"	NA	"recurrence"	1487	"deceased"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	15	80	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6f592f17-e00b-4d04-a45b-d9d4cf4c3075///days_to_birth: -17724///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1644///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 28f1bf15-8aeb-478c-83b4-d19d4437ca7f///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1487///days_to_last_followup: 1487///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 634///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1644-01B-01T-1051-07///unique_patient_id: TCGA-04-1644"
"TCGA.04.1646"	"TCGA-04-1646-01A-01T-0585-07"	"TCGA-04-1646"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	"y"	"y"	"n"	508	"recurrence"	848	"deceased"	NA	NA	"metastasis"	NA	"optimal"	0	1	99	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: d38ca631-ed5c-4182-a647-625060726fa7///days_to_birth: -22207///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1646///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6e0aedca-a9c4-4ced-be43-52fde9e4c113///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 848///days_to_last_followup: 848///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 508///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1646-01A-01T-0585-07///unique_patient_id: TCGA-04-1646"
"TCGA.04.1648"	"TCGA-04-1648-01A-01T-0585-07"	"TCGA-04-1648"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	57	"y"	"y"	"n"	871	"norecurrence"	871	"deceased"	NA	NA	NA	NA	"optimal"	0	5	80	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: NA///bcr_patient_uuid: cddce77f-21e6-4124-9f03-96fb5ca7cefa///days_to_birth: -21113///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1648///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 00200545-63d3-450e-82a8-e6edc4048449///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 871///days_to_last_followup: 871///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 412///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1648-01A-01T-0585-07///unique_patient_id: TCGA-04-1648"
"TCGA.04.1649"	"TCGA-04-1649-01A-01T-0585-07"	"TCGA-04-1649"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"y"	"n"	"n"	1672	"recurrence"	1966	"living"	NA	NA	"metastasis"	NA	"optimal"	0	15	85	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 314e446d-3a57-4c91-ac2e-4fc211456ee6///days_to_birth: -27165///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1649///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f9735bfe-c3b8-450d-9d52-4b36a3a90e03///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1966///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1672///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: PET; Other method FNA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1649-01A-01T-0585-07///unique_patient_id: TCGA-04-1649"
"TCGA.04.1651"	"TCGA-04-1651-01A-01T-0585-07"	"TCGA-04-1651"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	53	"y"	"y"	"n"	990	"recurrence"	1102	"deceased"	NA	NA	"metastasis"	NA	"optimal"	0	9	89	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 55153632-1673-487a-85c0-f156377db1fc///days_to_birth: -19628///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1651///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f182f145-563e-4e9e-9d35-77b5e6e2dcae///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1102///days_to_last_followup: 1102///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 990///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1651-01A-01T-0585-07///unique_patient_id: TCGA-04-1651"
"TCGA.04.1652"	"TCGA-04-1652-01A-01T-0585-07"	"TCGA-04-1652"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	76	"y"	"y"	"n"	880	"recurrence"	969	"deceased"	NA	NA	"locoregional"	"completeresponse"	NA	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: Right///bcr_patient_uuid: d86adfac-56be-4a69-9315-5a90b4113e65///days_to_birth: -28101///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1652///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: cbce6aad-81f9-4b94-9970-869f1d53218e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 969///days_to_last_followup: 969///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 880///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125; Other method FNA of pelvis mass///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1652-01A-01T-0585-07///unique_patient_id: TCGA-04-1652"
"TCGA.04.1654"	"TCGA-04-1654-01A-02T-0656-07"	"TCGA-04-1654"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	69	"y"	"y"	"n"	808	"recurrence"	1451	"deceased"	NA	NA	"metastasis"	NA	"optimal"	0	5	92	NA	"age_at_initial_pathologic_diagnosis: 69///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ff33db70-91d4-4dbb-a4fc-d81a128d0f32///days_to_birth: -25386///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1654///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a39da768-d60a-4a09-aab6-9a21b6ff50c2///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1451///days_to_last_followup: 1451///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 808///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1654-01A-02T-0656-07///unique_patient_id: TCGA-04-1654"
"TCGA.04.1655"	"TCGA-04-1655-01A-01T-0567-07"	"TCGA-04-1655"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	49	"y"	"y"	"n"	819	"recurrence"	1379	"deceased"	NA	NA	"metastasis"	NA	"optimal"	0	6	92	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f8a5547f-f1bc-4c01-8b68-25b5ee0caeab///days_to_birth: -17988///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1655///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6fdc0964-ba27-42bc-bb14-ff4240c2b90e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1379///days_to_last_followup: 1379///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 819///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study-ultra sound; Other method-biopsy///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1655-01A-01T-0567-07///unique_patient_id: TCGA-04-1655"
"TCGA.09.0364"	"TCGA-09-0364-01A-02T-0364-07"	"TCGA-09-0364"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	80	"y"	"y"	"n"	395	"recurrence"	887	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 80///anatomic_organ_subdivision: Right///bcr_patient_uuid: 6746533a-8d0b-4ebc-87ec-49c8738121a8///days_to_birth: -29261///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 364///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c1122b65-e8b1-4c58-99b9-d78c3678332c///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 887///days_to_last_followup: 887///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 395///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abdom pelvic enhanced & CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-0364-01A-02T-0364-07///unique_patient_id: TCGA-09-0364"
"TCGA.09.0365"	"TCGA-09-0365-01A-02T-0364-07"	"TCGA-09-0365"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	70	"y"	"y"	"n"	251	"recurrence"	288	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 70///anatomic_organ_subdivision: Left///bcr_patient_uuid: 7621ed77-98bc-4b4e-8011-e18fcd014071///days_to_birth: -25702///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 365///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: d6b85df6-097b-473c-b7bf-794e3fda6850///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 288///days_to_last_followup: 288///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 251///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-0365-01A-02T-0364-07///unique_patient_id: TCGA-09-0365"
"TCGA.09.0366"	"TCGA-09-0366-01A-01T-0364-07"	"TCGA-09-0366"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	"n"	"y"	"n"	189	"recurrence"	1756	"deceased"	NA	NA	"locoregional"	"stabledisease"	"optimal"	0	2	98	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 23771dab-2aab-4d2b-95e2-9af7092cee6b///days_to_birth: -20440///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 366///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 06ba5b59-0675-4fde-a4aa-237171de4442///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: 189///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1756///days_to_last_followup: 1756///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 189///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT  & CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-0366-01A-01T-0364-07///unique_patient_id: TCGA-09-0366"
"TCGA.09.0367"	"TCGA-09-0367-01A-01T-0364-07"	"TCGA-09-0367"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"n"	"y"	"n"	546	"norecurrence"	546	"deceased"	NA	NA	NA	"progressivedisease"	"optimal"	0	7	92	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9bbc01b4-056c-4ddc-aca4-ff20718646d0///days_to_birth: -24473///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 367///pretreatment_history: NO///race: NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 76060e1e-8ff9-4936-8b9a-5dd98ffb89b3///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 546///days_to_last_followup: 546///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-0367-01A-01T-0364-07///unique_patient_id: TCGA-09-0367"
"TCGA.09.0369"	"TCGA-09-0369-01A-01T-0364-07"	"TCGA-09-0369"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	56	"n"	"y"	"n"	273	"recurrence"	1081	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Left///bcr_patient_uuid: 1d9893c8-0de3-4b07-b0ba-a53019b23eb4///days_to_birth: -20705///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 369///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 1df2523e-6d80-4fbd-b56a-101649dd493a///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: 325///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1081///days_to_last_followup: 1081///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 273///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT spleen  Other; CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-0369-01A-01T-0364-07///unique_patient_id: TCGA-09-0369"
"TCGA.09.1659"	"TCGA-09-1659-01B-01T-0541-07"	"TCGA-09-1659"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	"y"	"y"	"n"	303	"norecurrence"	303	"deceased"	NA	NA	NA	"stabledisease"	"suboptimal"	11	0	82	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 644a88a7-dc56-468a-af5c-60278aab7642///days_to_birth: -18733///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1659///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 43fa1bf4-aebc-4742-975b-f4fac71b3092///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 303///days_to_last_followup: 303///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-1659-01B-01T-0541-07///unique_patient_id: TCGA-09-1659"
"TCGA.09.1661"	"TCGA-09-1661-01B-01T-0541-07"	"TCGA-09-1661"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	75	"y"	"y"	"n"	1169	"norecurrence"	1169	"deceased"	NA	NA	NA	"stabledisease"	"optimal"	24	0	72	NA	"age_at_initial_pathologic_diagnosis: 75///anatomic_organ_subdivision: Right///bcr_patient_uuid: f8e9d538-7291-4fe7-b3f2-d01676a027f9///days_to_birth: -27486///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1661///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9763f5ee-7f9a-4e7b-8fd1-98ce241e0d5f///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1169///days_to_last_followup: 1169///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: persistant disease///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-1661-01B-01T-0541-07///unique_patient_id: TCGA-09-1661"
"TCGA.09.1662"	"TCGA-09-1662-01A-01T-0541-07"	"TCGA-09-1662"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	58	"y"	"y"	"n"	1046	"recurrence"	2717	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	9	0	87	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Left///bcr_patient_uuid: 867f9563-16c9-45a8-b519-6df61ba1b6b7///days_to_birth: -21246///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1662///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 0b2f4ddb-fa9e-45ec-97ab-a8fc3d0f4be8///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 1081///days_to_additional_surgery_metastatic_procedure: 1081///days_to_death: 2717///days_to_last_followup: 2717///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1046///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: PET; Other method CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-1662-01A-01T-0541-07///unique_patient_id: TCGA-09-1662"
"TCGA.09.1664"	"TCGA-09-1664-01A-01T-0585-07"	"TCGA-09-1664"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	37	"y"	"n"	"n"	2278	"norecurrence"	2278	"deceased"	NA	NA	NA	"completeresponse"	"optimal"	12	6	80	NA	"age_at_initial_pathologic_diagnosis: 37///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3438c018-9856-4628-ae59-7d365713647f///days_to_birth: -13739///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G1///patient_id: 1664///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c96ac4bb-27ed-4e18-8939-9b1cfc8ead4d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2278///days_to_last_followup: 2278///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-1664-01A-01T-0585-07///unique_patient_id: TCGA-09-1664"
"TCGA.09.1665"	"TCGA-09-1665-01B-01T-0541-07"	"TCGA-09-1665"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	73	"y"	"y"	"n"	468	"recurrence"	1265	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	18	2	76	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: Left///bcr_patient_uuid: 9d25cd0e-0a3e-4ee0-b1a3-58ffab348c9d///days_to_birth: -27010///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 1665///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 85d0d258-5285-40e6-bfd7-45c246449c8e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1265///days_to_last_followup: 1265///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 468///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-1665-01B-01T-0541-07///unique_patient_id: TCGA-09-1665"
"TCGA.09.1666"	"TCGA-09-1666-01A-01T-0541-07"	"TCGA-09-1666"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	480	"recurrence"	1751	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	93	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 4eac2c98-86d2-4ee6-a1d3-157d013c78dc///days_to_birth: -21066///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1666///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f21016c7-5541-4378-869b-7dcadae9392c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 567///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1751///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 480///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: YES///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT, MRI///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1666-01A-01T-0541-07///unique_patient_id: TCGA-09-1666"
"TCGA.09.1667"	"TCGA-09-1667-01C-01T-0541-07"	"TCGA-09-1667"	"tumor"	"ser"	"ov"	NA	"low"	"early"	2	"c"	2	61	"y"	"y"	"n"	460	"recurrence"	1882	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	2	7	86	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 32d4d200-1fdf-44ed-b81f-1954a9c93926///days_to_birth: -22306///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1667///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 8bed668f-c2de-4768-9bb9-ff8adf3d84e3///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 511///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1882///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 460///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT, PET; Other Method- CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1667-01C-01T-0541-07///unique_patient_id: TCGA-09-1667"
"TCGA.09.1668"	"TCGA-09-1668-01B-01T-0541-07"	"TCGA-09-1668"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"n"	"n"	1684	"norecurrence"	1684	"living"	NA	NA	NA	"completeresponse"	NA	0	8	88	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Right///bcr_patient_uuid: 0e475b3d-be3c-431a-ab12-5a867ea8f6cd///days_to_birth: -20971///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1668///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4c6e3ed8-1d30-4366-96fc-60bfa0104dfd///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1684///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1668-01B-01T-0541-07///unique_patient_id: TCGA-09-1668"
"TCGA.09.1669"	"TCGA-09-1669-01A-01T-0541-07"	"TCGA-09-1669"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	54	"y"	"y"	"n"	927	"norecurrence"	927	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	35	60	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Right///bcr_patient_uuid: b1c90c69-6149-4105-8182-ab9212f196be///days_to_birth: -20052///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1669///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: be4d9604-3e6b-4bf2-bd2a-0be49751832a///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 927///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1669-01A-01T-0541-07///unique_patient_id: TCGA-09-1669"
"TCGA.09.1670"	"TCGA-09-1670-01A-01T-0567-07"	"TCGA-09-1670"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	547	"recurrence"	547	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 60014a6e-6a13-4f92-bbfd-eeeee9632f98///days_to_birth: -21146///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1670///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 80b17801-1c09-408a-bb5b-a95402c021c0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 547///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 547///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1670-01A-01T-0567-07///unique_patient_id: TCGA-09-1670"
"TCGA.09.1672"	"TCGA-09-1672-01A-01T-0567-07"	"TCGA-09-1672"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	78	"y"	"y"	"n"	178	"norecurrence"	178	"living"	NA	NA	NA	NA	NA	0	32	68	NA	"age_at_initial_pathologic_diagnosis: 78///anatomic_organ_subdivision: Right///bcr_patient_uuid: 66dc6379-a98b-498f-8109-e3a811d043ea///days_to_birth: -28555///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G1///patient_id: 1672///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a4b07c67-1c4e-4d96-97dc-9cc364302992///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 178///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1672-01A-01T-0567-07///unique_patient_id: TCGA-09-1672"
"TCGA.09.1673"	"TCGA-09-1673-01A-01T-0567-07"	"TCGA-09-1673"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	50	"y"	"y"	"n"	92	"norecurrence"	92	"living"	NA	NA	NA	NA	"suboptimal"	0	5	86	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 4e6f88de-7624-4719-8234-4c9e5b2e2988///days_to_birth: -18599///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1673///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7596faa8-43be-4930-a899-cefee1f4f8c7///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 92///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1673-01A-01T-0567-07///unique_patient_id: TCGA-09-1673"
"TCGA.09.1674"	"TCGA-09-1674-01A-01T-0567-07"	"TCGA-09-1674"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	79	"y"	"y"	"n"	260	"norecurrence"	260	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	5	90	NA	"age_at_initial_pathologic_diagnosis: 79///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1ede8063-e0e9-466d-891c-ac8916f1b5fa///days_to_birth: -28878///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1674///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ab2e6ae3-6c0c-435d-b0a5-93e3643cd442///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 260///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1674-01A-01T-0567-07///unique_patient_id: TCGA-09-1674"
"TCGA.09.1675"	"TCGA-09-1675-01B-01T-0567-07"	"TCGA-09-1675"	"tumor"	"ser"	"ov"	NA	"low"	"early"	1	"c"	2	50	"y"	"y"	"n"	2967	"norecurrence"	2967	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Left///bcr_patient_uuid: 0fc8777c-8f12-472f-a0ea-085139b35d1f///days_to_birth: -18596///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1675///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b6bc98b0-daf9-4803-aed3-b2fa0751638a///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2967///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1675-01B-01T-0567-07///unique_patient_id: TCGA-09-1675"
"TCGA.09.2043"	"TCGA-09-2043-01A-01T-0712-07"	"TCGA-09-2043"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	69	NA	NA	NA	187	"norecurrence"	187	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 69///anatomic_organ_subdivision: Left///bcr_patient_uuid: 2e05cd3a-a55f-43b8-b2a9-72fb742b89c9///days_to_birth: -25480///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2043///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4c13cde4-7fc0-4c9a-bcf9-cc338506c17c///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 187///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-2043-01A-01T-0712-07///unique_patient_id: TCGA-09-2043"
"TCGA.09.2044"	"TCGA-09-2044-01B-01T-0712-07"	"TCGA-09-2044"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"b"	3	77	"y"	"y"	"n"	186	"norecurrence"	186	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	7	92	NA	"age_at_initial_pathologic_diagnosis: 77///anatomic_organ_subdivision: Right///bcr_patient_uuid: 7d03ddb6-f3fe-4b50-8bba-514aa65e7d0e///days_to_birth: -28230///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2044///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ec42f6f2-8d69-40be-a123-4b0a090af2d2///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 186///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-2044-01B-01T-0712-07///unique_patient_id: TCGA-09-2044"
"TCGA.09.2045"	"TCGA-09-2045-01A-01T-0712-07"	"TCGA-09-2045"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	50	"y"	"y"	"n"	631	"recurrence"	1069	"deceased"	NA	NA	"locoregional"	"stabledisease"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3768d34f-1527-40db-b116-cd80cee5ec3a///days_to_birth: -18285///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 2045///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1996///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0174cdfc-8808-4567-97bc-03c86ce40b50///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1069///days_to_last_followup: 1069///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 631///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study and Other method was CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-2045-01A-01T-0712-07///unique_patient_id: TCGA-09-2045"
"TCGA.09.2048"	"TCGA-09-2048-01A-01T-0712-07"	"TCGA-09-2048"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	NA	NA	NA	137	"norecurrence"	137	"deceased"	NA	NA	NA	"stabledisease"	"optimal"	0	5	92	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 184aac07-44c1-47f1-8adf-50acbcc1762c///days_to_birth: -23043///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2048///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7d525bd5-fc5d-4c60-aff2-5dbece847b51///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 137///days_to_last_followup: 137///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-2048-01A-01T-0712-07///unique_patient_id: TCGA-09-2048"
"TCGA.09.2049"	"TCGA-09-2049-01D-01T-0712-07"	"TCGA-09-2049"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	64	"y"	"y"	"n"	3418	"norecurrence"	3418	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	0	12	88	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Left///bcr_patient_uuid: 05eb8bd5-d31b-4595-921a-366e53ea5a8b///days_to_birth: -23410///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2049///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5b946b52-500f-4b9c-b99f-10c53af9b68f///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 3418///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 952///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Image study done by another physician; Other method CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-2049-01D-01T-0712-07///unique_patient_id: TCGA-09-2049"
"TCGA.09.2050"	"TCGA-09-2050-01A-01T-0712-07"	"TCGA-09-2050"	"tumor"	"ser"	"ov"	NA	"low"	"early"	2	"c"	2	65	"y"	"y"	"n"	2163	"norecurrence"	2163	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3c037acf-f453-4513-a6dd-129163ddde2a///days_to_birth: -23987///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 2050///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIA///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d376dd7b-c6c2-4e3b-88ce-db3121b2f006///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2163///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-2050-01A-01T-0712-07///unique_patient_id: TCGA-09-2050"
"TCGA.09.2051"	"TCGA-09-2051-01A-01T-0712-07"	"TCGA-09-2051"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	42	"y"	"y"	"n"	583	"recurrence"	1919	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 02594e5e-8751-47c1-9245-90c66984b665///days_to_birth: -15650///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2051///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 94294882-49ef-4a27-9a2a-03646c87209d///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 875///days_to_death: NA///days_to_last_followup: 1919///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 583///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Other method Ca 125 rising///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-2051-01A-01T-0712-07///unique_patient_id: TCGA-09-2051"
"TCGA.09.2053"	"TCGA-09-2053-01C-01T-0671-07"	"TCGA-09-2053"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	72	"y"	"y"	"n"	1209	"norecurrence"	1209	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 72///anatomic_organ_subdivision: Left///bcr_patient_uuid: ea605be2-6578-4e01-8ec3-bbd84c0b7f1d///days_to_birth: -26433///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2053///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 634220c4-f1be-44e0-b294-0277c24ff97d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1209///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-2053-01C-01T-0671-07///unique_patient_id: TCGA-09-2053"
"TCGA.09.2054"	"TCGA-09-2054-01A-01T-0671-07"	"TCGA-09-2054"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	636	"norecurrence"	636	"deceased"	NA	NA	NA	"progressivedisease"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cbd87697-7708-4b69-9e50-9ee474feabe1///days_to_birth: -21285///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2054///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2616c4a0-cee6-4a82-941f-c30445131b82///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 636///days_to_last_followup: 636///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-2054-01A-01T-0671-07///unique_patient_id: TCGA-09-2054"
"TCGA.09.2055"	"TCGA-09-2055-01B-01T-0712-07"	"TCGA-09-2055"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	48	"y"	"y"	"n"	819	"norecurrence"	819	"living"	NA	NA	NA	"completeresponse"	"optimal"	1	10	82	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Left///bcr_patient_uuid: 838778c3-0b33-4fc5-97fc-5da163475485///days_to_birth: -17545///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2055///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fac2d6fc-13cf-49fc-9201-6997dd4cb7a0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 819///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-2055-01B-01T-0712-07///unique_patient_id: TCGA-09-2055"
"TCGA.09.2056"	"TCGA-09-2056-01B-01T-0671-07"	"TCGA-09-2056"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	62	"y"	"y"	"n"	379	"norecurrence"	379	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ea6405c4-0fe4-4f37-bef2-275072f91e39///days_to_birth: -22863///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2056///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d88c100c-2a42-4ea1-8cf3-60def08194e0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 379///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-2056-01B-01T-0671-07///unique_patient_id: TCGA-09-2056"
"TCGA.10.0925"	"TCGA-10-0925-01B-01T-0656-07"	"TCGA-10-0925"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	1	58	"y"	"y"	"n"	558	"recurrence"	1652	"deceased"	NA	NA	"metastasis"	"partialresponse"	"optimal"	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 869c9aae-85eb-4faa-8893-b3f487e8981c///days_to_birth: -21498///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G1///patient_id: 925///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c1c5689d-52ce-407d-a8da-6e7c103202d9///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1652///days_to_last_followup: 1652///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 558///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan of Abd/pelvis and Other method- CA 125:5000///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-10-0925-01B-01T-0656-07///unique_patient_id: TCGA-10-0925"
"TCGA.10.0926"	"TCGA-10-0926-01A-01T-0407-07"	"TCGA-10-0926"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"y"	"n"	287	"recurrence"	788	"deceased"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	4	0	96	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e641aed9-1dd8-4c30-b231-f12b20a76df0///days_to_birth: -23307///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 926///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 7f3cdaf9-ed64-4b9a-8f24-2e9037eb0f86///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 788///days_to_last_followup: 788///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 287///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT of Abd and Pelvis; CA125:99 Elevated///radiation_therapy: YES///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0926-01A-01T-0407-07///unique_patient_id: TCGA-10-0926"
"TCGA.10.0927"	"TCGA-10-0927-01A-02T-0407-07"	"TCGA-10-0927"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	65	"y"	"y"	"n"	1001	"recurrence"	2490	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	8	18	75	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 933dbfbd-4697-403e-bd73-c17cb300c94b///days_to_birth: -23981///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 927///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 086690da-aa4d-4658-a679-f871fa293b7c///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2490///days_to_last_followup: 2478///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1001///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan of Abd and Pelvis; CA125;63///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0927-01A-02T-0407-07///unique_patient_id: TCGA-10-0927"
"TCGA.10.0928"	"TCGA-10-0928-01A-02T-0407-07"	"TCGA-10-0928"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	NA	NA	NA	562	"norecurrence"	562	"deceased"	NA	NA	NA	NA	"optimal"	5	5	90	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 29d26e7e-f4ae-4476-9a3f-27d5ec2ccb8a///days_to_birth: -26066///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 928///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c87807df-3345-4970-807a-a338040b2c38///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 562///days_to_last_followup: 562///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0928-01A-02T-0407-07///unique_patient_id: TCGA-10-0928"
"TCGA.10.0930"	"TCGA-10-0930-01A-01T-0407-07"	"TCGA-10-0930"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	70	"y"	"y"	"n"	680	"recurrence"	1040	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	5	10	85	NA	"age_at_initial_pathologic_diagnosis: 70///anatomic_organ_subdivision: Left///bcr_patient_uuid: 99f1ae02-86ec-4d93-8cd4-650bf6f02c10///days_to_birth: -25736///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 930///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 7e161c2d-e784-4e5e-927a-f8aceb86f854///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1040///days_to_last_followup: 1011///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 680///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study- no info///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0930-01A-01T-0407-07///unique_patient_id: TCGA-10-0930"
"TCGA.10.0931"	"TCGA-10-0931-01A-01T-0407-07"	"TCGA-10-0931"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	44	"y"	"y"	"n"	300	"recurrence"	1000	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	2	8	90	NA	"age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e07a61e2-bcd2-4a96-80df-97e04aafbd32///days_to_birth: -16261///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 931///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: c2b9ac2e-f094-4664-81f1-ba7e9a64ca33///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1000///days_to_last_followup: 982///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 300///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: YES///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan and CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0931-01A-01T-0407-07///unique_patient_id: TCGA-10-0931"
"TCGA.10.0933"	"TCGA-10-0933-01A-01T-0407-07"	"TCGA-10-0933"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	77	"y"	"y"	"n"	356	"recurrence"	446	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	5	8	88	NA	"age_at_initial_pathologic_diagnosis: 77///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9446e349-71e6-455a-aa8f-53ec96597146///days_to_birth: -28433///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 933///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 4cddfc2f-91c2-4d1b-959e-a407436f1faf///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 446///days_to_last_followup: 356///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 356///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Other-CA125:147 elevated///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0933-01A-01T-0407-07///unique_patient_id: TCGA-10-0933"
"TCGA.10.0934"	"TCGA-10-0934-01A-01T-0407-07"	"TCGA-10-0934"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	110	"recurrence"	203	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"optimal"	5	10	85	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 65ddccd2-70a7-48b3-88e1-9d6fd1dcd11b///days_to_birth: -18602///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 934///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 0d547712-8f13-4099-8c98-dbbd9132acee///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 74///days_to_death: 203///days_to_last_followup: 118///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 110///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0934-01A-01T-0407-07///unique_patient_id: TCGA-10-0934"
"TCGA.10.0935"	"TCGA-10-0935-01A-01T-0407-07"	"TCGA-10-0935"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	68	"y"	"y"	"n"	1077	"norecurrence"	1077	"deceased"	NA	NA	NA	NA	"optimal"	3	8	88	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 48f8afa8-7712-4428-b0d0-d8c3340504b6///days_to_birth: -25098///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 935///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 74b6de98-2a0e-4043-994a-8903a06b781e///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1077///days_to_last_followup: 1077///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0935-01A-01T-0407-07///unique_patient_id: TCGA-10-0935"
"TCGA.10.0936"	"TCGA-10-0936-01A-01T-0407-07"	"TCGA-10-0936"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	69	"y"	"y"	"n"	NA	"recurrence"	1123	"deceased"	NA	NA	"locoregional"	"partialresponse"	"suboptimal"	5	5	90	NA	"age_at_initial_pathologic_diagnosis: 69///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7016714b-6af8-45dd-8341-1493927e5515///days_to_birth: -25454///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 936///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8a1857ba-c686-4630-b137-6c45ba21274c///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1123///days_to_last_followup: 1089///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan nodularity in pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0936-01A-01T-0407-07///unique_patient_id: TCGA-10-0936"
"TCGA.10.0937"	"TCGA-10-0937-01A-02T-0407-07"	"TCGA-10-0937"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	44	"y"	"y"	"n"	235	"recurrence"	608	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	5	18	78	NA	"age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a5030259-cf9c-4a58-8710-b9da8ee59320///days_to_birth: -16221///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 937///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 33721cd1-5029-49c4-bc36-64ee90e76df1///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 608///days_to_last_followup: 460///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 235///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan of Abd; Other method-FNA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0937-01A-02T-0407-07///unique_patient_id: TCGA-10-0937"
"TCGA.10.0938"	"TCGA-10-0938-01A-02T-0407-07"	"TCGA-10-0938"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	80	"y"	"n"	"n"	NA	"recurrence"	636	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"suboptimal"	8	18	75	NA	"age_at_initial_pathologic_diagnosis: 80///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7ca97692-0bf5-4bbd-81ce-10a051d04bd5///days_to_birth: -29557///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 938///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 18a036e5-6796-4246-8bb6-2f23e0727ca7///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 362///days_to_death: 636///days_to_last_followup: 604///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 362///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 2///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan of abd and pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-10-0938-01A-02T-0407-07///unique_patient_id: TCGA-10-0938"
"TCGA.13.0714"	"TCGA-13-0714-01A-01T-0364-07"	"TCGA-13-0714"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	55	"y"	"y"	"n"	189	"norecurrence"	189	"deceased"	NA	NA	NA	"progressivedisease"	"optimal"	14	NA	85	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1e14f098-17b2-4f54-8e4f-e38088008df7///days_to_birth: -20109///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 714///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7fe913a4-d022-4890-a2a8-82c1b9c72755///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 189///days_to_last_followup: 189///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 110///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0714-01A-01T-0364-07///unique_patient_id: TCGA-13-0714"
"TCGA.13.0717"	"TCGA-13-0717-01A-01T-0364-07"	"TCGA-13-0717"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	54	"y"	"y"	"n"	294	"recurrence"	748	"deceased"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	14	NA	82	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3867e193-c82f-4693-9b32-bac76b5f4d06///days_to_birth: -20042///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 717///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e6fab168-c489-442f-82ab-85ef871f703d///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 748///days_to_last_followup: 748///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 294///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study, Molecular marker///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0717-01A-01T-0364-07///unique_patient_id: TCGA-13-0717"
"TCGA.13.0720"	"TCGA-13-0720-01A-01T-0364-07"	"TCGA-13-0720"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	48	"y"	"y"	"n"	292	"recurrence"	1355	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	8	2	89	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0d23fa5b-95f8-4626-a4d2-c72ad3cc553b///days_to_birth: -17798///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 720///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7da47e49-e807-4f7f-834c-1ade13aca50c///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1355///days_to_last_followup: 1355///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 292///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0720-01A-01T-0364-07///unique_patient_id: TCGA-13-0720"
"TCGA.13.0723"	"TCGA-13-0723-01A-02T-0364-07"	"TCGA-13-0723"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"y"	"n"	1204	"norecurrence"	1204	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	14	2	76	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ff530f28-0ec0-4494-bb54-44bb055bae1c///days_to_birth: -23093///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 723///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6575a21c-5073-473d-8606-98a740946cb5///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1204///days_to_last_followup: 1204///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 210///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0723-01A-02T-0364-07///unique_patient_id: TCGA-13-0723"
"TCGA.13.0724"	"TCGA-13-0724-01A-01T-0364-07"	"TCGA-13-0724"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	72	"y"	"n"	"n"	83	"norecurrence"	83	"deceased"	NA	NA	NA	"progressivedisease"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 72///anatomic_organ_subdivision: Right///bcr_patient_uuid: a9abe7a7-4126-414b-87d2-a6d25abcf1fa///days_to_birth: -26341///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 724///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f97cc3a0-d1f0-4e85-bcb8-52e1d2d9cd79///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 83///days_to_last_followup: 83///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 83///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0724-01A-01T-0364-07///unique_patient_id: TCGA-13-0724"
"TCGA.13.0725"	"TCGA-13-0725-01A-01T-0364-07"	"TCGA-13-0725"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	44	"y"	"y"	"n"	190	"recurrence"	377	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	20	10	75	NA	"age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 446ce2a3-d328-443c-a419-3344baad0e16///days_to_birth: -16086///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 725///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 24a9120f-4794-4b42-8edf-6794e062f04d///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 377///days_to_last_followup: 377///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 190///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0725-01A-01T-0364-07///unique_patient_id: TCGA-13-0725"
"TCGA.13.0726"	"TCGA-13-0726-01A-01T-0364-07"	"TCGA-13-0726"	"tumor"	"ser"	"ov"	NA	NA	"late"	3	"c"	NA	55	"y"	"y"	"n"	392	"recurrence"	948	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	35	65	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 32960bc7-839a-42c5-9460-3917fa578ffc///days_to_birth: -20134///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 726///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b95035b9-c865-4fe8-88c3-f5723ea3ad15///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 948///days_to_last_followup: 945///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 392///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0726-01A-01T-0364-07///unique_patient_id: TCGA-13-0726"
"TCGA.13.0727"	"TCGA-13-0727-01A-01T-0364-07"	"TCGA-13-0727"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	253	"recurrence"	462	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	12	5	82	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 90f4b65c-cfd4-4066-a5b9-842885c172e2///days_to_birth: -26184///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 727///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c54b18db-aeab-4253-8e80-49aeae62f572///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 462///days_to_last_followup: 462///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 253///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0727-01A-01T-0364-07///unique_patient_id: TCGA-13-0727"
"TCGA.13.0730"	"TCGA-13-0730-01A-01T-0364-07"	"TCGA-13-0730"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	NA	NA	NA	NA	"norecurrence"	NA	NA	NA	NA	NA	NA	"suboptimal"	0	10	85	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2ebb738c-4829-4720-931a-96c0fd117e2a///days_to_birth: -26086///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 730///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: NA///chemo_therapy: NA///day_of_form_completion: NA///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: NA///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: NA///year_of_form_completion: NA///Extract.Name: TCGA-13-0730-01A-01T-0364-07///unique_patient_id: TCGA-13-0730"
"TCGA.13.0751"	"TCGA-13-0751-01A-01T-0364-07"	"TCGA-13-0751"	"tumor"	"ser"	"ov"	NA	NA	"late"	3	"c"	NA	44	"y"	"y"	"n"	653	"recurrence"	1678	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	2	5	94	NA	"age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 15c84da3-16e5-4909-aea9-cb5894b0f8af///days_to_birth: -16303///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 751///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 830bb982-a48a-4d97-8836-251f0cd6440d///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1678///days_to_last_followup: 1678///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 653///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0751-01A-01T-0364-07///unique_patient_id: TCGA-13-0751"
"TCGA.13.0755"	"TCGA-13-0755-01A-01T-0364-07"	"TCGA-13-0755"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	75	"y"	"n"	"n"	NA	"recurrence"	75	"deceased"	NA	NA	"locoregional"	"progressivedisease"	"optimal"	10	NA	89	NA	"age_at_initial_pathologic_diagnosis: 75///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2956e414-f167-438f-8747-a46fe0723622///days_to_birth: -27438///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 755///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b113f83e-be11-460a-9ade-2f5c506930f9///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 75///days_to_last_followup: 75///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 34///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 40///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: Recurrence disease was found at both sites at time of first recurrence. 2:19A///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0755-01A-01T-0364-07///unique_patient_id: TCGA-13-0755"
"TCGA.13.0757"	"TCGA-13-0757-01A-01T-0364-07"	"TCGA-13-0757"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	293	"recurrence"	340	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	15	3	75	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2c69f3a4-c26c-4fbb-a1c0-b1f57554c43a///days_to_birth: -25999///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 757///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: b853f249-6500-468b-b059-179d7b1f5628///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 340///days_to_last_followup: 340///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 293///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular markers///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0757-01A-01T-0364-07///unique_patient_id: TCGA-13-0757"
"TCGA.13.0758"	"TCGA-13-0758-01A-01T-0364-07"	"TCGA-13-0758"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	60	"y"	"y"	"n"	NA	"recurrence"	346	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	15	1	80	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 514aa64e-a58d-48c2-aff9-498604cc11d6///days_to_birth: -22088///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 758///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5574373d-18ca-42bc-a604-5803d33e993b///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 346///days_to_last_followup: 346///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 211///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0758-01A-01T-0364-07///unique_patient_id: TCGA-13-0758"
"TCGA.13.0760"	"TCGA-13-0760-01A-01T-0364-07"	"TCGA-13-0760"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	63	NA	NA	NA	351	"norecurrence"	351	"deceased"	NA	NA	NA	NA	"optimal"	5	20	84	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: d8d13aa4-45d5-4e1a-a6cf-895bdf05e7b2///days_to_birth: -23036///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 760///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 3203ab30-8200-473e-ac09-004d20628514///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 351///days_to_last_followup: 351///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0760-01A-01T-0364-07///unique_patient_id: TCGA-13-0760"
"TCGA.13.0761"	"TCGA-13-0761-01A-01T-0364-07"	"TCGA-13-0761"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	51	"y"	"n"	"n"	423	"recurrence"	1036	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	2	10	92	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 00630714-7ab3-44e1-afff-186300edae44///days_to_birth: -18697///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 761///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0304c298-144b-43f2-997d-be1fb1d59cab///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1036///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 423///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0761-01A-01T-0364-07///unique_patient_id: TCGA-13-0761"
"TCGA.13.0762"	"TCGA-13-0762-01A-01T-0364-07"	"TCGA-13-0762"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"y"	"n"	981	"norecurrence"	981	"living"	NA	NA	NA	"completeresponse"	"optimal"	2	10	92	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6485b68f-caa7-45cd-9bc5-78c2add8191d///days_to_birth: -23960///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 762///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 42abf706-0f37-4c0a-944b-88df5792202d///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 981///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0762-01A-01T-0364-07///unique_patient_id: TCGA-13-0762"
"TCGA.13.0764"	"TCGA-13-0764-01A-03T-0364-07"	"TCGA-13-0764"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	62	"y"	"y"	"n"	272	"recurrence"	944	"living"	NA	NA	"metastasis"	"partialresponse"	"optimal"	11	NA	88	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 034825d0-e8b7-4ac0-be31-25f6038cb04a///days_to_birth: -22965///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 764///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d0beab0f-0202-4c06-8b19-f10a92e8cf28///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 944///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 272///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0764-01A-03T-0364-07///unique_patient_id: TCGA-13-0764"
"TCGA.13.0765"	"TCGA-13-0765-01A-01T-0364-07"	"TCGA-13-0765"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	668	"recurrence"	869	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	5	96	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 774ce281-96b2-467a-9170-079797ee10f7///days_to_birth: -18574///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 765///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2a56cd1f-6cf2-4e9d-842a-b2a72e8dc65f///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 869///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 668///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0765-01A-01T-0364-07///unique_patient_id: TCGA-13-0765"
"TCGA.13.0766"	"TCGA-13-0766-01A-02T-0364-07"	"TCGA-13-0766"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	42	"y"	"y"	"n"	628	"recurrence"	651	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	20	NA	77	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8fe44099-b313-4bfd-a94a-27e72f2a818c///days_to_birth: -15570///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 766///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 6f218d11-5224-464e-a2ee-d18e3eaf0dc5///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 651///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 628///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study, loco-regional///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0766-01A-02T-0364-07///unique_patient_id: TCGA-13-0766"
"TCGA.13.0768"	"TCGA-13-0768-01A-01T-0364-07"	"TCGA-13-0768"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	"y"	"y"	"n"	256	"norecurrence"	256	"living"	NA	NA	NA	"completeresponse"	"optimal"	8	1	87	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e732f81c-9b7d-44bd-a905-ff53fbed5009///days_to_birth: -26999///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 768///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3c46ff04-2725-424b-a388-c837eb62ceec///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 256///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0768-01A-01T-0364-07///unique_patient_id: TCGA-13-0768"
"TCGA.13.0792"	"TCGA-13-0792-01A-01T-0364-07"	"TCGA-13-0792"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	40	"y"	"y"	"n"	816	"recurrence"	1117	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	22	78	NA	"age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c11cae7e-91cd-4470-a9d8-188a4f6b8fa1///days_to_birth: -14729///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 792///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1b6ba623-902c-40fa-bd13-a9e55cf9d4b0///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1117///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 816///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0792-01A-01T-0364-07///unique_patient_id: TCGA-13-0792"
"TCGA.13.0793"	"TCGA-13-0793-01A-01T-0364-07"	"TCGA-13-0793"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	40	"y"	"y"	"n"	351	"recurrence"	873	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	15	85	NA	"age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Left///bcr_patient_uuid: 5e90e1ed-cbfd-44ba-a6ff-63ff576b3c73///days_to_birth: -14707///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 793///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: a19d6f1b-9782-4721-89d1-65d0aaf06ea7///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 873///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 351///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: YES///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0793-01A-01T-0364-07///unique_patient_id: TCGA-13-0793"
"TCGA.13.0794"	"TCGA-13-0794-01A-01T-0364-07"	"TCGA-13-0794"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	"y"	"n"	"n"	845	"recurrence"	923	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	6	94	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b63cad1b-b4c7-4e50-8acb-5cee4e9ce4a9///days_to_birth: -21945///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 794///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9805702d-3f0c-44bf-a09e-b342a981b370///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 923///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 845///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: Imaging study///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0794-01A-01T-0364-07///unique_patient_id: TCGA-13-0794"
"TCGA.13.0795"	"TCGA-13-0795-01A-01T-0364-07"	"TCGA-13-0795"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"y"	"y"	"n"	325	"recurrence"	595	"living"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b1e11e94-646b-4c44-9d33-1ca67d8356fb///days_to_birth: -24403///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 795///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ca8e4422-c168-479c-a85b-b3b7807d6443///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 595///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 325///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0795-01A-01T-0364-07///unique_patient_id: TCGA-13-0795"
"TCGA.13.0797"	"TCGA-13-0797-01A-01T-0364-07"	"TCGA-13-0797"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	49	"y"	"y"	"n"	265	"norecurrence"	265	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0de910b1-edaf-47e4-a265-727ee12ac1c3///days_to_birth: -18051///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 797///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7a9f7b35-642f-4607-89fb-d55ba2600b53///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 265///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0797-01A-01T-0364-07///unique_patient_id: TCGA-13-0797"
"TCGA.13.0799"	"TCGA-13-0799-01A-01T-0364-07"	"TCGA-13-0799"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	44	"y"	"y"	"n"	237	"norecurrence"	237	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b9418c6d-94f7-4db4-a1e4-f384b09d54cb///days_to_birth: -16170///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 799///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 20105ff9-cc71-41ab-942d-44454c233406///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 237///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0799-01A-01T-0364-07///unique_patient_id: TCGA-13-0799"
"TCGA.13.0800"	"TCGA-13-0800-01A-01T-0364-07"	"TCGA-13-0800"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	52	"y"	"y"	"n"	247	"norecurrence"	247	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	25	72	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 390eed6b-50af-48a9-9fd6-3a68a2bbb7f9///days_to_birth: -19086///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 800///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 217432e2-4489-425f-a6e6-79c90c55f1f9///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 247///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0800-01A-01T-0364-07///unique_patient_id: TCGA-13-0800"
"TCGA.13.0801"	"TCGA-13-0801-01A-01T-0364-07"	"TCGA-13-0801"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	46	"y"	"y"	"n"	252	"norecurrence"	252	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	90	NA	"age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b8c3d99c-429b-42a3-b486-6fbcb90cc2e0///days_to_birth: -16811///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 801///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 7198f423-8333-4349-8ee6-65e5a4322771///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 252///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0801-01A-01T-0364-07///unique_patient_id: TCGA-13-0801"
"TCGA.13.0802"	"TCGA-13-0802-01A-01T-0364-07"	"TCGA-13-0802"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	79	"y"	"y"	"n"	249	"norecurrence"	249	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 79///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3c8b5986-f9d5-4e7e-9dd4-3ad301451279///days_to_birth: -29075///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 802///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 7d5cd3ae-c5d9-45a0-9372-c0cec72673e1///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 249///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0802-01A-01T-0364-07///unique_patient_id: TCGA-13-0802"
"TCGA.13.0803"	"TCGA-13-0803-01A-01T-0364-07"	"TCGA-13-0803"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	81	"y"	"y"	"n"	1333	"norecurrence"	1333	"deceased"	NA	NA	NA	"completeresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 81///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 54cf3bfe-51c0-4cca-9054-bf76b05a9371///days_to_birth: -29685///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 803///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f2f628f8-dfed-4f61-9678-1be00a4dea71///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1333///days_to_last_followup: 1333///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 336///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0803-01A-01T-0364-07///unique_patient_id: TCGA-13-0803"
"TCGA.13.0804"	"TCGA-13-0804-01A-01T-0364-07"	"TCGA-13-0804"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	"y"	"y"	"n"	329	"recurrence"	1073	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	4	95	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7e34d3c1-1fab-4326-9a69-4260d2bac558///days_to_birth: -27021///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 804///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 3a4fad46-797d-4276-b625-8cc78d3545f1///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1073///days_to_last_followup: 1073///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 329///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular markers///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0804-01A-01T-0364-07///unique_patient_id: TCGA-13-0804"
"TCGA.13.0805"	"TCGA-13-0805-01A-01T-0364-07"	"TCGA-13-0805"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	NA	"recurrence"	1074	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"optimal"	0	22	78	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2a3a6222-f477-4198-ab9e-cdf527c1a6cf///days_to_birth: -21014///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 805///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 83b411a0-6a00-4c33-a14a-243c680e9403///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1074///days_to_last_followup: 1073///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 176///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker, loco-regional mets///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0805-01A-01T-0364-07///unique_patient_id: TCGA-13-0805"
"TCGA.13.0807"	"TCGA-13-0807-01B-01T-0407-07"	"TCGA-13-0807"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	54	"y"	"y"	"n"	414	"norecurrence"	414	"deceased"	NA	NA	NA	NA	"suboptimal"	0	20	70	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: NA///bcr_patient_uuid: 067c5c61-d147-4b08-ab8a-32c30969d564///days_to_birth: -19889///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 807///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 76c34f52-9a39-4378-9c5f-a27baccaac51///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 414///days_to_last_followup: 414///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0807-01B-01T-0407-07///unique_patient_id: TCGA-13-0807"
"TCGA.13.0883"	"TCGA-13-0883-01A-02T-0407-07"	"TCGA-13-0883"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	"y"	"y"	"n"	818	"recurrence"	2096	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	15	0	83	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5c159ab5-8475-4d93-89b8-b6befed4a5b3///days_to_birth: -22395///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 883///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0ad0a258-a395-4214-915d-499fb9671a1e///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2096///days_to_last_followup: 2096///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 818///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0883-01A-02T-0407-07///unique_patient_id: TCGA-13-0883"
"TCGA.13.0884"	"TCGA-13-0884-01B-01T-0455-07"	"TCGA-13-0884"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	39	"y"	"y"	"n"	1251	"recurrence"	3260	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 39///anatomic_organ_subdivision: NA///bcr_patient_uuid: 63a75e0b-9241-4f0e-9236-01a2e2c05b7e///days_to_birth: -14538///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 884///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e819d979-7efe-4737-b8b4-0a64e5588d4b///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 3260///days_to_last_followup: 3260///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1251///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0884-01B-01T-0455-07///unique_patient_id: TCGA-13-0884"
"TCGA.13.0885"	"TCGA-13-0885-01A-02T-0407-07"	"TCGA-13-0885"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	70	"y"	"y"	"n"	2780	"norecurrence"	2780	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	20	0	78	NA	"age_at_initial_pathologic_diagnosis: 70///anatomic_organ_subdivision: Left///bcr_patient_uuid: 2a924999-1fbf-470a-97bd-fd2276a9a366///days_to_birth: -25762///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 885///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: dc9ec5ec-5e34-40f1-baef-f0a594f2a4cb///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2780///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0885-01A-02T-0407-07///unique_patient_id: TCGA-13-0885"
"TCGA.13.0886"	"TCGA-13-0886-01A-01T-0407-07"	"TCGA-13-0886"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"y"	"y"	"n"	2259	"norecurrence"	2259	"living"	NA	NA	NA	"completeresponse"	"optimal"	30	0	66	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 91de8a74-a1e6-46b6-a06e-70aedf2c3eaf///days_to_birth: -24723///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 886///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 3e55773f-fd8a-4ea5-a2c0-b27dc4999829///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2259///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0886-01A-01T-0407-07///unique_patient_id: TCGA-13-0886"
"TCGA.13.0887"	"TCGA-13-0887-01A-01T-0407-07"	"TCGA-13-0887"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	42	"y"	"y"	"n"	513	"recurrence"	2027	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	8	0	87	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 14c58def-60ee-48e0-a74b-da4eb77ef344///days_to_birth: -15669///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 887///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 5db4b8a6-caf0-4a60-9eb5-01711d0b7af9///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2027///days_to_last_followup: 2027///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 513///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0887-01A-01T-0407-07///unique_patient_id: TCGA-13-0887"
"TCGA.13.0888"	"TCGA-13-0888-01A-01T-0407-07"	"TCGA-13-0888"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	78	"y"	"y"	"n"	2141	"norecurrence"	2141	"living"	NA	NA	NA	"partialresponse"	"optimal"	15	0	68	NA	"age_at_initial_pathologic_diagnosis: 78///anatomic_organ_subdivision: Right///bcr_patient_uuid: 6cf9f872-2e59-45cf-bb5e-ebd7fa1b3caf///days_to_birth: -28498///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 888///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 5da77845-7980-438e-b5bb-94e293431a72///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2141///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0888-01A-01T-0407-07///unique_patient_id: TCGA-13-0888"
"TCGA.13.0889"	"TCGA-13-0889-01A-01T-0407-07"	"TCGA-13-0889"	"tumor"	"ser"	"ov"	NA	NA	"late"	4	NA	NA	75	"y"	"y"	"n"	1880	"norecurrence"	1880	"living"	NA	NA	NA	"completeresponse"	"optimal"	20	0	77	NA	"age_at_initial_pathologic_diagnosis: 75///anatomic_organ_subdivision: Right///bcr_patient_uuid: e3712e5a-4575-440f-89d1-8db9498baa88///days_to_birth: -27674///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 889///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f2a35721-d4a7-426d-baa6-7c0f749ad28c///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1880///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0889-01A-01T-0407-07///unique_patient_id: TCGA-13-0889"
"TCGA.13.0890"	"TCGA-13-0890-01A-01T-0407-07"	"TCGA-13-0890"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	56	"y"	"y"	"n"	2068	"norecurrence"	2068	"living"	NA	NA	NA	"completeresponse"	"optimal"	20	0	77	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ee0a4a13-613e-4c5d-96c3-8083a013702d///days_to_birth: -20770///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 890///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: d9c71fdd-8bd6-48a6-a691-7be7c78c0ae1///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2068///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0890-01A-01T-0407-07///unique_patient_id: TCGA-13-0890"
"TCGA.13.0891"	"TCGA-13-0891-01A-01T-0407-07"	"TCGA-13-0891"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	73	"y"	"y"	"n"	761	"recurrence"	2099	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	8	0	92	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0740321b-f8a5-4e1d-b390-ca6187598fac///days_to_birth: -26886///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 891///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 86624f11-e43c-4e2a-8e31-1b53b70c599e///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2099///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 761///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker and loco regional mets///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0891-01A-01T-0407-07///unique_patient_id: TCGA-13-0891"
"TCGA.13.0893"	"TCGA-13-0893-01B-01T-0455-07"	"TCGA-13-0893"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	48	"y"	"y"	"n"	461	"recurrence"	1319	"deceased"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 15170c7f-5880-4fb6-82ce-68d3df0dfb68///days_to_birth: -17573///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 893///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2e198688-0234-4ff0-bae5-0472ce5af182///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1319///days_to_last_followup: 1319///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 461///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0893-01B-01T-0455-07///unique_patient_id: TCGA-13-0893"
"TCGA.13.0894"	"TCGA-13-0894-01B-01T-0455-07"	"TCGA-13-0894"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	53	"y"	"y"	"n"	565	"recurrence"	1509	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: NA///bcr_patient_uuid: e8372916-7ac7-4535-ae97-0248208224f5///days_to_birth: -19466///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 894///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5f3daf92-4a48-465c-a5a1-c4ea0a54d15e///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1509///days_to_last_followup: 1509///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 565///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan; Moleuclar marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0894-01B-01T-0455-07///unique_patient_id: TCGA-13-0894"
"TCGA.13.0897"	"TCGA-13-0897-01A-01T-0407-07"	"TCGA-13-0897"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	54	"y"	"y"	"n"	553	"recurrence"	1748	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	10	0	88	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Right///bcr_patient_uuid: 79e6e31c-22a1-481c-903b-ab5499cbd450///days_to_birth: -19894///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 897///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 575c5f5c-ba76-49e9-8a0b-fe1f1223bd4d///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: 567///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1748///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 553///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0897-01A-01T-0407-07///unique_patient_id: TCGA-13-0897"
"TCGA.13.0899"	"TCGA-13-0899-01A-01T-0407-07"	"TCGA-13-0899"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	"y"	"y"	"n"	547	"recurrence"	1708	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	20	0	79	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5c6f3cd4-19c5-418d-b1be-d3fbf63e99db///days_to_birth: -22031///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 899///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: fd6b2332-5712-4df7-bf7b-366934559985///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1708///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 547///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0899-01A-01T-0407-07///unique_patient_id: TCGA-13-0899"
"TCGA.13.0900"	"TCGA-13-0900-01B-01T-0455-07"	"TCGA-13-0900"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	59	"y"	"y"	"n"	1736	"norecurrence"	1736	"living"	NA	NA	NA	"completeresponse"	NA	0	18	80	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: NA///bcr_patient_uuid: 9e48a4b1-6917-4625-9d78-e4832eb816a5///days_to_birth: -21698///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 900///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 62a46c9c-b36f-4c67-9dcd-7c820b5e8a3c///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1736///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0900-01B-01T-0455-07///unique_patient_id: TCGA-13-0900"
"TCGA.13.0901"	"TCGA-13-0901-01B-01T-0455-07"	"TCGA-13-0901"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	41	"y"	"y"	"n"	390	"recurrence"	589	"living"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 41///anatomic_organ_subdivision: NA///bcr_patient_uuid: 27920e1e-b9ab-4587-970a-0cba7025becb///days_to_birth: -15333///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 901///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 98ec4905-62a5-4fb5-9da0-a73e7e2b4368///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 589///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 390///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker CA-125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0901-01B-01T-0455-07///unique_patient_id: TCGA-13-0901"
"TCGA.13.0903"	"TCGA-13-0903-01A-01T-0407-07"	"TCGA-13-0903"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	42	"y"	"y"	"n"	1441	"norecurrence"	1441	"living"	NA	NA	NA	"completeresponse"	"optimal"	10	0	75	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8783e4b0-2b62-45d5-8cd9-f5a71cc0138e///days_to_birth: -15705///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 903///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: af4c2496-e373-4d64-bd57-acdf6bfe34ae///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1441///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0903-01A-01T-0407-07///unique_patient_id: TCGA-13-0903"
"TCGA.13.0904"	"TCGA-13-0904-01A-02T-0407-07"	"TCGA-13-0904"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"y"	"n"	NA	"recurrence"	1470	"living"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	9	1	89	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0b519c08-9f23-4ceb-9a13-e16509ca55d7///days_to_birth: -23278///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 904///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: ab164d3c-baee-40a5-b0fd-dbb870fa1f3b///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1470///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 329///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0904-01A-02T-0407-07///unique_patient_id: TCGA-13-0904"
"TCGA.13.0905"	"TCGA-13-0905-01B-01T-0455-07"	"TCGA-13-0905"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	"y"	"y"	"n"	1455	"norecurrence"	1455	"living"	NA	NA	NA	"completeresponse"	NA	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: NA///bcr_patient_uuid: 2038fd65-d8f1-4b16-af90-b1c8f9a379a7///days_to_birth: -18757///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 905///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: bbd54f4d-22ab-4f0a-9678-3e2a9d683ac7///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1455///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0905-01B-01T-0455-07///unique_patient_id: TCGA-13-0905"
"TCGA.13.0906"	"TCGA-13-0906-01A-01T-0407-07"	"TCGA-13-0906"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	1367	"norecurrence"	1367	"living"	NA	NA	NA	"completeresponse"	"optimal"	24	0	55	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e43d3769-e25f-4fb7-9080-ea26defaf094///days_to_birth: -18383///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 906///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d883d22d-c87c-475b-8d85-05b7b688c3ef///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1367///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0906-01A-01T-0407-07///unique_patient_id: TCGA-13-0906"
"TCGA.13.0908"	"TCGA-13-0908-01B-01T-0455-07"	"TCGA-13-0908"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	58	"y"	"y"	"n"	552	"recurrence"	1364	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0ba7b6cc-e5f5-47d7-859a-24e31aa336ab///days_to_birth: -21421///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 908///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 93339bf4-f92d-41ed-bba7-29236a13ccd3///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1364///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 552///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0908-01B-01T-0455-07///unique_patient_id: TCGA-13-0908"
"TCGA.13.0910"	"TCGA-13-0910-01A-01T-0407-07"	"TCGA-13-0910"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	1128	"norecurrence"	1128	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b783f33b-734a-4801-bf39-b559a2035c6f///days_to_birth: -21473///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 910///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 895d2750-b01e-4251-8e26-7d30e2eb6983///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1128///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0910-01A-01T-0407-07///unique_patient_id: TCGA-13-0910"
"TCGA.13.0911"	"TCGA-13-0911-01A-01T-0407-07"	"TCGA-13-0911"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	55	"y"	"y"	"n"	842	"norecurrence"	842	"living"	NA	NA	NA	"partialresponse"	"optimal"	0	10	82	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8cad4217-5699-4735-9be3-fc0015a8d262///days_to_birth: -20276///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 911///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 18191146-bbb5-4110-af84-0c6698d2afc0///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 842///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 278///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0911-01A-01T-0407-07///unique_patient_id: TCGA-13-0911"
"TCGA.13.0912"	"TCGA-13-0912-01A-01T-0407-07"	"TCGA-13-0912"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	468	"recurrence"	1036	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	5	4	90	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 58d34254-4f5b-40a4-9e9f-7160062fb2a4///days_to_birth: -21427///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 912///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8236ba4d-8089-40c1-93ae-156ca8543db8///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1036///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 468///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0912-01A-01T-0407-07///unique_patient_id: TCGA-13-0912"
"TCGA.13.0916"	"TCGA-13-0916-01A-01T-0407-07"	"TCGA-13-0916"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	49	"y"	"y"	"n"	643	"norecurrence"	643	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5f60bc2d-738f-43fc-a3fb-61ec6e80e3d4///days_to_birth: -18189///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 916///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e104764b-efb0-4872-8f3f-d164a3d89d09///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 643///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0916-01A-01T-0407-07///unique_patient_id: TCGA-13-0916"
"TCGA.13.0919"	"TCGA-13-0919-01A-01T-0407-07"	"TCGA-13-0919"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	52	"y"	"y"	"n"	453	"norecurrence"	453	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	35	65	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 45957be6-e4df-4245-acf8-39dfc118ee19///days_to_birth: -19337///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 919///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f48b87bd-e3fb-4c13-a59d-3aba2fbf2585///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 453///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0919-01A-01T-0407-07///unique_patient_id: TCGA-13-0919"
"TCGA.13.0920"	"TCGA-13-0920-01A-01T-0407-07"	"TCGA-13-0920"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"n"	"n"	297	"recurrence"	420	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 85a85a11-7200-4e96-97af-6ba26d680d59///days_to_birth: -24063///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 920///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7520c61e-b168-410f-9eeb-cda2deaed2a7///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 420///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 297///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0920-01A-01T-0407-07///unique_patient_id: TCGA-13-0920"
"TCGA.13.0921"	"TCGA-13-0921-01A-01T-0407-07"	"TCGA-13-0921"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	72	"y"	"y"	"n"	141	"norecurrence"	141	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 72///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 31b997dd-aaea-4003-a64d-11d3e19b0bbc///days_to_birth: -26606///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 921///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: cf7eb88e-6c76-400b-8ad2-7e85d16f6fcc///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 141///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0921-01A-01T-0407-07///unique_patient_id: TCGA-13-0921"
"TCGA.13.0923"	"TCGA-13-0923-01A-01T-0407-07"	"TCGA-13-0923"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"y"	"y"	"n"	195	"norecurrence"	195	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	18	78	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Right///bcr_patient_uuid: 378f7ea2-86b4-4072-80b8-e12d67193106///days_to_birth: -27080///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 923///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 490be56a-1798-44b3-9506-10b9657852fa///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 195///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0923-01A-01T-0407-07///unique_patient_id: TCGA-13-0923"
"TCGA.13.0924"	"TCGA-13-0924-01A-01T-0407-07"	"TCGA-13-0924"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	45	"y"	"y"	"n"	185	"norecurrence"	185	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: fbb45305-de8d-4baf-8bd0-047b29c2e9d9///days_to_birth: -16670///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 924///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fae23792-aeda-4037-82cf-b8d048036938///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 185///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0924-01A-01T-0407-07///unique_patient_id: TCGA-13-0924"
"TCGA.13.1403"	"TCGA-13-1403-01A-01T-0455-07"	"TCGA-13-1403"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	48	"y"	"y"	"n"	331	"norecurrence"	331	"living"	NA	NA	NA	"completeresponse"	NA	0	8	90	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0d5e232d-5aa2-4f6f-be58-ffd5f15ee0b8///days_to_birth: -17697///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1403///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1b8ebf1f-79f6-4198-ad79-00cec38ef301///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 331///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1403-01A-01T-0455-07///unique_patient_id: TCGA-13-1403"
"TCGA.13.1404"	"TCGA-13-1404-01A-01T-0455-07"	"TCGA-13-1404"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	48	"y"	"y"	"n"	201	"norecurrence"	201	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	20	77	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 8e107f4b-1912-4d3e-814a-b863e2d65ed7///days_to_birth: -17783///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1404///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b605a929-f33e-4bfa-98c1-3bd3d2ce980a///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 201///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1404-01A-01T-0455-07///unique_patient_id: TCGA-13-1404"
"TCGA.13.1405"	"TCGA-13-1405-01A-01T-0455-07"	"TCGA-13-1405"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	49	"y"	"y"	"n"	224	"norecurrence"	224	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	15	84	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: NA///bcr_patient_uuid: 29dccd25-4c4a-463b-a353-38a193337f38///days_to_birth: -18218///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1405///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 94feaf68-9597-4648-bc84-fe7e67afc7c7///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 224///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1405-01A-01T-0455-07///unique_patient_id: TCGA-13-1405"
"TCGA.13.1407"	"TCGA-13-1407-01A-01T-0455-07"	"TCGA-13-1407"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	"y"	"y"	"n"	184	"norecurrence"	184	"living"	NA	NA	NA	"completeresponse"	NA	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: NA///bcr_patient_uuid: f2dcf4cc-609d-4532-a90d-6ae2bbb53365///days_to_birth: -18895///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1407///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 019f9660-f6a5-40c5-a156-998044af77a1///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 184///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1407-01A-01T-0455-07///unique_patient_id: TCGA-13-1407"
"TCGA.13.1408"	"TCGA-13-1408-01A-01T-0455-07"	"TCGA-13-1408"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	59	"y"	"y"	"n"	180	"norecurrence"	180	"living"	NA	NA	NA	"partialresponse"	"suboptimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: NA///bcr_patient_uuid: 8fac8e40-beac-4059-9d54-7ee530598cfd///days_to_birth: -21635///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1408///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b5ebd8fe-77ce-48fc-b3de-f0ac628225e4///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 180///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1408-01A-01T-0455-07///unique_patient_id: TCGA-13-1408"
"TCGA.13.1409"	"TCGA-13-1409-01A-01T-0455-07"	"TCGA-13-1409"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	"y"	"y"	"n"	208	"norecurrence"	208	"living"	NA	NA	NA	NA	"optimal"	0	15	80	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: NA///bcr_patient_uuid: 18e0e996-8f23-4f53-94a5-dde38b550863///days_to_birth: -26835///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1409///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 581da1f9-2a0c-42d4-953b-7a311eeacbb6///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 208///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1409-01A-01T-0455-07///unique_patient_id: TCGA-13-1409"
"TCGA.13.1410"	"TCGA-13-1410-01A-01T-0455-07"	"TCGA-13-1410"	"tumor"	"ser"	"ov"	NA	NA	"late"	4	NA	NA	57	"y"	"y"	"n"	143	"norecurrence"	143	"living"	NA	NA	NA	"completeresponse"	NA	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: NA///bcr_patient_uuid: c3f9ee36-d34f-472b-ac7f-801a0d400aa4///days_to_birth: -20950///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 1410///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 498f0f25-c651-48d1-a28a-371ba22a446d///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 143///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1410-01A-01T-0455-07///unique_patient_id: TCGA-13-1410"
"TCGA.13.1411"	"TCGA-13-1411-01A-01T-0455-07"	"TCGA-13-1411"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	81	"y"	"y"	"n"	128	"norecurrence"	128	"living"	NA	NA	NA	"partialresponse"	"suboptimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 81///anatomic_organ_subdivision: NA///bcr_patient_uuid: a9d3a7b0-faf8-4e56-8600-d9e6882a4f23///days_to_birth: -29873///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1411///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: aea78ebe-c26b-47e2-a50f-000c9e792fa0///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 128///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1411-01A-01T-0455-07///unique_patient_id: TCGA-13-1411"
"TCGA.13.1412"	"TCGA-13-1412-01A-01T-0455-07"	"TCGA-13-1412"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	41	"y"	"y"	"n"	162	"norecurrence"	162	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 41///anatomic_organ_subdivision: NA///bcr_patient_uuid: 44493c23-82e9-4d9f-8e3c-7b3f9ae44970///days_to_birth: -15119///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1412///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a831a5dd-ab90-4720-9a9d-91228986100a///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 162///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1412-01A-01T-0455-07///unique_patient_id: TCGA-13-1412"
"TCGA.13.1477"	"TCGA-13-1477-01A-01T-0480-07"	"TCGA-13-1477"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	49	"y"	"y"	"n"	NA	"recurrence"	1661	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"optimal"	0	18	80	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 13f5814c-1f99-4ffa-84a4-3bbd8979faae///days_to_birth: -18111///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1477///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 15ee294f-4702-4ca4-a8b5-3926ef50fb20///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1661///days_to_last_followup: 1661///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 234///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1477-01A-01T-0480-07///unique_patient_id: TCGA-13-1477"
"TCGA.13.1481"	"TCGA-13-1481-01A-01T-0480-07"	"TCGA-13-1481"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	76	"y"	"y"	"n"	2648	"norecurrence"	2648	"deceased"	NA	NA	NA	"completeresponse"	"optimal"	0	28	70	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: Right///bcr_patient_uuid: c5355491-e1e8-46a4-a05e-bafcaf2e7459///days_to_birth: -27898///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1481///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ad6484b6-fb62-4ffe-a5f7-0728b7654d8e///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2648///days_to_last_followup: 2648///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1481-01A-01T-0480-07///unique_patient_id: TCGA-13-1481"
"TCGA.13.1482"	"TCGA-13-1482-01A-01T-0480-07"	"TCGA-13-1482"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	52	"y"	"y"	"n"	602	"recurrence"	1877	"deceased"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	18	82	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: NA///bcr_patient_uuid: f3af727e-b592-4828-94f5-22008666cf8c///days_to_birth: -19177///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1482///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6827f11a-2b5c-4f30-9223-474c514708e6///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1877///days_to_last_followup: 1877///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 602///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1482-01A-01T-0480-07///unique_patient_id: TCGA-13-1482"
"TCGA.13.1483"	"TCGA-13-1483-01A-01T-0480-07"	"TCGA-13-1483"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	"y"	"y"	"n"	894	"norecurrence"	894	"deceased"	NA	NA	NA	"partialresponse"	"suboptimal"	0	42	50	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: NA///bcr_patient_uuid: 611600a6-43ec-4029-9682-cd6d6a3312ec///days_to_birth: -22342///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1483///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0d764ff1-764e-47b7-9bf2-dfd722372daa///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 894///days_to_last_followup: 894///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 296///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1483-01A-01T-0480-07///unique_patient_id: TCGA-13-1483"
"TCGA.13.1484"	"TCGA-13-1484-01A-01T-0480-07"	"TCGA-13-1484"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	62	"y"	"y"	"n"	496	"recurrence"	2982	"living"	NA	NA	"metastasis"	"completeresponse"	NA	0	4	95	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: NA///bcr_patient_uuid: ead71c90-cc5e-42ce-8754-c3cf15a41134///days_to_birth: -22698///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1484///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 30eccca8-a390-4c88-bffa-de7070c2fed6///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2982///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 496///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1484-01A-01T-0480-07///unique_patient_id: TCGA-13-1484"
"TCGA.13.1485"	"TCGA-13-1485-01A-02T-0480-07"	"TCGA-13-1485"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	48	"y"	"y"	"n"	NA	"recurrence"	629	"deceased"	NA	NA	"metastasis"	"partialresponse"	"optimal"	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 49bfd0fe-48ce-49db-9f76-ce2310410950///days_to_birth: -17641///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1485///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c541cbcc-09ee-4152-b710-60d9f09f384d///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 629///days_to_last_followup: 629///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 170///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1485-01A-02T-0480-07///unique_patient_id: TCGA-13-1485"
"TCGA.13.1487"	"TCGA-13-1487-01A-01T-0480-07"	"TCGA-13-1487"	"tumor"	"ser"	"ov"	NA	NA	"late"	4	NA	NA	74	"y"	"y"	"n"	412	"recurrence"	681	"deceased"	NA	NA	"metastasis"	"completeresponse"	NA	0	22	75	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: NA///bcr_patient_uuid: c9e28934-8379-4511-817c-d787f2c4ca3a///days_to_birth: -27176///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 1487///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 07b2d67b-3f42-45db-8fc3-334fad4ceaee///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 681///days_to_last_followup: 681///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 412///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1487-01A-01T-0480-07///unique_patient_id: TCGA-13-1487"
"TCGA.13.1488"	"TCGA-13-1488-01A-01T-0480-07"	"TCGA-13-1488"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	59	"y"	"y"	"n"	351	"recurrence"	2154	"deceased"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	0	22	75	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a85f6f9c-1e1d-44fc-85eb-3b2d96cfbc61///days_to_birth: -21726///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1488///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f8cc6ee8-0004-4c4c-9d2e-38888cd6c5c4///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2154///days_to_last_followup: 2154///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 351///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan; Molecular marker Ca 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1488-01A-01T-0480-07///unique_patient_id: TCGA-13-1488"
"TCGA.13.1491"	"TCGA-13-1491-01A-01T-0480-07"	"TCGA-13-1491"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	"y"	"y"	"n"	508	"recurrence"	1595	"deceased"	NA	NA	"metastasis"	"partialresponse"	NA	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c8febeef-8e7e-459e-88cb-8086692dc559///days_to_birth: -20261///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1491///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 89c0fc41-0c77-4699-b8f9-44ca68ef7c2a///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1298///days_to_death: 1595///days_to_last_followup: 1595///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 508///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1491-01A-01T-0480-07///unique_patient_id: TCGA-13-1491"
"TCGA.13.1492"	"TCGA-13-1492-01A-01T-0480-07"	"TCGA-13-1492"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"y"	"y"	"n"	2237	"norecurrence"	2237	"living"	NA	NA	NA	"completeresponse"	NA	0	1	94	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: NA///bcr_patient_uuid: 63c6a89b-b28c-434a-a632-5de6545db731///days_to_birth: -24331///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1492///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 62de4389-6bb4-42ff-84a9-3ab406e99c05///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2237///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1492-01A-01T-0480-07///unique_patient_id: TCGA-13-1492"
"TCGA.13.1494"	"TCGA-13-1494-01A-01T-0480-07"	"TCGA-13-1494"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	43	"y"	"y"	"n"	693	"recurrence"	1161	"living"	NA	NA	"metastasis"	"completeresponse"	NA	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f50ee039-1da9-43d9-ac01-657ec77a7f32///days_to_birth: -15993///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1494///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 0ddc7119-70bd-4d8b-985a-0fbe4758e999///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 767///days_to_death: NA///days_to_last_followup: 1161///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 693///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1494-01A-01T-0480-07///unique_patient_id: TCGA-13-1494"
"TCGA.13.1495"	"TCGA-13-1495-01A-01T-0480-07"	"TCGA-13-1495"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	60	"y"	"y"	"n"	977	"recurrence"	1497	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	20	79	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 74dcdfb4-a637-4111-9a22-4b4bc7bbc8f7///days_to_birth: -22046///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1495///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: ff28eb04-b270-4a74-9b59-fcdc531eaeaf///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: 984///days_to_additional_surgery_metastatic_procedure: 984///days_to_death: NA///days_to_last_followup: 1497///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 977///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1495-01A-01T-0480-07///unique_patient_id: TCGA-13-1495"
"TCGA.13.1496"	"TCGA-13-1496-01A-01T-0480-07"	"TCGA-13-1496"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"y"	"n"	129	"norecurrence"	129	"deceased"	NA	NA	NA	NA	"suboptimal"	0	1	94	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e5a329ec-e50e-4786-901d-b58474f8ea65///days_to_birth: -23992///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1496///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8df03585-7754-4f4b-a868-bfb88530f053///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 129///days_to_last_followup: 129///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1496-01A-01T-0480-07///unique_patient_id: TCGA-13-1496"
"TCGA.13.1497"	"TCGA-13-1497-01A-01T-0480-07"	"TCGA-13-1497"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	47	"y"	"y"	"n"	813	"recurrence"	1652	"living"	NA	NA	"metastasis"	"completeresponse"	NA	0	5	82	NA	"age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: NA///bcr_patient_uuid: bc4bc342-20bf-40c3-af26-2c6f942da93d///days_to_birth: -17528///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1497///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: d8a1710d-bba3-4b22-9c76-124568b7b543///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 861///days_to_death: NA///days_to_last_followup: 1652///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 813///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1497-01A-01T-0480-07///unique_patient_id: TCGA-13-1497"
"TCGA.13.1498"	"TCGA-13-1498-01A-01T-0480-07"	"TCGA-13-1498"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	"y"	"y"	"n"	NA	"recurrence"	1144	"living"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	8	87	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: NA///bcr_patient_uuid: 56a30462-2819-4c18-95be-8e73880a4921///days_to_birth: -26820///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1498///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9bef7216-b734-4d71-b19d-86c2b34ba46e///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1144///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 533///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and PET scans; Molecular Marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1498-01A-01T-0480-07///unique_patient_id: TCGA-13-1498"
"TCGA.13.1499"	"TCGA-13-1499-01A-01T-0480-07"	"TCGA-13-1499"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	56	"y"	"y"	"n"	582	"recurrence"	1167	"living"	NA	NA	"metastasis"	"completeresponse"	NA	0	20	77	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: NA///bcr_patient_uuid: b25570ed-baca-4e3f-87c6-2ef18119ba49///days_to_birth: -20668///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1499///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 23f13a5e-8099-432a-a6a2-a3e2d887b8ba///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: 594///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1167///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 582///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1499-01A-01T-0480-07///unique_patient_id: TCGA-13-1499"
"TCGA.13.1500"	"TCGA-13-1500-01A-01T-0480-07"	"TCGA-13-1500"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	425	"norecurrence"	425	"deceased"	NA	NA	NA	"partialresponse"	"suboptimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a285786d-120e-4c88-b48b-8111f4413988///days_to_birth: -26172///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1500///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4ea742f9-e3d0-493b-bf36-ce751235de74///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 425///days_to_last_followup: 425///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 253///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-1500-01A-01T-0480-07///unique_patient_id: TCGA-13-1500"
"TCGA.13.1501"	"TCGA-13-1501-01A-01T-0480-07"	"TCGA-13-1501"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	50	"y"	"y"	"n"	NA	"recurrence"	999	"living"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 561968ce-da9a-4d69-8bc2-bc87b9550f93///days_to_birth: -18392///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1501///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 567ddcdb-f843-4f51-81bc-9074b6b2c0a8///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 999///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 392///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan and Molecular marker CA-125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1501-01A-01T-0480-07///unique_patient_id: TCGA-13-1501"
"TCGA.13.1504"	"TCGA-13-1504-01A-01T-0480-07"	"TCGA-13-1504"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	68	"y"	"y"	"n"	504	"norecurrence"	504	"living"	NA	NA	NA	"completeresponse"	NA	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cd49126a-ec15-43fa-9e43-3f7460d43f2b///days_to_birth: -25008///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1504///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7c17b972-4f30-4f6f-8771-949a26381448///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 504///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1504-01A-01T-0480-07///unique_patient_id: TCGA-13-1504"
"TCGA.13.1505"	"TCGA-13-1505-01A-01T-0480-07"	"TCGA-13-1505"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"y"	"n"	128	"norecurrence"	128	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	15	85	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 914f84bf-578b-4f4d-93cb-378228ea58f6///days_to_birth: -23238///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1505///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e5c8ba1b-3e68-4637-acf7-695582f4474b///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 128///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1505-01A-01T-0480-07///unique_patient_id: TCGA-13-1505"
"TCGA.13.1506"	"TCGA-13-1506-01A-01T-0480-07"	"TCGA-13-1506"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	45	"y"	"n"	"n"	134	"norecurrence"	134	"living"	NA	NA	NA	"completeresponse"	NA	0	1	98	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1cc02c64-a34e-46ae-9bc7-5d50f2fefb31///days_to_birth: -16733///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1506///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c38894f1-b486-48fd-acc2-f53027cb3ffa///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 134///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1506-01A-01T-0480-07///unique_patient_id: TCGA-13-1506"
"TCGA.13.1507"	"TCGA-13-1507-01A-01T-0480-07"	"TCGA-13-1507"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	77	"y"	"y"	"n"	145	"norecurrence"	145	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	5	90	NA	"age_at_initial_pathologic_diagnosis: 77///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 502e8d02-2953-4514-a2e1-6179dd94da73///days_to_birth: -28444///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1507///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 211ff326-c0af-4317-8b10-c19cc527b139///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 145///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1507-01A-01T-0480-07///unique_patient_id: TCGA-13-1507"
"TCGA.13.1509"	"TCGA-13-1509-01A-01T-0480-07"	"TCGA-13-1509"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	64	"y"	"y"	"n"	126	"norecurrence"	126	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	85	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: fe402983-70da-44db-b7b1-c32702ddde26///days_to_birth: -23481///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1509///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 770c3446-50ed-4950-b822-5710cfea1b64///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 126///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 40///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1509-01A-01T-0480-07///unique_patient_id: TCGA-13-1509"
"TCGA.13.1510"	"TCGA-13-1510-01A-02T-0480-07"	"TCGA-13-1510"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	62	"y"	"y"	"n"	78	"norecurrence"	78	"living"	NA	NA	NA	NA	"optimal"	0	5	75	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: Left///bcr_patient_uuid: dac96910-0cb2-44ea-b108-2d6d51b07112///days_to_birth: -22708///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1510///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d8c042c4-cd72-4511-b639-9c2e3d05248c///chemo_therapy: NA///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 78///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1510-01A-02T-0480-07///unique_patient_id: TCGA-13-1510"
"TCGA.13.1511"	"TCGA-13-1511-01A-01T-0480-07"	"TCGA-13-1511"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	52	"y"	"n"	"n"	118	"norecurrence"	118	"living"	NA	NA	NA	"partialresponse"	"suboptimal"	0	5	90	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 756f6768-e69a-4fe9-aa41-7c58aabe4577///days_to_birth: -19258///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1511///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4b9ab047-2f5e-4454-8f69-f40a45d563cf///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 118///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1511-01A-01T-0480-07///unique_patient_id: TCGA-13-1511"
"TCGA.13.1512"	"TCGA-13-1512-01A-01T-0480-07"	"TCGA-13-1512"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	49	"y"	"y"	"n"	94	"norecurrence"	94	"living"	NA	NA	NA	NA	"optimal"	0	1	92	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 82093ed9-a3c8-4e34-931f-4ec7ae745711///days_to_birth: -18134///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1512///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 440d2b6f-c84d-4658-b921-7d114ea5c138///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 94///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1512-01A-01T-0480-07///unique_patient_id: TCGA-13-1512"
"TCGA.13.2057"	"TCGA-13-2057-01A-02T-1051-07"	"TCGA-13-2057"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	59	"y"	"y"	"n"	433	"norecurrence"	433	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	50	50	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 56c4bd48-ab15-4b49-ae2f-968653052b50///days_to_birth: -21554///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2057///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 23aa1dcb-47f5-4846-9390-de68cc075309///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 433///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-13-2057-01A-02T-1051-07///unique_patient_id: TCGA-13-2057"
"TCGA.13.2059"	"TCGA-13-2059-01A-01T-1051-07"	"TCGA-13-2059"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	372	"norecurrence"	372	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f4b56568-a74a-4a2e-89d9-11722ecf5948///days_to_birth: -18449///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2059///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c56f861f-aa37-426d-968e-651e12e8c707///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 372///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-13-2059-01A-01T-1051-07///unique_patient_id: TCGA-13-2059"
"TCGA.13.2060"	"TCGA-13-2060-01A-01T-0712-07"	"TCGA-13-2060"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	51	"y"	"y"	"n"	261	"norecurrence"	261	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	85	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 196f4600-b6c9-4652-9f77-65c92883f8c1///days_to_birth: -18635///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2060///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 970fa6e8-453c-4cff-b1e0-f5cadfc60973///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 261///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 12///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-2060-01A-01T-0712-07///unique_patient_id: TCGA-13-2060"
"TCGA.13.2061"	"TCGA-13-2061-01A-01T-1051-07"	"TCGA-13-2061"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	328	"norecurrence"	328	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	86	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a22c1451-7841-4fa3-b2f2-5d5cd8aa67d3///days_to_birth: -21543///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2061///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ee9b0f94-0f32-4777-ba2e-56f6abd2c7bb///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 328///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-13-2061-01A-01T-1051-07///unique_patient_id: TCGA-13-2061"
"TCGA.13.2065"	"TCGA-13-2065-01A-01T-1051-07"	"TCGA-13-2065"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	266	"norecurrence"	266	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	35	65	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8d1dcf21-efd3-4fbe-ad44-f43a19239383///days_to_birth: -25972///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2065///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 85387f59-4a1c-40e5-b5fb-1c151e51ee15///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 266///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-13-2065-01A-01T-1051-07///unique_patient_id: TCGA-13-2065"
"TCGA.13.2066"	"TCGA-13-2066-01A-01T-1051-07"	"TCGA-13-2066"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	49	"y"	"y"	"n"	295	"norecurrence"	295	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	5	90	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: bcb87812-94e3-4dc0-867e-d049b44a2690///days_to_birth: -18170///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2066///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: da230e2d-a08b-4cf3-8411-47128770411c///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 295///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-13-2066-01A-01T-1051-07///unique_patient_id: TCGA-13-2066"
"TCGA.13.2071"	"TCGA-13-2071-01A-02T-1051-07"	"TCGA-13-2071"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	63	"y"	"y"	"n"	191	"norecurrence"	191	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	12	88	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0d15e5aa-2483-4f81-973a-ff469296c911///days_to_birth: -23367///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2071///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 557458c9-a795-4c0c-bd75-106debd147c0///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 191///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-13-2071-01A-02T-1051-07///unique_patient_id: TCGA-13-2071"
"TCGA.20.0987"	"TCGA-20-0987-01A-02T-0438-07"	"TCGA-20-0987"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	"y"	"y"	"n"	442	"recurrence"	701	"deceased"	NA	NA	"locoregional"	NA	"optimal"	16	1	72	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: NA///bcr_patient_uuid: 34f285ab-6c31-4865-a0a7-a57af3567df0///days_to_birth: -22287///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 987///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2c19c195-d623-46e6-9244-dbd3d124989d///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 701///days_to_last_followup: 701///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 442///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study, Molecular marker-CA 125-137///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-20-0987-01A-02T-0438-07///unique_patient_id: TCGA-20-0987"
"TCGA.20.0990"	"TCGA-20-0990-01A-01T-0438-07"	"TCGA-20-0990"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"y"	"y"	"n"	870	"recurrence"	789	"living"	NA	NA	"locoregional"	NA	NA	12	2	84	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: NA///bcr_patient_uuid: c9524775-6b50-4793-8858-24b6a6d3e4e6///days_to_birth: -27170///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 990///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c08304fa-042d-4a64-a8c1-165686740dd1///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 789///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 870///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-0990-01A-01T-0438-07///unique_patient_id: TCGA-20-0990"
"TCGA.20.0991"	"TCGA-20-0991-01A-01T-0438-07"	"TCGA-20-0991"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"b"	3	78	"y"	"n"	"n"	797	"norecurrence"	797	"living"	NA	NA	NA	"completeresponse"	"optimal"	2	0	94	NA	"age_at_initial_pathologic_diagnosis: 78///anatomic_organ_subdivision: NA///bcr_patient_uuid: 36595b52-2b5f-4e87-80eb-37c29109e92a///days_to_birth: -28694///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 991///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 974f709b-2b9a-4a59-86a5-15974cdd107b///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 797///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-0991-01A-01T-0438-07///unique_patient_id: TCGA-20-0991"
"TCGA.20.1682"	"TCGA-20-1682-01A-01T-0567-07"	"TCGA-20-1682"	"tumor"	"ser"	"ov"	NA	NA	"late"	3	"c"	NA	56	"y"	"y"	"n"	836	"norecurrence"	836	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	0	26	72	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 94bd4c68-4bfc-4db3-9365-97c867747133///days_to_birth: -20583///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: GX///patient_id: 1682///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: c82c3d5f-bdba-4a46-bfd1-92e930c8674b///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 836///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-1682-01A-01T-0567-07///unique_patient_id: TCGA-20-1682"
"TCGA.20.1683"	"TCGA-20-1683-01A-01T-0567-07"	"TCGA-20-1683"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"y"	"n"	618	"recurrence"	772	"living"	NA	NA	"locoregional"	"stabledisease"	"optimal"	0	25	68	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Right///bcr_patient_uuid: ac2e88ff-8b1e-4691-9a96-5a581f98d827///days_to_birth: -24006///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1683///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: bbb59b9b-39a7-4e23-89cd-1c5b0514362a///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 772///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 618///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-1683-01A-01T-0567-07///unique_patient_id: TCGA-20-1683"
"TCGA.20.1684"	"TCGA-20-1684-01A-01T-0567-07"	"TCGA-20-1684"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	"y"	"y"	"n"	580	"norecurrence"	580	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	19	78	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 94030805-8beb-441a-af73-11a80768edb5///days_to_birth: -18755///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1684///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: c1f2eb5c-51d5-469f-9319-30cfcaec69e4///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 580///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-1684-01A-01T-0567-07///unique_patient_id: TCGA-20-1684"
"TCGA.20.1685"	"TCGA-20-1685-01A-01T-0567-07"	"TCGA-20-1685"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	45	"y"	"y"	"n"	507	"norecurrence"	507	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	14	85	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cbc5b936-ead5-4858-ab90-e639402789b0///days_to_birth: -16745///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1685///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f74f942b-3336-4eab-b6f5-96ea2715a52e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 507///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-1685-01A-01T-0567-07///unique_patient_id: TCGA-20-1685"
"TCGA.20.1686"	"TCGA-20-1686-01A-01T-0567-07"	"TCGA-20-1686"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	75	"y"	"y"	"n"	89	"norecurrence"	89	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	32	68	NA	"age_at_initial_pathologic_diagnosis: 75///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f007fa7a-7da9-4cb0-8aea-623af1a122c5///days_to_birth: -27587///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1686///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: e8bfa672-1402-4260-a0e1-041491db061c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 89///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-1686-01A-01T-0567-07///unique_patient_id: TCGA-20-1686"
"TCGA.20.1687"	"TCGA-20-1687-01A-01T-0567-07"	"TCGA-20-1687"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	46	"y"	"y"	"n"	81	"norecurrence"	81	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9bf16a89-2fc7-4c08-93bc-3105eec5c3cc///days_to_birth: -16960///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1687///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f16936bd-4107-4e50-bcd0-da8f76ba03eb///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 81///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-1687-01A-01T-0567-07///unique_patient_id: TCGA-20-1687"
"TCGA.23.1021"	"TCGA-23-1021-01B-01T-0438-07"	"TCGA-23-1021"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	45	"y"	"y"	"n"	1446	"norecurrence"	1446	"deceased"	NA	NA	NA	"partialresponse"	"suboptimal"	0	0	NA	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: NA///bcr_patient_uuid: b923ac70-70ea-4a82-8466-46350c5803bf///days_to_birth: -16483///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1021///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: deff0c2e-9b3e-4181-97d6-13ddfc9f115a///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: 1181///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1446///days_to_last_followup: 1446///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1021-01B-01T-0438-07///unique_patient_id: TCGA-23-1021"
"TCGA.23.1022"	"TCGA-23-1022-01A-01T-0438-07"	"TCGA-23-1022"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"y"	"y"	"n"	450	"recurrence"	1511	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	7	8	85	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: NA///bcr_patient_uuid: d0673efd-3315-4dd5-8ab6-912bfa07dceb///days_to_birth: -24798///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1022///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b55a527b-1275-4988-9dd9-7451a0b6a70c///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1511///days_to_last_followup: 1293///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 450///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1022-01A-01T-0438-07///unique_patient_id: TCGA-23-1022"
"TCGA.23.1023"	"TCGA-23-1023-01R-01T-0811-07"	"TCGA-23-1023"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"y"	"n"	490	"recurrence"	1233	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: NA///bcr_patient_uuid: 9e18238f-ae85-4b75-ae87-d92da9731a40///days_to_birth: -23825///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1023///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a457d6c8-d9cb-4d35-8e5c-54d0ef69de98///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: 1209///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1233///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 490///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: YES///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Colonoscopy///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1023-01R-01T-0811-07///unique_patient_id: TCGA-23-1023"
"TCGA.23.1024"	"TCGA-23-1024-01A-02T-0438-07"	"TCGA-23-1024"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	52	"y"	"y"	"n"	468	"norecurrence"	468	"living"	NA	NA	NA	"completeresponse"	"optimal"	8	5	88	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: NA///bcr_patient_uuid: 8ac6ce06-ab50-4ab4-a469-9f8bf01be963///days_to_birth: -19051///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1024///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 3e1241b4-c16c-4299-b793-b22309184b85///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 468///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1024-01A-02T-0438-07///unique_patient_id: TCGA-23-1024"
"TCGA.23.1026"	"TCGA-23-1026-01B-01T-0438-07"	"TCGA-23-1026"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	45	"y"	"y"	"n"	797	"recurrence"	816	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: NA///bcr_patient_uuid: c6ede8ae-881c-47a0-a0ef-745ed4b7764a///days_to_birth: -16442///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1026///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: adc0c0f8-0f93-40af-862a-f2efc4dd6cf1///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: 816///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 816///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 797///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1026-01B-01T-0438-07///unique_patient_id: TCGA-23-1026"
"TCGA.23.1027"	"TCGA-23-1027-01A-02T-0438-07"	"TCGA-23-1027"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	48	"y"	"y"	"n"	965	"norecurrence"	975	"deceased"	NA	NA	NA	"progressivedisease"	"optimal"	5	8	88	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: c9e58844-9d61-44a2-aee6-1760bc19711b///days_to_birth: -17588///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1027///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 517a109a-a6a8-4855-837c-b8d6a48412d3///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 975///days_to_last_followup: 965///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 114///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1027-01A-02T-0438-07///unique_patient_id: TCGA-23-1027"
"TCGA.23.1028"	"TCGA-23-1028-01A-01T-0438-07"	"TCGA-23-1028"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	43	"y"	"y"	"n"	133	"recurrence"	1503	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	12	10	72	NA	"age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: NA///bcr_patient_uuid: df53c3c0-3605-4d2b-bdc7-96d9beab27ea///days_to_birth: -16018///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1028///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 775ea41c-8d7e-4dd1-af91-41ee25e480d1///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1503///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 133///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1028-01A-01T-0438-07///unique_patient_id: TCGA-23-1028"
"TCGA.23.1029"	"TCGA-23-1029-01B-01T-0585-07"	"TCGA-23-1029"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	46	"y"	"y"	"n"	268	"norecurrence"	268	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	20	78	NA	"age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Right///bcr_patient_uuid: 4d71dd15-cd01-4dae-ad70-6dc325140207///days_to_birth: -16889///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1029///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: b21097d0-d714-4e0c-a8b9-fecac7ce4111///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 268///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1029-01B-01T-0585-07///unique_patient_id: TCGA-23-1029"
"TCGA.23.1030"	"TCGA-23-1030-01A-02T-0438-07"	"TCGA-23-1030"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	64	"y"	"y"	"n"	543	"recurrence"	885	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	5	2	90	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: NA///bcr_patient_uuid: cbcf6922-a3c0-43a1-826e-642918b0a635///days_to_birth: -23416///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1030///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: b97fdad8-b975-4f01-a9ac-cbedb5e7a9b6///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 885///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 543///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1030-01A-02T-0438-07///unique_patient_id: TCGA-23-1030"
"TCGA.23.1031"	"TCGA-23-1031-01A-01T-0438-07"	"TCGA-23-1031"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	60	"y"	"y"	"n"	574	"norecurrence"	574	"deceased"	NA	NA	NA	"partialresponse"	"optimal"	8	5	80	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: NA///bcr_patient_uuid: c7c3fe4a-327a-4b7e-a259-989b72971209///days_to_birth: -22225///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1031///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2c5cf608-bf49-4d20-9963-e592a4b39096///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 574///days_to_last_followup: 574///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1031-01A-01T-0438-07///unique_patient_id: TCGA-23-1031"
"TCGA.23.1032"	"TCGA-23-1032-01A-02T-0438-07"	"TCGA-23-1032"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	73	NA	NA	NA	68	"norecurrence"	84	"deceased"	NA	NA	NA	NA	"optimal"	15	5	72	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: NA///bcr_patient_uuid: d1976840-35f7-4423-8458-12fb32a52b33///days_to_birth: -26715///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1032///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 22b559e9-5e92-444d-93ca-0d357461bd74///chemo_therapy: NO///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 84///days_to_last_followup: 68///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1032-01A-02T-0438-07///unique_patient_id: TCGA-23-1032"
"TCGA.23.1107"	"TCGA-23-1107-01A-01T-0438-07"	"TCGA-23-1107"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	59	NA	NA	NA	9	"norecurrence"	9	"deceased"	NA	NA	NA	NA	"suboptimal"	0	0	0	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: NA///bcr_patient_uuid: acb7ec56-8a47-495f-a11b-2c9fb5d8fe95///days_to_birth: -21561///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1107///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 83880442-ee2e-4ba6-a679-94c04b632568///chemo_therapy: NO///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 9///days_to_last_followup: 9///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1107-01A-01T-0438-07///unique_patient_id: TCGA-23-1107"
"TCGA.23.1109"	"TCGA-23-1109-01A-01T-0438-07"	"TCGA-23-1109"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	62	NA	NA	NA	987	"recurrence"	1562	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: NA///bcr_patient_uuid: 7c466a5f-a6b4-4d1a-a0f5-ddcd7ef90ff1///days_to_birth: -23002///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1109///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: bf98d383-003d-451a-b7fa-7986df387d5c///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 987///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1562///days_to_last_followup: 1562///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 987///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1109-01A-01T-0438-07///unique_patient_id: TCGA-23-1109"
"TCGA.23.1110"	"TCGA-23-1110-01A-01T-0438-07"	"TCGA-23-1110"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	42	"y"	"y"	"n"	326	"recurrence"	1658	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: NA///bcr_patient_uuid: 9fb1ba57-2007-4477-b000-2d36f163efd2///days_to_birth: -15383///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1110///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 412125d8-6e4b-4ece-9596-a1bb77f81e61///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1658///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 326///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CAT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1110-01A-01T-0438-07///unique_patient_id: TCGA-23-1110"
"TCGA.23.1111"	"TCGA-23-1111-01A-01T-0585-07"	"TCGA-23-1111"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"y"	"n"	98	"norecurrence"	98	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Right///bcr_patient_uuid: 6b2a9f9a-fe96-4311-a330-925c4ad36fe7///days_to_birth: -23171///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1111///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 5e8299c1-4db5-4867-afc7-db96e4f3fe68///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 98///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1111-01A-01T-0585-07///unique_patient_id: TCGA-23-1111"
"TCGA.23.1113"	"TCGA-23-1113-01A-01T-0438-07"	"TCGA-23-1113"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	48	"y"	"y"	"n"	949	"norecurrence"	949	"deceased"	NA	NA	NA	"partialresponse"	"optimal"	0	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 6209e80d-a115-4f8e-bf0d-18461401a1c6///days_to_birth: -17791///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1113///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 8f74e7a1-1849-44b8-8387-31bff5e4bfb7///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 949///days_to_last_followup: 949///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1113-01A-01T-0438-07///unique_patient_id: TCGA-23-1113"
"TCGA.23.1114"	"TCGA-23-1114-01B-01T-0567-07"	"TCGA-23-1114"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	"y"	"y"	"n"	634	"recurrence"	2089	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Left///bcr_patient_uuid: c0c3caab-9277-4a31-a96c-c607e38d5ccc///days_to_birth: -20409///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1114///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 02402e47-4ca1-4879-9d04-12415831d9c0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 634///days_to_death: 2089///days_to_last_followup: 2089///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 634///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1114-01B-01T-0567-07///unique_patient_id: TCGA-23-1114"
"TCGA.23.1116"	"TCGA-23-1116-01A-01T-0438-07"	"TCGA-23-1116"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	83	"y"	"y"	"n"	139	"norecurrence"	139	"living"	NA	NA	NA	NA	"suboptimal"	0	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 83///anatomic_organ_subdivision: NA///bcr_patient_uuid: 70fe08bd-a0b4-4a88-b82e-813b176f8e40///days_to_birth: -30463///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1116///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e5378114-5a3c-43f3-9de2-0e3a86b3c462///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 139///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1116-01A-01T-0438-07///unique_patient_id: TCGA-23-1116"
"TCGA.23.1117"	"TCGA-23-1117-01A-02T-0438-07"	"TCGA-23-1117"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	42	"y"	"n"	"n"	418	"recurrence"	1013	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: NA///bcr_patient_uuid: a88b7e66-5f12-4023-a7e2-fcfbd1f25977///days_to_birth: -15690///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1117///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7a1fbb0f-3052-4169-b736-a2ad807a71ec///chemo_therapy: NO///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 438///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1013///days_to_last_followup: 1013///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 418///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Biopsy///radiation_therapy: YES///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1117-01A-02T-0438-07///unique_patient_id: TCGA-23-1117"
"TCGA.23.1118"	"TCGA-23-1118-01A-01T-0438-07"	"TCGA-23-1118"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	45	"y"	"n"	"n"	2616	"norecurrence"	2616	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	NA	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: NA///bcr_patient_uuid: 700e91bb-d675-41b2-bbbd-935767c7b447///days_to_birth: -16470///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1118///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2c2e8996-31a2-4d40-ae52-a14131eb9684///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2616///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1118-01A-01T-0438-07///unique_patient_id: TCGA-23-1118"
"TCGA.23.1119"	"TCGA-23-1119-01A-02T-0438-07"	"TCGA-23-1119"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	64	"y"	"n"	"n"	3378	"recurrence"	3953	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	0	0	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: NA///bcr_patient_uuid: 2dfd8a0e-e642-49b3-abd7-f0334927eebb///days_to_birth: -23686///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1119///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: ad69caa2-16b6-43a8-aa18-1569f9bd7522///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 3953///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 3378///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Biopsy///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1119-01A-02T-0438-07///unique_patient_id: TCGA-23-1119"
"TCGA.23.1120"	"TCGA-23-1120-01A-02T-0438-07"	"TCGA-23-1120"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	"y"	"y"	"n"	130	"norecurrence"	130	"living"	NA	NA	NA	NA	"optimal"	0	0	0	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: NA///bcr_patient_uuid: fdf83fdf-dfbb-4306-9a1b-b4487d18b402///days_to_birth: -22147///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1120///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1f657a1b-69cb-4138-929b-aecb50c96b69///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 130///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1120-01A-02T-0438-07///unique_patient_id: TCGA-23-1120"
"TCGA.23.1121"	"TCGA-23-1121-01A-01T-0438-07"	"TCGA-23-1121"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	"y"	"y"	"n"	194	"norecurrence"	194	"living"	NA	NA	NA	NA	"suboptimal"	0	0	0	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: NA///bcr_patient_uuid: 81005bae-686a-4598-8994-49d90ebac56f///days_to_birth: -18982///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1121///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: dd6b393a-53e8-4bcd-a130-effa676d9a02///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 194///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1121-01A-01T-0438-07///unique_patient_id: TCGA-23-1121"
"TCGA.23.1122"	"TCGA-23-1122-01A-01T-0438-07"	"TCGA-23-1122"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	53	"y"	"n"	"n"	447	"recurrence"	1189	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: NA///bcr_patient_uuid: d2c0d320-d1c5-4eed-af4f-15540e60db0b///days_to_birth: -19537///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1122///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 835873b9-9590-4af3-b5ac-33688f902940///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1189///days_to_last_followup: 1189///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 447///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and MRI///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1122-01A-01T-0438-07///unique_patient_id: TCGA-23-1122"
"TCGA.23.1123"	"TCGA-23-1123-01A-01T-0438-07"	"TCGA-23-1123"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	59	"y"	"y"	"n"	1018	"norecurrence"	1018	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	0	0	0	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: NA///bcr_patient_uuid: 60cce7ac-d27d-44a6-9873-ecf91da5e906///days_to_birth: -21551///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1123///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c472da3f-a91f-41a5-b7e9-345a90ed3ada///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1018///days_to_last_followup: 1018///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1123-01A-01T-0438-07///unique_patient_id: TCGA-23-1123"
"TCGA.23.1124"	"TCGA-23-1124-01A-01T-0438-07"	"TCGA-23-1124"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	62	"y"	"y"	"n"	641	"recurrence"	1768	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	0	0	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: NA///bcr_patient_uuid: 8a6d2ce3-cc57-451b-9b07-8263782aa23f///days_to_birth: -23005///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1124///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: c90aa1d1-772f-417c-b113-a6161625f250///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1768///days_to_last_followup: 1768///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 641///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1124-01A-01T-0438-07///unique_patient_id: TCGA-23-1124"
"TCGA.23.1809"	"TCGA-23-1809-01A-01T-0567-07"	"TCGA-23-1809"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	63	"y"	"y"	"n"	16	"norecurrence"	16	"living"	NA	NA	NA	NA	"optimal"	0	20	70	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Right///bcr_patient_uuid: bc3e0b74-ea09-46a5-9f61-16bd15ffd883///days_to_birth: -23111///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1809///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 834f38af-e051-41c8-aae9-1f2ff067b02e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 16///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1809-01A-01T-0567-07///unique_patient_id: TCGA-23-1809"
"TCGA.23.2072"	"TCGA-23-2072-01A-01T-0671-07"	"TCGA-23-2072"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	58	"y"	"y"	"n"	476	"recurrence"	759	"deceased"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	0	8	90	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Right///bcr_patient_uuid: 1592af8e-8d11-4325-8a2b-e0c690b15b58///days_to_birth: -21523///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2072///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 3bba6ccf-5cb0-46d4-b223-f5e07789ada6///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 759///days_to_last_followup: 759///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 476///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-2072-01A-01T-0671-07///unique_patient_id: TCGA-23-2072"
"TCGA.23.2077"	"TCGA-23-2077-01A-01T-0671-07"	"TCGA-23-2077"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	45	"y"	"y"	"n"	1232	"recurrence"	3525	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Left///bcr_patient_uuid: ef57bc45-858f-4d4e-8407-b7eadfa43be5///days_to_birth: -16551///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2077///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f560f5c0-882a-44ba-b631-892ccda55b7e///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: 1345///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 3525///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1232///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-2077-01A-01T-0671-07///unique_patient_id: TCGA-23-2077"
"TCGA.23.2078"	"TCGA-23-2078-01A-01T-0671-07"	"TCGA-23-2078"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"y"	"y"	"n"	2661	"norecurrence"	2661	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ebe677e6-94b6-45be-a58d-eaae4cf63d12///days_to_birth: -24222///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2078///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a7bc8fe5-86cb-4da0-a383-0be6d1f16c49///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2661///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-2078-01A-01T-0671-07///unique_patient_id: TCGA-23-2078"
"TCGA.23.2079"	"TCGA-23-2079-01A-01T-0841-07"	"TCGA-23-2079"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	46	"y"	"y"	"n"	283	"recurrence"	2788	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e3ea5137-76b8-4afc-9b80-ed74714e7172///days_to_birth: -17122///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2079///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0b186b74-05f4-4e60-86de-30afe98b56e3///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: 2488///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2788///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 283///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-2079-01A-01T-0841-07///unique_patient_id: TCGA-23-2079"
"TCGA.23.2081"	"TCGA-23-2081-01A-01T-0671-07"	"TCGA-23-2081"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	49	"y"	"y"	"n"	2342	"norecurrence"	2342	"deceased"	NA	NA	NA	"progressivedisease"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 41178cbc-db73-4007-b5d8-febebf7f578d///days_to_birth: -18161///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2081///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3bed5a01-64cb-41cf-9ed8-4d91eecc4adf///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: 250///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2342///days_to_last_followup: 2342///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-2081-01A-01T-0671-07///unique_patient_id: TCGA-23-2081"
"TCGA.23.2084"	"TCGA-23-2084-01A-02T-0671-07"	"TCGA-23-2084"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	45	"y"	"y"	"n"	619	"recurrence"	1516	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	1	12	88	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Right///bcr_patient_uuid: 2cb82948-7cbe-4b6c-8414-c02f662de2d0///days_to_birth: -16493///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2084///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 64e0a5f8-5338-401d-9c5b-85d0b1c484d4///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: 627///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1516///days_to_last_followup: 1516///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 619///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker- Ca 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-2084-01A-02T-0671-07///unique_patient_id: TCGA-23-2084"
"TCGA.23.2641"	"TCGA-23-2641-01A-01T-1051-07"	"TCGA-23-2641"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	85	NA	NA	NA	84	"norecurrence"	84	"living"	NA	NA	NA	NA	"optimal"	0	8	88	NA	"age_at_initial_pathologic_diagnosis: 85///anatomic_organ_subdivision: Left///bcr_patient_uuid: 49e5ee61-a1c9-4038-84ac-92683e573a65///days_to_birth: -31231///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2641///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a0a46d22-1029-40b7-b01c-a0d2322c130b///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 84///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-2641-01A-01T-1051-07///unique_patient_id: TCGA-23-2641"
"TCGA.23.2643"	"TCGA-23-2643-01A-01T-1051-07"	"TCGA-23-2643"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"y"	"y"	"n"	143	"norecurrence"	143	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Right///bcr_patient_uuid: 5554a003-da6f-4ddf-9f05-6785987ac46c///days_to_birth: -27092///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2643///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0a29aa5b-6fa4-47e6-88bf-d5463886261d///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 143///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-2643-01A-01T-1051-07///unique_patient_id: TCGA-23-2643"
"TCGA.23.2645"	"TCGA-23-2645-01A-01T-1051-07"	"TCGA-23-2645"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	54	NA	NA	NA	137	"norecurrence"	137	"living"	NA	NA	NA	NA	"optimal"	0	18	82	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Right///bcr_patient_uuid: 66a0df9b-096b-4e8e-9b9c-54bf8637720b///days_to_birth: -19758///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2645///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 71f12d16-2ab6-4744-b46d-f2021677b3e4///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 137///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-2645-01A-01T-1051-07///unique_patient_id: TCGA-23-2645"
"TCGA.23.2647"	"TCGA-23-2647-01A-01T-1051-07"	"TCGA-23-2647"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	49	NA	NA	NA	135	"norecurrence"	135	"living"	NA	NA	NA	NA	"optimal"	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 246404ae-3bc4-4db7-aee3-0346ca3f7322///days_to_birth: -18205///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2647///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b5927514-b7c2-406a-8d24-0911d1f849ff///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 135///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-2647-01A-01T-1051-07///unique_patient_id: TCGA-23-2647"
"TCGA.23.2649"	"TCGA-23-2649-01A-01T-1051-07"	"TCGA-23-2649"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	NA	NA	NA	116	"norecurrence"	116	"living"	NA	NA	NA	NA	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Left///bcr_patient_uuid: ae5fa7cb-1984-423f-aa88-571314860943///days_to_birth: -22210///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2649///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 62d9fa88-d505-4cf2-b3f5-6512e940dba6///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 116///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-2649-01A-01T-1051-07///unique_patient_id: TCGA-23-2649"
"TCGA.24.0966"	"TCGA-24-0966-01A-01T-0407-07"	"TCGA-24-0966"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	78	"y"	"y"	"n"	232	"norecurrence"	232	"living"	NA	NA	NA	"stabledisease"	"suboptimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 78///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: fef1696c-a8f4-4db6-8615-e486522baaaa///days_to_birth: -28528///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 966///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 23c1520b-680f-4177-ab0b-e2188bbe2e81///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 232///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-0966-01A-01T-0407-07///unique_patient_id: TCGA-24-0966"
"TCGA.24.0968"	"TCGA-24-0968-01A-01T-0438-07"	"TCGA-24-0968"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	59	"y"	"y"	"n"	NA	"recurrence"	597	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	15	85	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: NA///bcr_patient_uuid: 619b14f3-b8cc-4c0a-8304-6719853d592a///days_to_birth: -21664///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 968///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f0d9fae8-b67d-4afc-b337-8433ef184f86///chemo_therapy: YES///day_of_form_completion: 10///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 597///days_to_last_followup: 597///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Chest, Pelvis, Abdominal CT; Molucular CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-0968-01A-01T-0438-07///unique_patient_id: TCGA-24-0968"
"TCGA.24.0970"	"TCGA-24-0970-01B-01T-0438-07"	"TCGA-24-0970"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"y"	"n"	280	"recurrence"	354	"deceased"	NA	NA	"locoregional"	"partialresponse"	"suboptimal"	0	0	NA	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: NA///bcr_patient_uuid: 95e58015-a7c0-4bdc-bf64-7617d24d0784///days_to_birth: -23276///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 970///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: cbaaeb30-6a61-4f76-b5fa-b61833e4fdf2///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 354///days_to_last_followup: 354///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 280///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: abdominal ct; Mollecular-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-0970-01B-01T-0438-07///unique_patient_id: TCGA-24-0970"
"TCGA.24.0975"	"TCGA-24-0975-01A-02T-0438-07"	"TCGA-24-0975"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	663	"norecurrence"	663	"deceased"	NA	NA	NA	"partialresponse"	"optimal"	0	18	80	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: NA///bcr_patient_uuid: 6a57948c-0dc5-4ea2-8043-380f26763752///days_to_birth: -21417///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 975///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: fc2f81ab-fa8a-47f3-a537-77a64d2c2bff///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 663///days_to_last_followup: 663///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: Abdominal CT; Molecular CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-0975-01A-02T-0438-07///unique_patient_id: TCGA-24-0975"
"TCGA.24.0979"	"TCGA-24-0979-01A-01T-0438-07"	"TCGA-24-0979"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	53	"y"	"y"	"n"	428	"recurrence"	1264	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	25	72	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: NA///bcr_patient_uuid: 9a30dee8-962a-49db-a85a-c39515c91b68///days_to_birth: -19594///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 979///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ebe9f336-2883-4474-a721-cb68273f0c20///chemo_therapy: YES///day_of_form_completion: 11///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1264///days_to_last_followup: 1264///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 428///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT, CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-0979-01A-01T-0438-07///unique_patient_id: TCGA-24-0979"
"TCGA.24.0980"	"TCGA-24-0980-01A-01T-0407-07"	"TCGA-24-0980"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	53	"y"	"y"	"n"	233	"norecurrence"	233	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: d1eeaca3-52c0-4a0c-916a-fd64cec911d9///days_to_birth: -19578///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 980///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 01a4cffe-47b2-431f-8a34-e56b0f5fa229///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 233///days_to_last_followup: 233///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 145///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: patient did not complete adjuvant chemo. Druing her chemo there had been interval development of multiople bilaterl nodules and a new low attentuation legion in the spleen///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-0980-01A-01T-0407-07///unique_patient_id: TCGA-24-0980"
"TCGA.24.0982"	"TCGA-24-0982-01A-01T-0438-07"	"TCGA-24-0982"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	77	"y"	"y"	"n"	152	"recurrence"	679	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 77///anatomic_organ_subdivision: NA///bcr_patient_uuid: 206ce0ed-36a4-47ab-ac8e-f6fca6ac5c18///days_to_birth: -28201///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 982///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: ac8e6667-9f37-442b-9a6e-6497824d60a9///chemo_therapy: YES///day_of_form_completion: 10///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 679///days_to_last_followup: 679///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 152///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT; Molecular CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-0982-01A-01T-0438-07///unique_patient_id: TCGA-24-0982"
"TCGA.24.1103"	"TCGA-24-1103-01A-01T-0438-07"	"TCGA-24-1103"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	677	"recurrence"	1645	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	0	0	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: NA///bcr_patient_uuid: f34aa3b6-e966-49c6-bc55-130545772c53///days_to_birth: -18583///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1103///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NA///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 37eac75a-a99b-46ea-ab5f-172ea3b9cbb4///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1645///days_to_last_followup: 1645///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 677///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CR;Mollecular-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1103-01A-01T-0438-07///unique_patient_id: TCGA-24-1103"
"TCGA.24.1104"	"TCGA-24-1104-01A-01T-0438-07"	"TCGA-24-1104"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	56	"y"	"y"	"n"	958	"recurrence"	1933	"deceased"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	NA	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: NA///bcr_patient_uuid: f9f44f86-10c7-4473-b156-5afbfa9a2ad0///days_to_birth: -20527///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1104///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e919193f-c3a5-4dc0-b6ce-3c6d7f1a727e///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1933///days_to_last_followup: 1933///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 958///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Head CT, Brain, Brainstem MR; Mollecular- CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1104-01A-01T-0438-07///unique_patient_id: TCGA-24-1104"
"TCGA.24.1105"	"TCGA-24-1105-01A-01T-0438-07"	"TCGA-24-1105"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	36	"y"	"y"	"n"	470	"recurrence"	1442	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	NA	NA	NA	NA	"age_at_initial_pathologic_diagnosis: 36///anatomic_organ_subdivision: NA///bcr_patient_uuid: 7e01f23a-0b0e-46a2-9f30-c3a9d2c779d2///days_to_birth: -13187///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1105///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: da2b0e1e-ff62-4999-aa12-32768135104d///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1442///days_to_last_followup: 1442///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 470///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1105-01A-01T-0438-07///unique_patient_id: TCGA-24-1105"
"TCGA.24.1413"	"TCGA-24-1413-01A-01T-0455-07"	"TCGA-24-1413"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	"y"	"y"	"n"	192	"norecurrence"	192	"living"	NA	NA	NA	"completeresponse"	"optimal"	30	0	55	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: NA///bcr_patient_uuid: 3fc8f799-5bd3-4f48-baf0-c458ce86ab7e///days_to_birth: -18845///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1413///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 00e61bdc-fccd-47a7-bd23-8ce0506d6b7b///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 192///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1413-01A-01T-0455-07///unique_patient_id: TCGA-24-1413"
"TCGA.24.1416"	"TCGA-24-1416-01A-01T-0480-07"	"TCGA-24-1416"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	34	"y"	"y"	"n"	194	"norecurrence"	194	"living"	NA	NA	NA	"completeresponse"	"optimal"	32	0	62	NA	"age_at_initial_pathologic_diagnosis: 34///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f9793a4b-c0e7-4475-bf80-69543b7ee2f6///days_to_birth: -12772///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1416///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: cf7ad1d4-c805-41b7-8c74-2e09210bfd7e///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 194///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1416-01A-01T-0480-07///unique_patient_id: TCGA-24-1416"
"TCGA.24.1417"	"TCGA-24-1417-01A-01T-0480-07"	"TCGA-24-1417"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	54	"y"	"y"	"n"	238	"norecurrence"	238	"living"	NA	NA	NA	"completeresponse"	"optimal"	15	0	72	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Left///bcr_patient_uuid: 48f831b0-5d91-44ae-bc4e-db57ca84fe46///days_to_birth: -19775///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1417///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6f2f5940-f189-4422-93fc-7571c6f994ba///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 238///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1417-01A-01T-0480-07///unique_patient_id: TCGA-24-1417"
"TCGA.24.1418"	"TCGA-24-1418-01A-01T-0480-07"	"TCGA-24-1418"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	68	"y"	"y"	"n"	243	"norecurrence"	243	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	15	0	80	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 195ecf43-06bd-4ffe-8d8b-a766f3f7179b///days_to_birth: -24842///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1418///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f9fbcec6-98e7-4e71-8bbd-99bbec66ca0f///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 243///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: Other///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: Per CRF notes: No Recurrence///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1418-01A-01T-0480-07///unique_patient_id: TCGA-24-1418"
"TCGA.24.1419"	"TCGA-24-1419-01A-01T-0480-07"	"TCGA-24-1419"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	62	"y"	"y"	"n"	239	"norecurrence"	239	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	20	0	79	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5e18b17d-4626-4b6d-8ac6-e560cee0376c///days_to_birth: -22659///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1419///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 96d20828-bb11-4024-9701-2e35ab3fc712///chemo_therapy: YES///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 239///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1419-01A-01T-0480-07///unique_patient_id: TCGA-24-1419"
"TCGA.24.1422"	"TCGA-24-1422-01A-01T-0480-07"	"TCGA-24-1422"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	82	NA	NA	NA	23	"norecurrence"	23	"deceased"	NA	NA	NA	NA	"optimal"	25	0	66	NA	"age_at_initial_pathologic_diagnosis: 82///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 05ba5839-e00a-4a9e-8ba3-ecb490781e62///days_to_birth: -30233///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1422///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 53ee42c9-00e7-4df7-9070-362b248e998a///chemo_therapy: NO///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 23///days_to_last_followup: 23///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1422-01A-01T-0480-07///unique_patient_id: TCGA-24-1422"
"TCGA.24.1423"	"TCGA-24-1423-01A-01T-0480-07"	"TCGA-24-1423"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	"y"	"y"	"n"	190	"norecurrence"	190	"living"	NA	NA	NA	"completeresponse"	"optimal"	18	0	72	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f64ebc7f-0e5a-42b4-af57-6cdb90d24f90///days_to_birth: -22281///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1423///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2c5edeaa-427c-44b6-893c-797f75cdd9a8///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 190///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1423-01A-01T-0480-07///unique_patient_id: TCGA-24-1423"
"TCGA.24.1424"	"TCGA-24-1424-01A-01T-0480-07"	"TCGA-24-1424"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"y"	"y"	"n"	183	"norecurrence"	183	"living"	NA	NA	NA	"completeresponse"	"optimal"	22	0	75	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c3e443b9-5dc5-4793-91e3-534f21485268///days_to_birth: -24545///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1424///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8c85cbc9-0f48-4310-ab56-f53b981e1ee6///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 183///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1424-01A-01T-0480-07///unique_patient_id: TCGA-24-1424"
"TCGA.24.1425"	"TCGA-24-1425-01A-02T-0505-07"	"TCGA-24-1425"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	45	"y"	"y"	"n"	181	"norecurrence"	181	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	28	67	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b120b701-c194-43d7-a491-3206fac38ec1///days_to_birth: -16763///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1425///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4a3aabd7-413a-42fe-a1dd-5af7e3935ec3///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 181///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1425-01A-02T-0505-07///unique_patient_id: TCGA-24-1425"
"TCGA.24.1426"	"TCGA-24-1426-01A-01T-0480-07"	"TCGA-24-1426"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	43	"y"	"y"	"n"	163	"norecurrence"	163	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c8acee1b-6854-409b-86ab-bf69dbe22ab6///days_to_birth: -15948///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1426///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: dcc9dd22-4227-46a6-b054-4b094b5f6718///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 163///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: Per Notes:No recurrence///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1426-01A-01T-0480-07///unique_patient_id: TCGA-24-1426"
"TCGA.24.1427"	"TCGA-24-1427-01A-01T-0480-07"	"TCGA-24-1427"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	146	"norecurrence"	146	"living"	NA	NA	NA	"partialresponse"	"suboptimal"	0	15	84	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 02d9aa2e-b16a-48ea-a420-5daed9fd51a6///days_to_birth: -21423///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1427///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: d5a10323-1f25-4c1f-9f25-44f6a2648a1d///chemo_therapy: YES///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 146///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: Per CRF notes:no recurrence///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1427-01A-01T-0480-07///unique_patient_id: TCGA-24-1427"
"TCGA.24.1428"	"TCGA-24-1428-01A-01T-0480-07"	"TCGA-24-1428"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	448	"recurrence"	528	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	87	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Left///bcr_patient_uuid: 9c744ff8-1cde-4176-b6d7-0ab62bf42620///days_to_birth: -18306///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1428///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 51f0a185-1a9f-486d-ae86-8816f919f682///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 528///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 448///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Per CRF Notes: No Recurrence; 06/11/10 Image study-pevlic and abdomen CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1428-01A-01T-0480-07///unique_patient_id: TCGA-24-1428"
"TCGA.24.1430"	"TCGA-24-1430-01A-01T-0480-07"	"TCGA-24-1430"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	68	"y"	"y"	"n"	448	"recurrence"	862	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3018efe7-13a1-47ae-a726-8fc967c73841///days_to_birth: -24939///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1430///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a1fbfc62-641e-41cd-bebb-0044b8433a52///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 862///days_to_last_followup: 862///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 448///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan of abdomin and pelvis; Molecular markers CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1430-01A-01T-0480-07///unique_patient_id: TCGA-24-1430"
"TCGA.24.1431"	"TCGA-24-1431-01A-01T-0480-07"	"TCGA-24-1431"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"y"	"y"	"n"	199	"recurrence"	583	"deceased"	NA	NA	"locoregional"	NA	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 384170fc-e8be-426a-a54e-bf1ca61f2986///days_to_birth: -24757///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1431///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: d6b3e869-46dd-40c8-ad63-998478c5b806///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 583///days_to_last_followup: 583///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 199///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen MRI Scan; Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1431-01A-01T-0480-07///unique_patient_id: TCGA-24-1431"
"TCGA.24.1434"	"TCGA-24-1434-01A-01T-0480-07"	"TCGA-24-1434"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	59	"y"	"y"	"n"	337	"recurrence"	568	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	15	82	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5503b3a1-7d03-41b2-9ec8-e478c5414d67///days_to_birth: -21809///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1434///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0e4f7bf8-affb-45c7-8d16-d2eb4a044257///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 568///days_to_last_followup: 568///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 337///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT;Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1434-01A-01T-0480-07///unique_patient_id: TCGA-24-1434"
"TCGA.24.1435"	"TCGA-24-1435-01A-01T-0480-07"	"TCGA-24-1435"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	505	"recurrence"	1324	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 49d2c0cf-a3f3-4519-a755-0a5f769df2ea///days_to_birth: -21107///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1435///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fab88b94-18a9-48a3-b679-10658361d8d8///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1324///days_to_last_followup: 1324///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 505///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT;Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1435-01A-01T-0480-07///unique_patient_id: TCGA-24-1435"
"TCGA.24.1436"	"TCGA-24-1436-01A-01T-0480-07"	"TCGA-24-1436"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	NA	"recurrence"	260	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	8	90	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Right///bcr_patient_uuid: 6e84e89d-4f35-43b8-b47d-b1343b8c1ab9///days_to_birth: -20881///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1436///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: cc0a65c7-68c1-48e5-8e0a-7fc5a09d1317///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 260///days_to_last_followup: 260///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular Marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1436-01A-01T-0480-07///unique_patient_id: TCGA-24-1436"
"TCGA.24.1463"	"TCGA-24-1463-01A-01T-0480-07"	"TCGA-24-1463"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	70	"y"	"y"	"n"	971	"recurrence"	2218	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	22	78	NA	"age_at_initial_pathologic_diagnosis: 70///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 171f7917-69eb-4a3f-9cc0-0e1dffd412c1///days_to_birth: -25733///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1463///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9b5f38dd-e6ee-4d19-af8b-c1a46f8b00c0///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2218///days_to_last_followup: 2218///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 971///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Pelvic/abdominal CT, CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1463-01A-01T-0480-07///unique_patient_id: TCGA-24-1463"
"TCGA.24.1464"	"TCGA-24-1464-01A-01T-0480-07"	"TCGA-24-1464"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	70	"y"	"y"	"n"	323	"recurrence"	379	"deceased"	NA	NA	"locoregional"	NA	"suboptimal"	0	14	85	NA	"age_at_initial_pathologic_diagnosis: 70///anatomic_organ_subdivision: Left///bcr_patient_uuid: 4160e048-f0b0-40f5-805b-e277a5893a3b///days_to_birth: -25874///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1464///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 77ea97ca-736c-4ab4-9670-0941b73c1bb3///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 379///days_to_last_followup: 379///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 323///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: MIR Abdomen, pelvis;Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1464-01A-01T-0480-07///unique_patient_id: TCGA-24-1464"
"TCGA.24.1466"	"TCGA-24-1466-01A-01T-0480-07"	"TCGA-24-1466"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"y"	"y"	"n"	491	"recurrence"	1373	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	9	90	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 098acb76-0bf5-44e5-bcae-f919cf5fa5e5///days_to_birth: -27307///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1466///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d74104a4-dfb4-4dfc-b627-ff418aba20ec///chemo_therapy: YES///day_of_form_completion: 17///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1373///days_to_last_followup: 1373///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 491///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1466-01A-01T-0480-07///unique_patient_id: TCGA-24-1466"
"TCGA.24.1467"	"TCGA-24-1467-01A-01T-0480-07"	"TCGA-24-1467"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	"y"	"y"	"n"	1252	"recurrence"	3224	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	12	88	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Right///bcr_patient_uuid: 34f545ab-d420-4dd2-8db4-3159896efd23///days_to_birth: -18652///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1467///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 0b7db63c-a9e8-47c4-8459-b34e4260d092///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1252///days_to_death: 3224///days_to_last_followup: 3224///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1252///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CT Scan, CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1467-01A-01T-0480-07///unique_patient_id: TCGA-24-1467"
"TCGA.24.1469"	"TCGA-24-1469-01A-01T-0505-07"	"TCGA-24-1469"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	277	"norecurrence"	277	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	4	95	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Right///bcr_patient_uuid: cd6e5d3d-1c86-40dd-9cb3-b2e2075dec56///days_to_birth: -25937///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1469///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a5d9372b-c1cc-4361-84ee-e8d6dd21dcfb///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 277///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1469-01A-01T-0505-07///unique_patient_id: TCGA-24-1469"
"TCGA.24.1470"	"TCGA-24-1470-01A-01T-0505-07"	"TCGA-24-1470"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	54	"y"	"y"	"n"	104	"norecurrence"	104	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	16	82	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a3898640-0d85-441d-a000-b5b8ff857399///days_to_birth: -20007///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1470///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 64784e56-eef8-4003-9cc8-7f8bc725b2bd///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 104///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1470-01A-01T-0505-07///unique_patient_id: TCGA-24-1470"
"TCGA.24.1471"	"TCGA-24-1471-01A-01T-0505-07"	"TCGA-24-1471"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	NA	NA	NA	36	"norecurrence"	36	"living"	NA	NA	NA	NA	"suboptimal"	0	1	98	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Left///bcr_patient_uuid: ceb19678-b453-4529-b6cb-d02f9cb101b4///days_to_birth: -22081///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1471///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 4a48ca18-4453-402f-b1b1-f98c79a2793e///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 36///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1471-01A-01T-0505-07///unique_patient_id: TCGA-24-1471"
"TCGA.24.1474"	"TCGA-24-1474-01A-01T-0505-07"	"TCGA-24-1474"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	331	"recurrence"	675	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	1	98	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Left///bcr_patient_uuid: d7b3156d-672a-4a55-868d-9ca6a09fcb0f///days_to_birth: -20902///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1474///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 76d29b08-30df-4efc-8cba-1bd4d4935300///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 675///days_to_last_followup: 675///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 331///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen and pelvis CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1474-01A-01T-0505-07///unique_patient_id: TCGA-24-1474"
"TCGA.24.1544"	"TCGA-24-1544-01A-01T-0541-07"	"TCGA-24-1544"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	NA	"recurrence"	820	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	20	72	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 21f6bf91-dfc6-4a59-8b76-88a0f95c7b47///days_to_birth: -26140///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1544///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 56ec21c8-c3b5-41b3-abdc-964351237f88///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 820///days_to_last_followup: 820///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 643///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal MIR; Moleuclar marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1544-01A-01T-0541-07///unique_patient_id: TCGA-24-1544"
"TCGA.24.1545"	"TCGA-24-1545-01A-01T-0541-07"	"TCGA-24-1545"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	69	"y"	"y"	"n"	861	"recurrence"	1745	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 69///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f2ec64f5-a414-4c34-99c7-d59bc4e831e0///days_to_birth: -25460///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1545///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 84f70a51-070e-4649-8a9e-df72b6b5e095///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1745///days_to_last_followup: 1745///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 861///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abd MRI, CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1545-01A-01T-0541-07///unique_patient_id: TCGA-24-1545"
"TCGA.24.1546"	"TCGA-24-1546-01A-01T-0541-07"	"TCGA-24-1546"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	46	"y"	"y"	"n"	1955	"norecurrence"	1955	"deceased"	NA	NA	NA	NA	"optimal"	0	40	60	NA	"age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9e7d3dea-5d81-4f10-819c-1c2a68ddd150///days_to_birth: -17129///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1546///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0b61178a-f8fb-4a88-8c08-54ae6e0ab3f0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1955///days_to_last_followup: 1955///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1546-01A-01T-0541-07///unique_patient_id: TCGA-24-1546"
"TCGA.24.1548"	"TCGA-24-1548-01A-01T-0541-07"	"TCGA-24-1548"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	207	"recurrence"	493	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	12	86	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 66c92b9e-de3c-4d1a-bb69-46ffbc6caf33///days_to_birth: -20944///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1548///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f784a2bc-8872-4f2a-ad6e-6a270a01e198///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 493///days_to_last_followup: 493///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 207///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal MIR; Moleuclar marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1548-01A-01T-0541-07///unique_patient_id: TCGA-24-1548"
"TCGA.24.1549"	"TCGA-24-1549-01A-01T-0505-07"	"TCGA-24-1549"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	58	"y"	"y"	"n"	1042	"recurrence"	1721	"deceased"	NA	NA	"locoregional"	"completeresponse"	NA	0	12	82	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3b81ec7c-0934-4649-9231-9919dd26dd15///days_to_birth: -21431///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1549///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 1c5bdf4e-cb21-4fd2-8079-c0390be43a7e///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1154///days_to_death: 1721///days_to_last_followup: 1721///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1042///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT scan;Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1549-01A-01T-0505-07///unique_patient_id: TCGA-24-1549"
"TCGA.24.1550"	"TCGA-24-1550-01A-01T-0505-07"	"TCGA-24-1550"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	49	"y"	"y"	"n"	892	"recurrence"	1249	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	18	75	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Left///bcr_patient_uuid: 1858b58f-fdf4-413c-9c29-96ae85b88a74///days_to_birth: -18048///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1550///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 5bda2645-5465-4ed5-a000-c378ffe3ba62///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: 1121///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1249///days_to_last_followup: 1249///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 892///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT Scan; Molucular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1550-01A-01T-0505-07///unique_patient_id: TCGA-24-1550"
"TCGA.24.1551"	"TCGA-24-1551-01A-01T-0505-07"	"TCGA-24-1551"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	53	"y"	"y"	"n"	764	"recurrence"	1579	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	85	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 499a9b57-ee1a-4012-bbab-c6ad955b5e0a///days_to_birth: -19661///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1551///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: bbe90a89-5f83-4b5d-9ef9-9a9e8a5159fd///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1579///days_to_last_followup: 1579///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 764///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen C scan; molecular markers CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1551-01A-01T-0505-07///unique_patient_id: TCGA-24-1551"
"TCGA.24.1552"	"TCGA-24-1552-01A-01T-0505-07"	"TCGA-24-1552"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	77	"y"	"y"	"n"	403	"recurrence"	1259	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	4	92	NA	"age_at_initial_pathologic_diagnosis: 77///anatomic_organ_subdivision: Left///bcr_patient_uuid: 62379be5-13f0-474b-94d3-6f944ec4ee96///days_to_birth: -28129///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1552///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9ea4de18-69c5-4737-b8ec-956d3c28d2c2///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1259///days_to_last_followup: 1259///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 403///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen MIR; Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1552-01A-01T-0505-07///unique_patient_id: TCGA-24-1552"
"TCGA.24.1553"	"TCGA-24-1553-01A-01T-0505-07"	"TCGA-24-1553"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	53	"y"	"y"	"n"	553	"recurrence"	1767	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 08c64000-d320-4e4d-974b-da503d48890c///days_to_birth: -19393///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1553///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7622d214-fe68-459f-80a3-c4740b69af22///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1767///days_to_last_followup: 1767///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 553///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT scan; Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1553-01A-01T-0505-07///unique_patient_id: TCGA-24-1553"
"TCGA.24.1555"	"TCGA-24-1555-01A-01T-0505-07"	"TCGA-24-1555"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	1577	"recurrence"	2692	"deceased"	NA	NA	"locoregional"	"completeresponse"	NA	0	22	78	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5d36676e-4140-44b5-aa0e-b2af092b7dc0///days_to_birth: -18403///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1555///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 5867b96d-991e-437a-9e0c-b4c7846721ad///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2692///days_to_last_followup: 2692///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1577///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT scan; Moleular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1555-01A-01T-0505-07///unique_patient_id: TCGA-24-1555"
"TCGA.24.1556"	"TCGA-24-1556-01A-01T-0541-07"	"TCGA-24-1556"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"b"	3	50	"y"	"y"	"n"	549	"recurrence"	2148	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Left///bcr_patient_uuid: 7592a659-7175-486f-a16e-24a4b4365a36///days_to_birth: -18516///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1556///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: ae13e174-65c7-41d1-a531-10166f114bfe///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 762///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2148///days_to_last_followup: 2148///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 549///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomin MIR; Molecular CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1556-01A-01T-0541-07///unique_patient_id: TCGA-24-1556"
"TCGA.24.1557"	"TCGA-24-1557-01A-01T-0541-07"	"TCGA-24-1557"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	49	"y"	"y"	"n"	NA	"recurrence"	1213	"deceased"	NA	NA	"locoregional"	"partialresponse"	"suboptimal"	0	9	88	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7dcc809b-e33a-4453-b92a-c00786f48cb0///days_to_birth: -17943///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1557///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 300786cc-f4e9-45c3-8987-c78cb62f21ea///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1213///days_to_last_followup: 1213///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 447///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomin MIR;Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1557-01A-01T-0541-07///unique_patient_id: TCGA-24-1557"
"TCGA.24.1558"	"TCGA-24-1558-01A-01T-0541-07"	"TCGA-24-1558"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	"y"	"y"	"n"	273	"recurrence"	594	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	2	98	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ba68f2cf-9271-41fd-9655-1fac7681f588///days_to_birth: -27004///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1558///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: e5c8a6ca-1b37-4965-bf50-3c988437af33///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 594///days_to_last_followup: 594///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 273///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal MRI; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1558-01A-01T-0541-07///unique_patient_id: TCGA-24-1558"
"TCGA.24.1560"	"TCGA-24-1560-01A-01T-0541-07"	"TCGA-24-1560"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	4	51	"y"	"y"	"n"	143	"recurrence"	1341	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	2	98	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Left///bcr_patient_uuid: afd92922-b8dc-48bd-a9c0-bc8d95855eb7///days_to_birth: -18670///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G4///patient_id: 1560///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f5657f7d-8bbe-49b7-875c-32d3c45a6b02///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1341///days_to_last_followup: 1341///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 143///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal MIR; Moleuclar marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1560-01A-01T-0541-07///unique_patient_id: TCGA-24-1560"
"TCGA.24.1562"	"TCGA-24-1562-01A-01T-0505-07"	"TCGA-24-1562"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"y"	"y"	"n"	228	"recurrence"	1384	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	82	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 4c18d9cf-4af4-4a86-8b1c-f78795fbbd7e///days_to_birth: -24747///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1562///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 28786767-c3fa-429e-a296-8677b91c77fe///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1384///days_to_last_followup: 1384///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 228///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT scan;Moleuclar markers CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1562-01A-01T-0505-07///unique_patient_id: TCGA-24-1562"
"TCGA.24.1563"	"TCGA-24-1563-01A-01T-0505-07"	"TCGA-24-1563"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"y"	"y"	"n"	396	"recurrence"	1451	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	20	77	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: Left///bcr_patient_uuid: 52386f66-2877-4c75-894e-5c1dc03e6ef4///days_to_birth: -24274///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1563///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4a3e5d73-58ba-403c-91a7-92653e760093///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1451///days_to_last_followup: 1451///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 396///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT scan; Molecular markers CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1563-01A-01T-0505-07///unique_patient_id: TCGA-24-1563"
"TCGA.24.1564"	"TCGA-24-1564-01A-01T-0505-07"	"TCGA-24-1564"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"y"	"y"	"n"	221	"recurrence"	787	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	15	84	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: d77ef9cf-f8e6-4ee9-8d4f-1106885f6b06///days_to_birth: -24667///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1564///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 69d2cd4f-e4ac-476b-a837-030181905bb8///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 787///days_to_last_followup: 787///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 221///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT Scan;Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1564-01A-01T-0505-07///unique_patient_id: TCGA-24-1564"
"TCGA.24.1565"	"TCGA-24-1565-01A-01T-0505-07"	"TCGA-24-1565"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"y"	"y"	"n"	145	"recurrence"	312	"deceased"	NA	NA	"metastasis"	"partialresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cf1e86ec-4bcb-403c-831b-d67bddef14eb///days_to_birth: -27048///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1565///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 213a13f2-5a06-4c77-ba1e-0a5fe7281956///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 312///days_to_last_followup: 312///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 145///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Pet Abdomen chest;Molecular marker Ca125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1565-01A-01T-0505-07///unique_patient_id: TCGA-24-1565"
"TCGA.24.1567"	"TCGA-24-1567-01A-01T-0541-07"	"TCGA-24-1567"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	54	"y"	"y"	"n"	524	"norecurrence"	524	"deceased"	NA	NA	NA	NA	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2cb50c2d-e749-4172-b101-d975507435c5///days_to_birth: -19843///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1567///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 282f1e10-3acf-4ade-bf0f-83cf6b487059///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 524///days_to_last_followup: 524///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 335///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1567-01A-01T-0541-07///unique_patient_id: TCGA-24-1567"
"TCGA.24.1603"	"TCGA-24-1603-01A-01T-0505-07"	"TCGA-24-1603"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	53	"y"	"y"	"n"	992	"recurrence"	2742	"deceased"	NA	NA	"locoregional"	"completeresponse"	NA	8	0	84	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 19427350-619b-4b9c-a3ba-37f667bb2843///days_to_birth: -19681///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1603///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1996///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 7aa0d9f9-ecbe-4159-89a9-08c599697834///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2742///days_to_last_followup: 2742///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 992///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT scan; Molecular markers CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1603-01A-01T-0505-07///unique_patient_id: TCGA-24-1603"
"TCGA.24.1604"	"TCGA-24-1604-01A-01T-0505-07"	"TCGA-24-1604"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"y"	"y"	"n"	NA	"recurrence"	2687	"deceased"	NA	NA	"metastasis"	"completeresponse"	NA	35	0	60	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 65435f50-a35d-49e3-a36e-b95d9e274ca0///days_to_birth: -24471///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1604///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1996///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 36c37a67-9b4f-42cc-93e8-4aea5cb551a4///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2687///days_to_last_followup: 2687///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan of brain;Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1604-01A-01T-0505-07///unique_patient_id: TCGA-24-1604"
"TCGA.24.1614"	"TCGA-24-1614-01A-01T-0505-07"	"TCGA-24-1614"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	644	"recurrence"	1470	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	8	90	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Right///bcr_patient_uuid: d3164236-c14a-4230-b527-ecd1a3992f02///days_to_birth: -20993///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1614///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 2e7f89f0-bf3f-4bb8-b6ac-2bb6fb323440///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1470///days_to_last_followup: 1470///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 644///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 100///month_of_form_completion: 5///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT Scan; Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1614-01A-01T-0505-07///unique_patient_id: TCGA-24-1614"
"TCGA.24.1616"	"TCGA-24-1616-01A-01T-0505-07"	"TCGA-24-1616"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	56	"y"	"y"	"n"	405	"recurrence"	1163	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	32	65	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5d7027f5-60a0-47ab-a79d-667c9acc0e54///days_to_birth: -20785///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1616///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 127c2b96-0ba3-4db7-8de7-af44da6aa3df///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1163///days_to_last_followup: 1163///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 405///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT scan;Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1616-01A-01T-0505-07///unique_patient_id: TCGA-24-1616"
"TCGA.24.1842"	"TCGA-24-1842-01A-01T-0585-07"	"TCGA-24-1842"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	49	"y"	"y"	"n"	253	"norecurrence"	253	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	15	85	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 09c77947-a333-4392-b18d-a6c1f08764a1///days_to_birth: -18227///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1842///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ea813aa8-df86-407b-aea1-092fb2c8608e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 253///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1842-01A-01T-0585-07///unique_patient_id: TCGA-24-1842"
"TCGA.24.1843"	"TCGA-24-1843-01A-01T-0585-07"	"TCGA-24-1843"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"y"	"y"	"n"	106	"norecurrence"	106	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	22	78	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: Right///bcr_patient_uuid: 9ec86cbd-8c74-4697-90da-529ab91ab835///days_to_birth: -24469///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1843///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9871548e-8f1f-4d83-87f7-e813b54143bc///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 106///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1843-01A-01T-0585-07///unique_patient_id: TCGA-24-1843"
"TCGA.24.1844"	"TCGA-24-1844-01A-01T-0585-07"	"TCGA-24-1844"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	64	"y"	"y"	"n"	113	"norecurrence"	113	"living"	NA	NA	NA	NA	"optimal"	0	15	85	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a36a4440-15ef-4837-904b-380a964d16f1///days_to_birth: -23542///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1844///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: cdb065d3-625b-4540-9004-d6477da35365///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 113///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1844-01A-01T-0585-07///unique_patient_id: TCGA-24-1844"
"TCGA.24.1845"	"TCGA-24-1845-01A-01T-0585-07"	"TCGA-24-1845"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	42	"y"	"y"	"n"	116	"norecurrence"	116	"living"	NA	NA	NA	NA	"optimal"	0	2	92	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a782352e-c4bb-4c3e-ba82-456a47c3689a///days_to_birth: -15599///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1845///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 589f82e0-f528-49ec-ab57-8efff59e192c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 116///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1845-01A-01T-0585-07///unique_patient_id: TCGA-24-1845"
"TCGA.24.1846"	"TCGA-24-1846-01A-01T-0585-07"	"TCGA-24-1846"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	45	"y"	"y"	"n"	133	"norecurrence"	133	"living"	NA	NA	NA	NA	"optimal"	0	8	75	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 67f526f1-def5-43b4-bc89-154baae190fc///days_to_birth: -16533///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1846///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e73b1ede-abff-4032-af69-0c538317414f///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 133///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1846-01A-01T-0585-07///unique_patient_id: TCGA-24-1846"
"TCGA.24.1847"	"TCGA-24-1847-01A-01T-0567-07"	"TCGA-24-1847"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	45	"n"	"y"	"n"	343	"norecurrence"	343	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 21966708-4e66-4211-add0-f1515b09e362///days_to_birth: -16529///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1847///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a302ccb0-5b86-4a6a-8121-fdf54689c24c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 343///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1847-01A-01T-0567-07///unique_patient_id: TCGA-24-1847"
"TCGA.24.1849"	"TCGA-24-1849-01A-01T-0585-07"	"TCGA-24-1849"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	80	"y"	"n"	"n"	175	"norecurrence"	175	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	18	82	NA	"age_at_initial_pathologic_diagnosis: 80///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 94efd4f9-69b0-4efa-8a0c-61106e898fdd///days_to_birth: -29555///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1849///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f8e9aba6-d282-480f-bbee-d180107708b2///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 175///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1849-01A-01T-0585-07///unique_patient_id: TCGA-24-1849"
"TCGA.24.1850"	"TCGA-24-1850-01A-01T-0585-07"	"TCGA-24-1850"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	72	"y"	"n"	"n"	167	"norecurrence"	167	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	15	82	NA	"age_at_initial_pathologic_diagnosis: 72///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b6b607cd-67b8-4c04-a212-a4e8c0743f05///days_to_birth: -26369///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1850///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1345a9a2-a18f-418a-94bf-ec8ab20404b7///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 167///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1850-01A-01T-0585-07///unique_patient_id: TCGA-24-1850"
"TCGA.24.1920"	"TCGA-24-1920-01A-01T-0656-07"	"TCGA-24-1920"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"y"	"y"	"n"	298	"norecurrence"	298	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Right///bcr_patient_uuid: 97efb80d-4f46-4aef-b95e-20d260de01b2///days_to_birth: -27042///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1920///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d6fe4337-d7f6-4b68-bd9f-e3473853b265///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 298///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-24-1920-01A-01T-0656-07///unique_patient_id: TCGA-24-1920"
"TCGA.24.1923"	"TCGA-24-1923-01A-01T-0656-07"	"TCGA-24-1923"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	"y"	"y"	"n"	343	"recurrence"	689	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	80	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8449955f-42d9-46f6-919a-5cc5d59e6284///days_to_birth: -18628///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1923///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a490cc6b-d715-4c9e-8039-8508af334257///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 689///days_to_last_followup: 689///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 343///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker-CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-1923-01A-01T-0656-07///unique_patient_id: TCGA-24-1923"
"TCGA.24.1924"	"TCGA-24-1924-01A-01T-0656-07"	"TCGA-24-1924"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"y"	"n"	320	"recurrence"	919	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	15	70	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 26558703-a659-43f2-86cb-0695989bc14e///days_to_birth: -23801///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1924///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 21cccc06-a7a4-4bdc-a840-cd5f49ce523a///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 919///days_to_last_followup: 919///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 320///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker- CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-1924-01A-01T-0656-07///unique_patient_id: TCGA-24-1924"
"TCGA.24.1927"	"TCGA-24-1927-01A-01T-0656-07"	"TCGA-24-1927"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	59	"y"	"y"	"n"	289	"recurrence"	499	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	2	90	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8c47ae58-91c7-4247-b420-50f31f5eb00d///days_to_birth: -21719///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1927///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 961f5963-db18-487d-b99d-18ca0a9c78f9///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 499///days_to_last_followup: 499///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 289///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: YES///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-1927-01A-01T-0656-07///unique_patient_id: TCGA-24-1927"
"TCGA.24.1928"	"TCGA-24-1928-01A-01T-0656-07"	"TCGA-24-1928"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	77	"y"	"y"	"n"	70	"recurrence"	336	"deceased"	NA	NA	"locoregional"	"progressivedisease"	"suboptimal"	0	12	80	NA	"age_at_initial_pathologic_diagnosis: 77///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b45c543a-40d9-423a-a7fa-98e4b325b487///days_to_birth: -28125///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1928///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 144f8c7e-e805-4c4c-92ff-e14d57b79a60///chemo_therapy: YES///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 336///days_to_last_followup: 336///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 70///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-1928-01A-01T-0656-07///unique_patient_id: TCGA-24-1928"
"TCGA.24.1930"	"TCGA-24-1930-01A-01T-0656-07"	"TCGA-24-1930"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	53	"y"	"y"	"n"	543	"recurrence"	2467	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 62efb5ae-43dc-4a4c-a898-6cd9c6dba027///days_to_birth: -19387///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1930///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 4e109663-798b-40df-a011-0527bb6151ff///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: 1922///days_to_additional_surgery_metastatic_procedure: 670///days_to_death: 2467///days_to_last_followup: 2467///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 543///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 100///month_of_form_completion: 4///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Brain MRI; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-1930-01A-01T-0656-07///unique_patient_id: TCGA-24-1930"
"TCGA.24.2019"	"TCGA-24-2019-01A-02T-0695-07"	"TCGA-24-2019"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	46	NA	NA	NA	148	"norecurrence"	148	"living"	NA	NA	NA	NA	"optimal"	0	26	72	NA	"age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: bbad2efe-e9c7-4f8f-924b-ebbbe4c181d4///days_to_birth: -17009///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2019///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 478f18ec-c7d2-485e-b83d-1b416c86ac20///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 148///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Other///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-24-2019-01A-02T-0695-07///unique_patient_id: TCGA-24-2019"
"TCGA.24.2020"	"TCGA-24-2020-01A-01T-0656-07"	"TCGA-24-2020"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"y"	"y"	"n"	723	"recurrence"	4623	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	2	95	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e20ea417-7296-4da8-9fdb-71cd1f45153a///days_to_birth: -24682///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2020///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1994///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a3abbfc8-e286-4861-8709-fbe623ad55c4///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 4623///days_to_last_followup: 4623///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 723///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2020-01A-01T-0656-07///unique_patient_id: TCGA-24-2020"
"TCGA.24.2023"	"TCGA-24-2023-01A-01T-0656-07"	"TCGA-24-2023"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	54	"y"	"y"	"n"	1069	"recurrence"	1364	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5201ee13-2aed-4641-9169-4d5ee07a23da///days_to_birth: -19900///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2023///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1994///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 478e3654-2c9e-4ee7-b80d-d63e0a5c5ebe///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1364///days_to_last_followup: 1364///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1069///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2023-01A-01T-0656-07///unique_patient_id: TCGA-24-2023"
"TCGA.24.2024"	"TCGA-24-2024-01A-02T-0695-07"	"TCGA-24-2024"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	72	"y"	"y"	"n"	421	"recurrence"	1769	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 72///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0a48873a-092a-4b25-822b-b0b3c18c08a8///days_to_birth: -26475///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2024///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1994///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ea9bc46b-5020-4f83-98a5-bb896df3f040///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: 419///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1769///days_to_last_followup: 1769///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 421///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125; Other-second look surgery///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2024-01A-02T-0695-07///unique_patient_id: TCGA-24-2024"
"TCGA.24.2026"	"TCGA-24-2026-01A-01T-0656-07"	"TCGA-24-2026"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	79	"y"	"y"	"n"	1059	"norecurrence"	1059	"deceased"	NA	NA	NA	NA	"suboptimal"	0	12	88	NA	"age_at_initial_pathologic_diagnosis: 79///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2517ca7a-6057-4c19-b7e1-f6d078e9881a///days_to_birth: -29050///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2026///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 69ced7f3-1e11-4515-89e8-2e5e148f5271///chemo_therapy: YES///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1059///days_to_last_followup: 1059///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2026-01A-01T-0656-07///unique_patient_id: TCGA-24-2026"
"TCGA.24.2027"	"TCGA-24-2027-01A-01T-0656-07"	"TCGA-24-2027"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	51	"y"	"y"	"n"	617	"recurrence"	3336	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	6	92	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 219f54ef-4235-482d-b799-f2fa9930105c///days_to_birth: -18835///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2027///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 734e79c4-b7b3-4238-aa0b-d3f1fe501a3b///chemo_therapy: YES///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 3336///days_to_last_followup: 3336///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 617///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker- CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2027-01A-01T-0656-07///unique_patient_id: TCGA-24-2027"
"TCGA.24.2029"	"TCGA-24-2029-01A-01T-0656-07"	"TCGA-24-2029"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	75	"y"	"y"	"n"	372	"recurrence"	439	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 75///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: bbbf1184-1e19-479a-b31f-daa692d52e02///days_to_birth: -27526///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2029///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d10c3674-b9e5-422d-8989-85abed51bc3d///chemo_therapy: YES///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 439///days_to_last_followup: 439///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 372///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2029-01A-01T-0656-07///unique_patient_id: TCGA-24-2029"
"TCGA.24.2030"	"TCGA-24-2030-01A-01T-0671-07"	"TCGA-24-2030"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	87	"y"	"y"	"n"	646	"recurrence"	1701	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	10	88	NA	"age_at_initial_pathologic_diagnosis: 87///anatomic_organ_subdivision: Left///bcr_patient_uuid: d2ccefea-c1d6-465f-97b1-e51e29c5f1f8///days_to_birth: -31899///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2030///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 074d1e6b-3a3f-4b8c-9638-617b4d07067a///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1701///days_to_last_followup: 1641///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 646///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal & Pelvic CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2030-01A-01T-0671-07///unique_patient_id: TCGA-24-2030"
"TCGA.24.2033"	"TCGA-24-2033-01A-01T-0695-07"	"TCGA-24-2033"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	87	"y"	"y"	"n"	351	"recurrence"	562	"deceased"	NA	NA	"locoregional"	"partialresponse"	"suboptimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 87///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 872d2922-7292-4681-adb7-d3b267eccbe7///days_to_birth: -31976///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2033///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 803d2c06-fa19-4069-8e38-943eb8afc387///chemo_therapy: YES///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 562///days_to_last_followup: 562///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 351///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2033-01A-01T-0695-07///unique_patient_id: TCGA-24-2033"
"TCGA.24.2035"	"TCGA-24-2035-01A-01T-0671-07"	"TCGA-24-2035"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"y"	"n"	287	"recurrence"	857	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	70	30	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Left///bcr_patient_uuid: 062982f8-9f49-425a-99e9-008af5ed9040///days_to_birth: -23854///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2035///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1996///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 629fe779-5b72-4d3e-92ff-c21f8cd387d0///chemo_therapy: YES///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 857///days_to_last_followup: 857///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 287///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2035-01A-01T-0671-07///unique_patient_id: TCGA-24-2035"
"TCGA.24.2036"	"TCGA-24-2036-01A-01T-0841-07"	"TCGA-24-2036"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	914	"recurrence"	1947	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: NA///bcr_patient_uuid: c9226204-cb61-40b8-8a94-a7e71c14ea3a///days_to_birth: -18582///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2036///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1996///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 18df747d-b014-45a6-a225-5400d8ac2b53///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 579///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1947///days_to_last_followup: 1947///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 914///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: Image Study- Abdominal; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2036-01A-01T-0841-07///unique_patient_id: TCGA-24-2036"
"TCGA.24.2038"	"TCGA-24-2038-01A-01T-0671-07"	"TCGA-24-2038"	"tumor"	"ser"	"ov"	NA	NA	"late"	3	"c"	NA	68	"y"	"y"	"n"	1169	"recurrence"	1353	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	22	78	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Right///bcr_patient_uuid: 17181157-c9e2-4bd6-8653-f5dce56f9053///days_to_birth: -24957///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GB///patient_id: 2038///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8fc55409-dfdb-43de-bd4e-9d1f31594ccc///chemo_therapy: NO///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 1183///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1353///days_to_last_followup: 1353///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1169///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT;Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2038-01A-01T-0671-07///unique_patient_id: TCGA-24-2038"
"TCGA.24.2254"	"TCGA-24-2254-01A-01T-0671-07"	"TCGA-24-2254"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"y"	"y"	"n"	606	"recurrence"	1736	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9af2248a-d86a-4277-93b4-8eba5a39bd3c///days_to_birth: -24406///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2254///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 096da4d1-b2b5-4325-b786-ed88b37ba349///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1736///days_to_last_followup: 1736///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 606///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2254-01A-01T-0671-07///unique_patient_id: TCGA-24-2254"
"TCGA.24.2260"	"TCGA-24-2260-01A-01T-0671-07"	"TCGA-24-2260"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	74	"y"	"y"	"n"	667	"recurrence"	1100	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	80	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f2ce00e4-0d4f-4faa-bee1-ddf1b306e97b///days_to_birth: -27111///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2260///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1992///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 77d1bfaa-a99b-4154-a8c1-787c70df57da///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1100///days_to_last_followup: 1100///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 667///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study-Abdominal CT; Molecular marker-CA 125: Other method- Needle aspirate of pelvic mass///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2260-01A-01T-0671-07///unique_patient_id: TCGA-24-2260"
"TCGA.24.2261"	"TCGA-24-2261-01A-01T-0671-07"	"TCGA-24-2261"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	76	NA	NA	NA	24	"norecurrence"	24	"deceased"	NA	NA	NA	NA	"suboptimal"	1	9	85	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: Left///bcr_patient_uuid: eec69ea9-ceb8-456a-aff4-41fb8a261e36///days_to_birth: -27896///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2261///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1992///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d38e75d8-914a-44fe-8f84-904c95b9a680///chemo_therapy: NO///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 24///days_to_last_followup: 24///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2261-01A-01T-0671-07///unique_patient_id: TCGA-24-2261"
"TCGA.24.2262"	"TCGA-24-2262-01A-01T-0712-07"	"TCGA-24-2262"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	NA	NA	NA	11	"norecurrence"	11	"deceased"	NA	NA	NA	NA	"optimal"	1	9	78	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Right///bcr_patient_uuid: 1d0225b5-f515-4197-bba7-3dc17e502b88///days_to_birth: -20861///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2262///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1992///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 30c94fb2-d573-4b84-a3c1-26710ad63770///chemo_therapy: NO///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 11///days_to_last_followup: 11///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2262-01A-01T-0712-07///unique_patient_id: TCGA-24-2262"
"TCGA.24.2267"	"TCGA-24-2267-01A-01T-0712-07"	"TCGA-24-2267"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"b"	3	58	"y"	"y"	"n"	512	"recurrence"	1446	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	9	90	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 99a61986-7b23-46b5-99a4-efba6bad3766///days_to_birth: -21293///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2267///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1993///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: a78cf572-e891-4896-a60b-698428cc5672///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 955///days_to_death: 1446///days_to_last_followup: 1446///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 512///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Image study-abdomen and pelic CT; Molecular marker-CA125 and Other-excision of skin with nodules///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2267-01A-01T-0712-07///unique_patient_id: TCGA-24-2267"
"TCGA.24.2271"	"TCGA-24-2271-01A-01T-0712-07"	"TCGA-24-2271"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	NA	NA	NA	827	"recurrence"	962	"deceased"	NA	NA	"metastasis"	NA	"suboptimal"	0	18	82	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a8c4a333-6b67-44c8-9000-516f8ccea788///days_to_birth: -20399///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2271///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: fd661ea5-f3fd-4b72-a100-02bd5ce517dc///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 22///days_to_death: 962///days_to_last_followup: 962///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 827///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Physical Examination///progression_determined_by_notes: Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2271-01A-01T-0712-07///unique_patient_id: TCGA-24-2271"
"TCGA.24.2280"	"TCGA-24-2280-01A-01T-0712-07"	"TCGA-24-2280"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"y"	"y"	"n"	534	"recurrence"	2143	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	12	86	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 97ad0360-3be4-401a-a94c-7f2800a1b519///days_to_birth: -27356///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2280///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c813bb0e-af6a-403d-a7b5-f3561ccc6326///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2143///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 534///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal Study; Molecular markers-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-24-2280-01A-01T-0712-07///unique_patient_id: TCGA-24-2280"
"TCGA.24.2281"	"TCGA-24-2281-01A-01T-0712-07"	"TCGA-24-2281"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	68	"y"	"y"	"n"	1356	"norecurrence"	1356	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	30	65	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 59b3fbfe-0b7c-41e5-b756-ee7e23730df5///days_to_birth: -25019///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2281///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5af8f13c-15ce-4bde-be6f-7adc93a93883///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1356///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-24-2281-01A-01T-0712-07///unique_patient_id: TCGA-24-2281"
"TCGA.24.2288"	"TCGA-24-2288-01A-01T-0712-07"	"TCGA-24-2288"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	70	"y"	"y"	"n"	25	"norecurrence"	25	"deceased"	NA	NA	NA	NA	"suboptimal"	0	10	85	NA	"age_at_initial_pathologic_diagnosis: 70///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 28ed2d42-5b4c-4bca-b2b2-6b2a6d3c42cf///days_to_birth: -25831///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2288///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b0b53cfc-c2f6-45cc-bd58-f3412c058ea3///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 25///days_to_last_followup: 25///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2288-01A-01T-0712-07///unique_patient_id: TCGA-24-2288"
"TCGA.24.2289"	"TCGA-24-2289-01A-01T-0712-07"	"TCGA-24-2289"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	68	"y"	"y"	"n"	568	"recurrence"	2049	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b867e933-e3e3-4491-9bb6-b18c48d6f173///days_to_birth: -25191///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2289///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1f1d7a75-371a-409e-abba-e228ad2397fc///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2049///days_to_last_followup: 2049///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 568///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2289-01A-01T-0712-07///unique_patient_id: TCGA-24-2289"
"TCGA.24.2290"	"TCGA-24-2290-01A-01T-0712-07"	"TCGA-24-2290"	"tumor"	"ser"	"other"	NA	"high"	"late"	3	"c"	3	56	"y"	"y"	"n"	324	"recurrence"	1102	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	10	80	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: NA///bcr_patient_uuid: 2b14123b-8fcd-402c-9399-4e7c47f20252///days_to_birth: -20529///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C48.1///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2290///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OMENTUM///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f90e554e-790a-4892-875c-01886dd88b5f///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1102///days_to_last_followup: 1102///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 324///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal; Molecular marker Ca125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2290-01A-01T-0712-07///unique_patient_id: TCGA-24-2290"
"TCGA.24.2293"	"TCGA-24-2293-01A-01T-0712-07"	"TCGA-24-2293"	"tumor"	"ser"	"other"	NA	"high"	NA	NA	NA	3	47	"y"	"y"	"n"	506	"norecurrence"	506	"deceased"	NA	NA	NA	"partialresponse"	"suboptimal"	50	0	48	NA	"age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Right///bcr_patient_uuid: bdd792e7-d75f-4aa3-b38e-f0708e112075///days_to_birth: -17235///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C48.1///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2293///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: NA///tumor_tissue_site: OMENTUM///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 65ef94b1-f432-43af-b82b-79eda4ec62be///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 506///days_to_last_followup: 506///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2293-01A-01T-0712-07///unique_patient_id: TCGA-24-2293"
"TCGA.24.2295"	"TCGA-24-2295-01A-01T-0712-07"	"TCGA-24-2295"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	69	"y"	"y"	"n"	281	"recurrence"	1007	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	5	0	92	NA	"age_at_initial_pathologic_diagnosis: 69///anatomic_organ_subdivision: Right///bcr_patient_uuid: 7bd1851f-7e2e-4dbc-9f0e-7cb2863371e1///days_to_birth: -25415///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2295///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 695ad248-871c-4957-b597-9f1f0d08470e///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1007///days_to_last_followup: 1007///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 281///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: High grade obstruction in the recto sigmoid area///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2295-01A-01T-0712-07///unique_patient_id: TCGA-24-2295"
"TCGA.24.2297"	"TCGA-24-2297-01A-01T-0712-07"	"TCGA-24-2297"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	56	"y"	"n"	"n"	1699	"norecurrence"	1699	"deceased"	NA	NA	NA	"completeresponse"	"suboptimal"	19	0	75	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2ab32e11-80d6-4ed0-a42e-da612219bbdd///days_to_birth: -20487///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2297///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1993///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 02c7c92c-2df2-46d9-a3db-88f6135c8fd6///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1699///days_to_last_followup: 1699///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2297-01A-01T-0712-07///unique_patient_id: TCGA-24-2297"
"TCGA.24.2298"	"TCGA-24-2298-01A-01T-0712-07"	"TCGA-24-2298"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	"y"	"y"	"n"	469	"recurrence"	1620	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	26	0	72	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7e4e7914-ec23-4c55-98d6-3c5eecffa8e4///days_to_birth: -20453///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2298///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1993///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7d8007b6-ce25-4492-aaf7-bea05f783983///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1620///days_to_last_followup: 1620///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 469///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal and pelvic CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2298-01A-01T-0712-07///unique_patient_id: TCGA-24-2298"
"TCGA.25.1312"	"TCGA-25-1312-01A-01T-0455-07"	"TCGA-25-1312"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	69	NA	NA	NA	31	"norecurrence"	31	"deceased"	NA	NA	NA	NA	"optimal"	0	12	88	NA	"age_at_initial_pathologic_diagnosis: 69///anatomic_organ_subdivision: NA///bcr_patient_uuid: 66face4a-f35c-4364-90e5-8f28e6372606///days_to_birth: -25537///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1312///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 988ebd14-2804-4352-b66e-133006ea6a1e///chemo_therapy: NA///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 31///days_to_last_followup: 31///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1312-01A-01T-0455-07///unique_patient_id: TCGA-25-1312"
"TCGA.25.1313"	"TCGA-25-1313-01A-01T-0455-07"	"TCGA-25-1313"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	62	"n"	"y"	"n"	819	"norecurrence"	819	"deceased"	NA	NA	NA	"completeresponse"	"optimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: NA///bcr_patient_uuid: d73a0a33-e4e8-44bd-9580-2038ab06583a///days_to_birth: -22982///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1313///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 61ada3f9-4015-4673-ac92-e08e99fa05b8///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 819///days_to_last_followup: 819///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 394///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: ca-125///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1313-01A-01T-0455-07///unique_patient_id: TCGA-25-1313"
"TCGA.25.1314"	"TCGA-25-1314-01A-01T-0455-07"	"TCGA-25-1314"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	42	"y"	"y"	"n"	973	"norecurrence"	1003	"deceased"	NA	NA	NA	"partialresponse"	"optimal"	0	4	96	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0b2ea4b7-98bb-4190-b682-2c75b447c90a///days_to_birth: -15462///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1314///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: fe94fad3-1f4c-4204-ad9b-d8a1ab9b75cc///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: 273///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1003///days_to_last_followup: 973///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 273///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1314-01A-01T-0455-07///unique_patient_id: TCGA-25-1314"
"TCGA.25.1315"	"TCGA-25-1315-01A-01T-0455-07"	"TCGA-25-1315"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"y"	"n"	1553	"norecurrence"	1583	"deceased"	NA	NA	NA	"partialresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: NA///bcr_patient_uuid: 635f5335-b008-428e-b005-615776a6643f///days_to_birth: -18263///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1315///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5f76897a-afa8-4e00-a593-08ad2e7a93d7///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: 153///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1583///days_to_last_followup: 1553///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 153///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1315-01A-01T-0455-07///unique_patient_id: TCGA-25-1315"
"TCGA.25.1316"	"TCGA-25-1316-01A-01T-0455-07"	"TCGA-25-1316"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	"n"	"y"	"n"	1126	"norecurrence"	1279	"deceased"	NA	NA	NA	"progressivedisease"	"optimal"	0	4	96	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: NA///bcr_patient_uuid: 58427bce-6b81-4083-aeda-25f59e292bbc///days_to_birth: -20331///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1316///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 66d2e9b2-0219-4b9a-aa62-d52e65461829///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1279///days_to_last_followup: 1126///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 276///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1316-01A-01T-0455-07///unique_patient_id: TCGA-25-1316"
"TCGA.25.1317"	"TCGA-25-1317-01A-01T-0455-07"	"TCGA-25-1317"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"n"	"y"	"n"	31	"norecurrence"	68	"deceased"	NA	NA	NA	NA	NA	0	35	60	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: NA///bcr_patient_uuid: 78777a80-cc6c-46c9-a14a-837ac7943719///days_to_birth: -24199///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1317///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 72ae7e80-c25a-4051-86da-8d77657354e5///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 68///days_to_last_followup: 31///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1317-01A-01T-0455-07///unique_patient_id: TCGA-25-1317"
"TCGA.25.1318"	"TCGA-25-1318-01A-01T-0455-07"	"TCGA-25-1318"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	54	"n"	"y"	"n"	185	"recurrence"	1064	"deceased"	NA	NA	"metastasis"	"partialresponse"	"optimal"	NA	12	82	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: NA///bcr_patient_uuid: 13319c20-02f6-4b5f-b24f-3d8f4084094c///days_to_birth: -19755///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1318///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: f632b553-5ecb-48ef-84bc-d5372657f82a///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1064///days_to_last_followup: 1064///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 185///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1318-01A-01T-0455-07///unique_patient_id: TCGA-25-1318"
"TCGA.25.1319"	"TCGA-25-1319-01A-01T-0455-07"	"TCGA-25-1319"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	"n"	"y"	"n"	1977	"norecurrence"	1977	"deceased"	NA	NA	NA	NA	"suboptimal"	5	22	70	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: NA///bcr_patient_uuid: 914d8613-3c25-4a10-be50-28b42f4d3a5d///days_to_birth: -26786///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1319///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 760f24c1-7601-415f-8c8f-79778d72eea4///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1977///days_to_last_followup: 1977///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 730///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1319-01A-01T-0455-07///unique_patient_id: TCGA-25-1319"
"TCGA.25.1320"	"TCGA-25-1320-01A-01T-0455-07"	"TCGA-25-1320"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"n"	"y"	"n"	423	"recurrence"	1154	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"optimal"	0	28	70	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: NA///bcr_patient_uuid: 46395c3d-5e51-477f-946e-e58b87cc7baa///days_to_birth: -24018///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1320///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 96391cfa-b15a-41b8-9967-3af1db0693fc///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1154///days_to_last_followup: 1124///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 423///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Mollecular CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1320-01A-01T-0455-07///unique_patient_id: TCGA-25-1320"
"TCGA.25.1321"	"TCGA-25-1321-01A-01T-0455-07"	"TCGA-25-1321"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"n"	"y"	"n"	453	"recurrence"	1033	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	10	88	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: NA///bcr_patient_uuid: 6ad8bc89-d8e9-48c2-bc25-c8e51f972b4d///days_to_birth: -23987///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1321///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 06fca474-4b69-4a35-8807-ee9385ccd71c///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1033///days_to_last_followup: 1033///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 453///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Mollecular CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1321-01A-01T-0455-07///unique_patient_id: TCGA-25-1321"
"TCGA.25.1322"	"TCGA-25-1322-01A-01T-0455-07"	"TCGA-25-1322"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	62	"n"	"y"	"n"	91	"norecurrence"	91	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	10	75	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: NA///bcr_patient_uuid: b520aae5-65a6-4b27-bc2a-10b02c7b1aeb///days_to_birth: -22645///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1322///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 841d1973-7063-4915-bfcc-de4685a2372d///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 91///days_to_last_followup: 91///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1322-01A-01T-0455-07///unique_patient_id: TCGA-25-1322"
"TCGA.25.1323"	"TCGA-25-1323-01A-01T-0455-07"	"TCGA-25-1323"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	72	"n"	"y"	"n"	365	"norecurrence"	395	"deceased"	NA	NA	NA	"completeresponse"	"optimal"	10	12	68	NA	"age_at_initial_pathologic_diagnosis: 72///anatomic_organ_subdivision: NA///bcr_patient_uuid: 2ee36d9d-128b-4761-aa1a-a637da106f3d///days_to_birth: -26602///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1323///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7dca5a46-41d3-4c92-bfbc-ff6a771731a1///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 395///days_to_last_followup: 365///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 365///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: Mollecular CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1323-01A-01T-0455-07///unique_patient_id: TCGA-25-1323"
"TCGA.25.1324"	"TCGA-25-1324-01A-01T-0455-07"	"TCGA-25-1324"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"n"	"y"	"n"	1035	"norecurrence"	1035	"deceased"	NA	NA	NA	NA	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: NA///bcr_patient_uuid: c73244fd-d486-439f-a94f-fb0bd4e9ac8f///days_to_birth: -27090///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1324///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 275c717d-977d-4a05-a58a-4b111387938a///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1035///days_to_last_followup: 1035///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1324-01A-01T-0455-07///unique_patient_id: TCGA-25-1324"
"TCGA.25.1325"	"TCGA-25-1325-01A-01T-0455-07"	"TCGA-25-1325"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	77	NA	NA	NA	976	"norecurrence"	976	"deceased"	NA	NA	NA	NA	"suboptimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 77///anatomic_organ_subdivision: NA///bcr_patient_uuid: 9471bc5e-18da-4356-bb0f-c78edd35ff99///days_to_birth: -28183///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1325///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f831163a-bda9-4cae-bb8a-0f303a988a52///chemo_therapy: NA///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 976///days_to_last_followup: 976///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1325-01A-01T-0455-07///unique_patient_id: TCGA-25-1325"
"TCGA.25.1326"	"TCGA-25-1326-01A-01T-0455-07"	"TCGA-25-1326"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	"n"	"y"	"n"	395	"recurrence"	1248	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	NA	20	68	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: NA///bcr_patient_uuid: 07a859fc-6f78-4905-9035-90e2403dbe8d///days_to_birth: -22339///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1326///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7a9ac328-f776-41a3-9f99-0fa250c41f24///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1248///days_to_last_followup: 944///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 395///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan; Mollecular CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1326-01A-01T-0455-07///unique_patient_id: TCGA-25-1326"
"TCGA.25.1328"	"TCGA-25-1328-01A-01T-0455-07"	"TCGA-25-1328"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	38	"n"	"y"	"n"	244	"recurrence"	2009	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	NA	8	80	NA	"age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: NA///bcr_patient_uuid: 79fd602b-3e8e-4353-aa78-4f5f170b607d///days_to_birth: -13910///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1328///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9b2cf6b3-c423-4721-90b4-ae9c1fb5c92f///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: 244///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2009///days_to_last_followup: 1979///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 244///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1328-01A-01T-0455-07///unique_patient_id: TCGA-25-1328"
"TCGA.25.1329"	"TCGA-25-1329-01A-01T-0455-07"	"TCGA-25-1329"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	76	NA	NA	NA	90	"norecurrence"	457	"deceased"	NA	NA	NA	NA	"suboptimal"	0	15	72	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: NA///bcr_patient_uuid: 955c80be-53df-4565-9303-a7abf96a2f81///days_to_birth: -28093///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1329///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f1c2ba9f-692a-4e14-a1ff-b522f182598b///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 457///days_to_last_followup: 90///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1329-01A-01T-0455-07///unique_patient_id: TCGA-25-1329"
"TCGA.25.1623"	"TCGA-25-1623-01A-01T-0541-07"	"TCGA-25-1623"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	71	"y"	"y"	"n"	342	"recurrence"	565	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	32	62	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 808eb134-9c7d-43bb-b86c-2f3259193954///days_to_birth: -26059///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1623///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3089d69d-a5cf-47d4-ae07-46478224b106///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 565///days_to_last_followup: 565///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 342///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1623-01A-01T-0541-07///unique_patient_id: TCGA-25-1623"
"TCGA.25.1625"	"TCGA-25-1625-01A-01T-0541-07"	"TCGA-25-1625"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"y"	"y"	"n"	526	"recurrence"	840	"deceased"	NA	NA	"metastasis"	"stabledisease"	"optimal"	22	8	65	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 88d61634-913c-435a-8d25-e019c8dab7da///days_to_birth: -24297///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1625///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 08af2828-7b39-4fa2-b029-1131f1b50b8d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 545///days_to_death: 840///days_to_last_followup: 548///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 526///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular Marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1625-01A-01T-0541-07///unique_patient_id: TCGA-25-1625"
"TCGA.25.1626"	"TCGA-25-1626-01A-01T-0541-07"	"TCGA-25-1626"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"y"	"n"	318	"recurrence"	517	"deceased"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	35	60	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Right///bcr_patient_uuid: 662d77d1-1a43-427a-813b-e11edd30868e///days_to_birth: -23932///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1626///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 827174ff-d45f-4226-80a0-df0bcc8d9f66///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 517///days_to_last_followup: 480///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 318///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular Maker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1626-01A-01T-0541-07///unique_patient_id: TCGA-25-1626"
"TCGA.25.1627"	"TCGA-25-1627-01A-01T-0541-07"	"TCGA-25-1627"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	NA	NA	NA	11	"norecurrence"	394	"deceased"	NA	NA	NA	NA	"optimal"	0	9	90	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cbe3309e-9b7b-4f62-87b5-0f5ed4218ada///days_to_birth: -26784///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1627///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 20c8251e-9302-47d0-b9fa-9e915447bc3d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 394///days_to_last_followup: 11///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1627-01A-01T-0541-07///unique_patient_id: TCGA-25-1627"
"TCGA.25.1628"	"TCGA-25-1628-01A-01T-0541-07"	"TCGA-25-1628"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"y"	"y"	"n"	286	"recurrence"	626	"deceased"	NA	NA	"metastasis"	"stabledisease"	"optimal"	0	10	85	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: NA///bcr_patient_uuid: 3f917550-89a6-404b-94df-938c99121411///days_to_birth: -24488///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1628///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 50828490-96eb-46a5-9103-3b979676fea8///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 482///days_to_death: 626///days_to_last_followup: 626///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 286///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT: Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1628-01A-01T-0541-07///unique_patient_id: TCGA-25-1628"
"TCGA.25.1630"	"TCGA-25-1630-01A-01T-0541-07"	"TCGA-25-1630"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	"y"	"y"	"n"	239	"norecurrence"	1162	"deceased"	NA	NA	NA	"completeresponse"	"optimal"	0	10	87	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 263e85e2-7b6f-453f-8fd0-e5ea1409fece///days_to_birth: -27005///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1630///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: be6e817c-e570-43da-88b6-2a0d1b07d6b6///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1162///days_to_last_followup: 239///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1630-01A-01T-0541-07///unique_patient_id: TCGA-25-1630"
"TCGA.25.1631"	"TCGA-25-1631-01A-01T-0541-07"	"TCGA-25-1631"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	NA	NA	NA	9	"norecurrence"	9	"deceased"	NA	NA	NA	NA	"optimal"	0	10	80	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6a1be87b-c4e0-4fd4-b050-50a245b22038///days_to_birth: -26687///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1631///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e5c704b8-3c25-452d-9629-1b554ad6dc1e///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 9///days_to_last_followup: 9///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1631-01A-01T-0541-07///unique_patient_id: TCGA-25-1631"
"TCGA.25.1632"	"TCGA-25-1632-01A-01T-0541-07"	"TCGA-25-1632"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	68	"y"	"y"	"n"	537	"recurrence"	1799	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c435627c-159d-4a6d-a819-30abac24bf4d///days_to_birth: -24992///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1632///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4ba05fe8-8855-4d63-a4a5-e711b36c1ae5///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1799///days_to_last_followup: 1732///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 537///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular Marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1632-01A-01T-0541-07///unique_patient_id: TCGA-25-1632"
"TCGA.25.1633"	"TCGA-25-1633-01A-01T-0541-07"	"TCGA-25-1633"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	64	"y"	"y"	"n"	616	"recurrence"	1891	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	12	86	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 20336269-5a5b-4ba7-8fe8-665a1f9af738///days_to_birth: -23407///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1633///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: bdb1af60-d13a-43c7-a60d-2e6e2406beba///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1891///days_to_last_followup: 1843///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 616///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1633-01A-01T-0541-07///unique_patient_id: TCGA-25-1633"
"TCGA.25.1634"	"TCGA-25-1634-01A-01T-0541-07"	"TCGA-25-1634"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	75	"y"	"y"	"n"	380	"recurrence"	1091	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	15	84	NA	"age_at_initial_pathologic_diagnosis: 75///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 15556b28-c6bd-455a-87b6-4b7b3e33d0e4///days_to_birth: -27749///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1634///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 116c7279-c17b-4dbb-8ff7-3939c33d41fb///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1091///days_to_last_followup: 1081///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 380///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: FNA lymph node///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1634-01A-01T-0541-07///unique_patient_id: TCGA-25-1634"
"TCGA.25.1635"	"TCGA-25-1635-01A-01T-0541-07"	"TCGA-25-1635"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	614	"recurrence"	1583	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	15	80	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: bc2591b0-65d7-48c3-a5cc-783f67b65869///days_to_birth: -26199///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1635///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: ba5104ee-89a9-455e-bff2-e4f3bec0a20b///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1583///days_to_last_followup: 1558///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 614///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1635-01A-01T-0541-07///unique_patient_id: TCGA-25-1635"
"TCGA.25.1870"	"TCGA-25-1870-01A-01T-0656-07"	"TCGA-25-1870"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	59	"y"	"n"	"n"	242	"recurrence"	454	"deceased"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 15f1a992-0724-4d76-a71a-702ac7753a41///days_to_birth: -21550///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1870///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1994///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: d8dd85e5-4709-40cf-8e60-34f345303195///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 242///days_to_death: 454///days_to_last_followup: 454///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 242///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1870-01A-01T-0656-07///unique_patient_id: TCGA-25-1870"
"TCGA.25.1871"	"TCGA-25-1871-01A-01T-0656-07"	"TCGA-25-1871"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	70	"y"	"y"	"n"	230	"recurrence"	760	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"suboptimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 70///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ff844242-7559-4b07-b09e-69ea40e5ac6b///days_to_birth: -25626///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1871///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1993///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 797eae07-f777-48e4-a573-c5cbad320184///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 334///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 760///days_to_last_followup: 760///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 230///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study-CT Scan; Molecular marker- CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1871-01A-01T-0656-07///unique_patient_id: TCGA-25-1871"
"TCGA.25.1877"	"TCGA-25-1877-01A-01T-0656-07"	"TCGA-25-1877"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	81	"y"	"y"	"n"	549	"recurrence"	730	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 81///anatomic_organ_subdivision: Left///bcr_patient_uuid: 077079c3-6877-467b-b9cc-5c650aae4f07///days_to_birth: -29614///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1877///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1993///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: be06d351-8800-477e-ba18-249a66a7fa24///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 730///days_to_last_followup: 549///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 549///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1877-01A-01T-0656-07///unique_patient_id: TCGA-25-1877"
"TCGA.25.1878"	"TCGA-25-1878-01A-01T-0656-07"	"TCGA-25-1878"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	"y"	"y"	"n"	971	"recurrence"	2587	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	10	88	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9bdbaccf-b43b-4ec3-8b9b-dff65215eb00///days_to_birth: -22034///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1878///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1994///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a827269a-ecd1-4a70-b55c-3a36cff2de7c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2587///days_to_last_followup: 2587///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 971///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1878-01A-01T-0656-07///unique_patient_id: TCGA-25-1878"
"TCGA.25.2042"	"TCGA-25-2042-01A-01T-0712-07"	"TCGA-25-2042"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	"y"	"y"	"n"	NA	"recurrence"	396	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"suboptimal"	0	68	30	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 818dc159-aba4-46bc-a4ed-68ee0f8c4461///days_to_birth: -22126///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2042///pretreatment_history: NO///race: AMERICAN INDIAN OR ALASKA NATIVE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 67cbdcbf-2e6a-4de9-9658-9bbd8ae0f47f///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 123///days_to_death: 396///days_to_last_followup: 396///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-2042-01A-01T-0712-07///unique_patient_id: TCGA-25-2042"
"TCGA.25.2391"	"TCGA-25-2391-01A-01T-0712-07"	"TCGA-25-2391"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	1492	"norecurrence"	1492	"deceased"	NA	NA	NA	"completeresponse"	"suboptimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f5033d52-ec36-4e67-88d8-b6d898b81b2f///days_to_birth: -20938///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2391///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6ec2f13a-7241-400e-ba92-e194af3034c7///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1492///days_to_last_followup: 1492///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2391-01A-01T-0712-07///unique_patient_id: TCGA-25-2391"
"TCGA.25.2392"	"TCGA-25-2392-01A-01T-0712-07"	"TCGA-25-2392"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	75	NA	NA	NA	31	"norecurrence"	31	"deceased"	NA	NA	NA	NA	"suboptimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 75///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7413c891-f74e-456f-bc70-69c83fb53c70///days_to_birth: -27666///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2392///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d9ebef02-cd9d-4ec0-851a-3192d9744cd5///chemo_therapy: NO///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 31///days_to_last_followup: 31///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2392-01A-01T-0712-07///unique_patient_id: TCGA-25-2392"
"TCGA.25.2393"	"TCGA-25-2393-01A-01T-0712-07"	"TCGA-25-2393"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	81	"y"	"y"	"n"	305	"recurrence"	1157	"deceased"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	1	14	80	NA	"age_at_initial_pathologic_diagnosis: 81///anatomic_organ_subdivision: Left///bcr_patient_uuid: b4b49027-7815-4813-9769-a3fe3a26a37a///days_to_birth: -29584///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2393///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: ca8b79a1-aba9-4f39-a940-ad6da40efd5b///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1157///days_to_last_followup: 1157///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 305///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2393-01A-01T-0712-07///unique_patient_id: TCGA-25-2393"
"TCGA.25.2396"	"TCGA-25-2396-01A-01T-0712-07"	"TCGA-25-2396"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	NA	NA	NA	92	"norecurrence"	92	"deceased"	NA	NA	NA	NA	"optimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6264e699-d40b-4ebc-b443-0a0edcb220dc///days_to_birth: -26144///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2396///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b232044d-3dba-49c2-93ae-c83e8d7469ef///chemo_therapy: NA///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 92///days_to_last_followup: 92///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2396-01A-01T-0712-07///unique_patient_id: TCGA-25-2396"
"TCGA.25.2397"	"TCGA-25-2397-01A-01T-0712-07"	"TCGA-25-2397"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	59	NA	NA	NA	365	"norecurrence"	365	"deceased"	NA	NA	NA	NA	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 4c099644-047c-42a3-8187-bfcbfe6662e4///days_to_birth: -21581///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2397///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3eeab957-b68a-427b-8555-1c33a30d4c18///chemo_therapy: NA///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 365///days_to_last_followup: 365///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2397-01A-01T-0712-07///unique_patient_id: TCGA-25-2397"
"TCGA.25.2398"	"TCGA-25-2398-01A-01T-0712-07"	"TCGA-25-2398"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	577	"recurrence"	1369	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	30	65	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: fd4740db-76a8-4362-be71-7b609479bb67///days_to_birth: -26266///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2398///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0fa5671b-b95a-432f-a2ef-0baed081c586///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1369///days_to_last_followup: 1369///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 577///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2398-01A-01T-0712-07///unique_patient_id: TCGA-25-2398"
"TCGA.25.2399"	"TCGA-25-2399-01A-01T-0712-07"	"TCGA-25-2399"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	80	"y"	"y"	"n"	243	"recurrence"	608	"deceased"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	5	90	NA	"age_at_initial_pathologic_diagnosis: 80///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ad2b1a0a-153f-483d-b228-5763eba3f6cc///days_to_birth: -29373///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2399///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f2ca0f5d-438c-46cf-af2a-976cf4036f11///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 608///days_to_last_followup: 608///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 243///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and Other Method- CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2399-01A-01T-0712-07///unique_patient_id: TCGA-25-2399"
"TCGA.25.2400"	"TCGA-25-2400-01A-01T-0712-07"	"TCGA-25-2400"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	76	"y"	"y"	"n"	577	"recurrence"	1278	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5c127332-5ca0-45f1-a5ac-4876ad94e491///days_to_birth: -27789///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2400///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 97a1075f-1009-4e51-ad56-1d86ab3f66fa///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1278///days_to_last_followup: 1278///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 577///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and Other Method0 CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2400-01A-01T-0712-07///unique_patient_id: TCGA-25-2400"
"TCGA.25.2401"	"TCGA-25-2401-01A-01T-0712-07"	"TCGA-25-2401"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	64	NA	NA	NA	90	"norecurrence"	90	"deceased"	NA	NA	NA	NA	"optimal"	0	14	82	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3bc8a74f-49bd-46b6-a3a4-68ca838e83c6///days_to_birth: -23711///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2401///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 94ff5853-4598-4507-831f-006d4aef14e2///chemo_therapy: NA///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 90///days_to_last_followup: 90///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2401-01A-01T-0712-07///unique_patient_id: TCGA-25-2401"
"TCGA.25.2404"	"TCGA-25-2404-01A-01T-0712-07"	"TCGA-25-2404"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	38	"y"	"y"	"n"	425	"recurrence"	882	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	1	21	78	NA	"age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 22178c3c-6b04-46d8-8041-dc83fa195029///days_to_birth: -14184///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2404///pretreatment_history: NO///race: AMERICAN INDIAN OR ALASKA NATIVE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 8b0b1002-3ed9-4317-ba15-982dc5522748///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 882///days_to_last_followup: 882///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 425///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and Molecular Marker - CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2404-01A-01T-0712-07///unique_patient_id: TCGA-25-2404"
"TCGA.25.2408"	"TCGA-25-2408-01A-01T-0712-07"	"TCGA-25-2408"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	37	"y"	"y"	"n"	333	"recurrence"	942	"deceased"	NA	NA	"metastasis"	"partialresponse"	"optimal"	1	9	90	NA	"age_at_initial_pathologic_diagnosis: 37///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: fdd4adb8-9295-480a-9352-305b5eb51187///days_to_birth: -13606///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2408///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NA///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: f82208f0-6255-4dd7-8523-c0c9da6e0800///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 333///days_to_death: 942///days_to_last_followup: 942///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 333///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2408-01A-01T-0712-07///unique_patient_id: TCGA-25-2408"
"TCGA.25.2409"	"TCGA-25-2409-01A-01T-0712-07"	"TCGA-25-2409"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	71	"y"	"n"	"n"	303	"recurrence"	820	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	1	4	94	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: dce71741-ccbe-40b7-a0b8-2048d07187a4///days_to_birth: -26267///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2409///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c42fe3b3-07fd-4f77-9037-972142140153///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 820///days_to_last_followup: 820///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 303///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and Other Method-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2409-01A-01T-0712-07///unique_patient_id: TCGA-25-2409"
"TCGA.29.1688"	"TCGA-29-1688-01A-01T-0567-07"	"TCGA-29-1688"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	39	"y"	"y"	"n"	183	"recurrence"	2399	"deceased"	NA	NA	"locoregional"	"stabledisease"	NA	0	0	100	NA	"age_at_initial_pathologic_diagnosis: 39///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 05019013-7ea5-4905-ac79-901146ba2ee2///days_to_birth: -14574///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1688///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1992///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: eb9c7a54-595c-42ce-bf50-83f92050181d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 183///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2399///days_to_last_followup: 2399///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 183///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1688-01A-01T-0567-07///unique_patient_id: TCGA-29-1688"
"TCGA.29.1690"	"TCGA-29-1690-01A-01T-0567-07"	"TCGA-29-1690"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	66	"y"	"y"	"n"	1360	"norecurrence"	1448	"deceased"	NA	NA	NA	NA	"suboptimal"	0	0	100	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6b06281b-d3a9-440e-a86c-ee7db003352a///days_to_birth: -24318///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1690///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1993///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6429b19f-5be1-4edf-9c06-a0a292dede40///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1448///days_to_last_followup: 1360///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1690-01A-01T-0567-07///unique_patient_id: TCGA-29-1690"
"TCGA.29.1691"	"TCGA-29-1691-01A-01T-0567-07"	"TCGA-29-1691"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	51	"y"	"y"	"n"	613	"recurrence"	1470	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	0	98	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b4225c44-b9b6-46c5-aabf-7b0d9a9fe20b///days_to_birth: -18664///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1691///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: cd9c0017-f19f-4f93-983c-3b4f58156aed///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 624///days_to_death: 1470///days_to_last_followup: 1435///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 613///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1691-01A-01T-0567-07///unique_patient_id: TCGA-29-1691"
"TCGA.29.1693"	"TCGA-29-1693-01A-01T-0567-07"	"TCGA-29-1693"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	72	"y"	"y"	"n"	694	"recurrence"	3095	"living"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	0	98	NA	"age_at_initial_pathologic_diagnosis: 72///anatomic_organ_subdivision: Left///bcr_patient_uuid: 6fb71a0c-bc50-48c8-acfa-db94be1e151a///days_to_birth: -26300///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1693///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 12658bed-f067-4263-b749-1e9839821a25///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 2050///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 3095///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 694///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Ct///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1693-01A-01T-0567-07///unique_patient_id: TCGA-29-1693"
"TCGA.29.1694"	"TCGA-29-1694-01A-01T-0567-07"	"TCGA-29-1694"	"tumor"	"ser"	"ov"	NA	NA	"late"	3	"c"	NA	45	"y"	"y"	"n"	NA	"recurrence"	1187	"deceased"	NA	NA	"locoregional"	"stabledisease"	"suboptimal"	0	18	82	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1db60f09-7f5a-4f21-8003-06a6abc781db///days_to_birth: -16522///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 1694///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a17e36f4-a75c-4d56-a8a4-f79d48e9513b///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 206///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1187///days_to_last_followup: 1172///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1694-01A-01T-0567-07///unique_patient_id: TCGA-29-1694"
"TCGA.29.1695"	"TCGA-29-1695-01A-01T-0567-07"	"TCGA-29-1695"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	62	NA	NA	NA	24	"norecurrence"	1229	"deceased"	NA	NA	NA	NA	"suboptimal"	0	0	99	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: Left///bcr_patient_uuid: 33d36b64-4688-40a7-9a4f-7cd3d4cc683d///days_to_birth: -22894///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1695///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1a796fc4-467e-422f-b7bf-d9857180bafa///chemo_therapy: NA///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1229///days_to_last_followup: 24///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1695-01A-01T-0567-07///unique_patient_id: TCGA-29-1695"
"TCGA.29.1696"	"TCGA-29-1696-01A-01T-0567-07"	"TCGA-29-1696"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	43	"y"	"y"	"n"	342	"recurrence"	1032	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	0	100	NA	"age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Right///bcr_patient_uuid: 8a98a6e6-b763-4824-858b-fd2738e6c9a3///days_to_birth: -15818///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1696///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 82bd749e-d9aa-4da7-bd7d-57255e9c7e2e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 454///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1032///days_to_last_followup: 1025///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 342///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1696-01A-01T-0567-07///unique_patient_id: TCGA-29-1696"
"TCGA.29.1697"	"TCGA-29-1697-01A-01T-0567-07"	"TCGA-29-1697"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	62	"y"	"y"	"n"	499	"recurrence"	948	"deceased"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	0	0	98	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 42ebd30b-175e-4ece-a806-e55cb7e40e96///days_to_birth: -22933///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1697///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9c6b4033-ddba-482d-a15c-ea455d16687e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 948///days_to_last_followup: 948///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 499///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1697-01A-01T-0567-07///unique_patient_id: TCGA-29-1697"
"TCGA.29.1698"	"TCGA-29-1698-01A-01T-0567-07"	"TCGA-29-1698"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	53	"y"	"y"	"n"	180	"recurrence"	2077	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	45	50	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 18d21132-a795-4551-83ba-66483de423a2///days_to_birth: -19611///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1698///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3f529423-5e1c-423a-82d2-6b60842e06f5///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 180///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2077///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 180///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1698-01A-01T-0567-07///unique_patient_id: TCGA-29-1698"
"TCGA.29.1699"	"TCGA-29-1699-01A-01T-0567-07"	"TCGA-29-1699"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	NA	NA	NA	NA	"norecurrence"	NA	NA	NA	NA	NA	NA	"optimal"	0	0	98	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: fe0e3851-d8cb-4533-9536-b4826cd25f87///days_to_birth: -21130///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1699///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: NA///chemo_therapy: NA///day_of_form_completion: NA///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: NA///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: NA///year_of_form_completion: NA///Extract.Name: TCGA-29-1699-01A-01T-0567-07///unique_patient_id: TCGA-29-1699"
"TCGA.29.1701"	"TCGA-29-1701-01A-01T-0567-07"	"TCGA-29-1701"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	56	"y"	"y"	"n"	298	"recurrence"	515	"deceased"	NA	NA	"locoregional"	"partialresponse"	NA	0	0	98	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 86b513ba-df09-485d-92d4-fb9e888f7350///days_to_birth: -20736///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1701///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 54915dda-c60b-4540-8ba8-7325a9fe50c7///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 515///days_to_last_followup: 514///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 298///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1701-01A-01T-0567-07///unique_patient_id: TCGA-29-1701"
"TCGA.29.1702"	"TCGA-29-1702-01A-01T-0567-07"	"TCGA-29-1702"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	84	"y"	"y"	"n"	285	"recurrence"	728	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	0	98	NA	"age_at_initial_pathologic_diagnosis: 84///anatomic_organ_subdivision: Right///bcr_patient_uuid: 0e1598d8-cbe5-4113-95f1-4bcda061239b///days_to_birth: -30910///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1702///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a69603c0-0756-4367-a239-b419edfc8130///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 728///days_to_last_followup: 567///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 285///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1702-01A-01T-0567-07///unique_patient_id: TCGA-29-1702"
"TCGA.29.1703"	"TCGA-29-1703-01A-01T-0567-07"	"TCGA-29-1703"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	56	"y"	"y"	"n"	324	"recurrence"	1815	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	0	94	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b3511675-fd68-4745-8020-e290ca0fd115///days_to_birth: -20622///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1703///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: aef081e4-4629-4f49-a25f-0787fe8e2ce5///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1815///days_to_last_followup: 1815///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 324///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1703-01A-01T-0567-07///unique_patient_id: TCGA-29-1703"
"TCGA.29.1704"	"TCGA-29-1704-01B-01T-0811-07"	"TCGA-29-1704"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	"y"	"y"	"n"	568	"recurrence"	1587	"living"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	15	85	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8e7f1c74-7cb3-43c0-b07c-bf69b780053f///days_to_birth: -22511///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1704///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 23a71c94-1e87-4ba8-ae02-bde47265ccdf///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 608///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1587///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 568///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1704-01B-01T-0811-07///unique_patient_id: TCGA-29-1704"
"TCGA.29.1711"	"TCGA-29-1711-01A-01T-0604-07"	"TCGA-29-1711"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	45	"y"	"n"	"n"	1053	"norecurrence"	1053	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	0	98	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f58e49fc-9641-4b46-be4c-766445ec70a3///days_to_birth: -16485///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1711///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 764f8125-40f5-4183-8365-5d97c30cbdf0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1053///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1711-01A-01T-0604-07///unique_patient_id: TCGA-29-1711"
"TCGA.29.1761"	"TCGA-29-1761-01A-01T-0567-07"	"TCGA-29-1761"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	80	"y"	"y"	"n"	517	"norecurrence"	528	"deceased"	NA	NA	NA	"stabledisease"	"suboptimal"	0	8	88	NA	"age_at_initial_pathologic_diagnosis: 80///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 374ea8df-ecc4-44b0-b519-33efa5078018///days_to_birth: -29337///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1761///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d8897df7-fd26-4fd4-b696-00efd70cb5fc///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 528///days_to_last_followup: 517///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1761-01A-01T-0567-07///unique_patient_id: TCGA-29-1761"
"TCGA.29.1762"	"TCGA-29-1762-01A-01T-0567-07"	"TCGA-29-1762"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	59	"y"	"y"	"n"	1374	"recurrence"	2634	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	5	80	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5495b18a-10ec-427b-83b8-03ef4b587b13///days_to_birth: -21879///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1762///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9362c381-3391-410c-8898-c0797a7bdab2///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2634///days_to_last_followup: 2606///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1374///eastern_cancer_oncology_group: 2///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CR///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1762-01A-01T-0567-07///unique_patient_id: TCGA-29-1762"
"TCGA.29.1763"	"TCGA-29-1763-01A-02T-0567-07"	"TCGA-29-1763"	"tumor"	"ser"	"ov"	NA	"low"	"early"	2	"c"	2	43	"y"	"y"	"n"	428	"recurrence"	2031	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	0	95	NA	"age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 242da7d0-8c6a-4395-9a0d-aa36e7c25ce6///days_to_birth: -16021///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1763///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5ab2d1a0-ed91-44b1-97ec-51a9f633cbea///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 1868///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2031///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 428///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Biopsy///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1763-01A-02T-0567-07///unique_patient_id: TCGA-29-1763"
"TCGA.29.1764"	"TCGA-29-1764-01A-01T-0567-07"	"TCGA-29-1764"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	49	"y"	"y"	"n"	792	"recurrence"	1914	"living"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	0	6	88	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c70228cc-79c0-4c00-8926-6671c1474701///days_to_birth: -18011///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1764///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8de913c5-72f9-4108-b6ec-8add802932b2///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1914///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 792///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1764-01A-01T-0567-07///unique_patient_id: TCGA-29-1764"
"TCGA.29.1766"	"TCGA-29-1766-01A-01T-0567-07"	"TCGA-29-1766"	"tumor"	"ser"	"other"	NA	"low"	"late"	3	"c"	2	74	"y"	"y"	"n"	672	"recurrence"	1198	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"suboptimal"	0	45	48	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Right///bcr_patient_uuid: 01ea6354-137b-47f3-9021-a01a382b1147///days_to_birth: -27359///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C48.2///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1766///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: PERITONEUM (OVARY)///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 043a6f1d-d0c2-411a-937d-9e5c790ed4ad///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1198///days_to_last_followup: 1189///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 672///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular markers-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1766-01A-01T-0567-07///unique_patient_id: TCGA-29-1766"
"TCGA.29.1768"	"TCGA-29-1768-01A-01T-0604-07"	"TCGA-29-1768"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	50	"y"	"y"	"n"	547	"recurrence"	952	"deceased"	NA	NA	"locoregional"	"stabledisease"	"suboptimal"	0	62	38	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 838693d5-1ae0-4d75-834b-e1b89b96b0ed///days_to_birth: -18395///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1768///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d01ce2b3-4094-4593-84d7-6372bfb8657e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 952///days_to_last_followup: 950///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 547///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1768-01A-01T-0604-07///unique_patient_id: TCGA-29-1768"
"TCGA.29.1769"	"TCGA-29-1769-01A-01T-0585-07"	"TCGA-29-1769"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	40	"y"	"y"	"n"	699	"norecurrence"	699	"living"	NA	NA	NA	"completeresponse"	"optimal"	5	10	85	NA	"age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 94769f2c-b6fd-48ec-af34-b41165340b7c///days_to_birth: -14753///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1769///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b97223f7-bb76-4b6f-a938-a615aa68414a///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 699///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: YES///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1769-01A-01T-0585-07///unique_patient_id: TCGA-29-1769"
"TCGA.29.1771"	"TCGA-29-1771-01A-01T-0567-07"	"TCGA-29-1771"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	76	"y"	"y"	"n"	594	"recurrence"	685	"living"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	40	60	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7b042fb2-8f53-4fb1-8a44-40cd2128b279///days_to_birth: -28093///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1771///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 61b33725-0889-4c2f-b027-45264eb718c5///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 685///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 594///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: YES///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1771-01A-01T-0567-07///unique_patient_id: TCGA-29-1771"
"TCGA.29.1774"	"TCGA-29-1774-01A-01T-0585-07"	"TCGA-29-1774"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	82	"y"	"n"	"n"	233	"recurrence"	526	"living"	NA	NA	"locoregional"	"progressivedisease"	"suboptimal"	0	20	78	NA	"age_at_initial_pathologic_diagnosis: 82///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: d3dd5e69-9752-4b50-9b1f-814afbc2c3dd///days_to_birth: -29991///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1774///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 19fa8c30-7468-4755-a242-b26569e255da///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 526///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 233///eastern_cancer_oncology_group: 2///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1774-01A-01T-0585-07///unique_patient_id: TCGA-29-1774"
"TCGA.29.1775"	"TCGA-29-1775-01A-01T-0585-07"	"TCGA-29-1775"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	51	"y"	"y"	"n"	341	"recurrence"	376	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	22	78	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a4a3fca9-723a-47f5-a49d-b3acb71c04a7///days_to_birth: -18943///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1775///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5beb42b4-f148-4115-849e-6d5be911a460///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 341///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 376///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 341///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1775-01A-01T-0585-07///unique_patient_id: TCGA-29-1775"
"TCGA.29.1776"	"TCGA-29-1776-01A-01T-0585-07"	"TCGA-29-1776"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"y"	"n"	NA	"recurrence"	360	"living"	NA	NA	"locoregional"	"stabledisease"	"suboptimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7472b3ba-9b15-4d97-8708-a2dd82ca0f45///days_to_birth: -23016///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1776///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fd4ab0eb-64c8-4130-b885-6ce0dabfa184///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 360///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1776-01A-01T-0585-07///unique_patient_id: TCGA-29-1776"
"TCGA.29.1777"	"TCGA-29-1777-01A-01T-0585-07"	"TCGA-29-1777"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	47	"y"	"n"	"n"	NA	"recurrence"	374	"living"	NA	NA	"locoregional"	"progressivedisease"	"suboptimal"	0	22	78	NA	"age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5ced5b58-fab4-4bcd-b706-d6e49ce0cfc5///days_to_birth: -17355///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1777///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 26534f1e-ae94-44af-8630-10166f59e9a1///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 374///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular markers CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1777-01A-01T-0585-07///unique_patient_id: TCGA-29-1777"
"TCGA.29.1778"	"TCGA-29-1778-01A-01T-0585-07"	"TCGA-29-1778"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	77	"y"	"y"	"n"	454	"norecurrence"	454	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 77///anatomic_organ_subdivision: Right///bcr_patient_uuid: 44e840c9-ea54-4dba-9b2a-264ef1f2c304///days_to_birth: -28146///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1778///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 04e3ce5f-feff-436c-82c2-ccf22cdc34ff///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 454///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1778-01A-01T-0585-07///unique_patient_id: TCGA-29-1778"
"TCGA.29.1781"	"TCGA-29-1781-01A-01T-0567-07"	"TCGA-29-1781"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	69	"y"	"y"	"n"	254	"norecurrence"	254	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	2	82	NA	"age_at_initial_pathologic_diagnosis: 69///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f6ebf3a7-31c6-4f4c-9a0b-74cf35bfedf6///days_to_birth: -25404///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1781///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1b223132-ee30-413c-b80b-15986f45f9a3///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 254///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1781-01A-01T-0567-07///unique_patient_id: TCGA-29-1781"
"TCGA.29.1783"	"TCGA-29-1783-01A-01T-0567-07"	"TCGA-29-1783"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	219	"norecurrence"	219	"living"	NA	NA	NA	NA	"optimal"	0	18	82	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Right///bcr_patient_uuid: 460616ec-f66f-483b-88c1-757edd86261d///days_to_birth: -21284///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1783///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 86e62f5a-909d-4d9b-971e-eccc8073dad3///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 219///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1783-01A-01T-0567-07///unique_patient_id: TCGA-29-1783"
"TCGA.29.1784"	"TCGA-29-1784-01A-02T-0567-07"	"TCGA-29-1784"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	"y"	"y"	"n"	163	"norecurrence"	163	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Right///bcr_patient_uuid: 23d32627-9fd2-4312-bcda-ee7409e3983f///days_to_birth: -20209///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1784///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 28926cc4-ceb1-40d1-b84d-c2e9bcb874e6///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 163///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1784-01A-02T-0567-07///unique_patient_id: TCGA-29-1784"
"TCGA.29.1785"	"TCGA-29-1785-01A-01T-0567-07"	"TCGA-29-1785"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	"y"	"y"	"n"	473	"recurrence"	1104	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	10	89	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Right///bcr_patient_uuid: 1aea3c25-d2bc-4ff5-bc27-32e939944e9d///days_to_birth: -20417///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1785///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 17f78a1a-2ea9-4f63-8106-86672d28f6df///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1104///days_to_last_followup: 1053///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 473///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1785-01A-01T-0567-07///unique_patient_id: TCGA-29-1785"
"TCGA.29.2414"	"TCGA-29-2414-01A-02T-0712-07"	"TCGA-29-2414"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	75	"y"	"y"	"n"	551	"recurrence"	2621	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	40	0	54	NA	"age_at_initial_pathologic_diagnosis: 75///anatomic_organ_subdivision: Left///bcr_patient_uuid: a2319490-b85d-4219-a1b0-fa1ec432d5c8///days_to_birth: -27417///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2414///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 955879e7-53f1-48e3-85c2-47d63a4b8113///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: 2222///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2621///days_to_last_followup: 2621///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 551///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Fine needle apsiration (cytology)///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-29-2414-01A-02T-0712-07///unique_patient_id: TCGA-29-2414"
"TCGA.29.2425"	"TCGA-29-2425-01A-01T-0712-07"	"TCGA-29-2425"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	60	"y"	"y"	"n"	NA	"recurrence"	1977	"living"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	12	80	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: NA///bcr_patient_uuid: 40635bf3-d8ba-4833-b623-547e55e5d07e///days_to_birth: -22089///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 2425///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: dbe47bcc-3e28-4fec-95cf-f4363c17e184///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: 1024///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1977///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 1577///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and Molecular Marker-CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-29-2425-01A-01T-0712-07///unique_patient_id: TCGA-29-2425"
"TCGA.29.2427"	"TCGA-29-2427-01A-01T-0712-07"	"TCGA-29-2427"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	"y"	"y"	"n"	1900	"norecurrence"	1900	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	0	15	80	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Left///bcr_patient_uuid: 6f25001a-f890-4fd0-a994-e62a9ea5c6f3///days_to_birth: -21940///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2427///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 43e966c8-610e-48a8-9e83-b2635e874aa0///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1900///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1581///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-29-2427-01A-01T-0712-07///unique_patient_id: TCGA-29-2427"
"TCGA.29.2428"	"TCGA-29-2428-01A-01T-0712-07"	"TCGA-29-2428"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	1372	"norecurrence"	1372	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	0	12	85	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Left///bcr_patient_uuid: b0585c7a-7205-4dac-9d54-6da89674accb///days_to_birth: -21391///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2428///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1aae8af8-d856-4054-bdcd-5cd78895a694///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1372///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-29-2428-01A-01T-0712-07///unique_patient_id: TCGA-29-2428"
"TCGA.29.2429"	"TCGA-29-2429-01A-01T-1051-07"	"TCGA-29-2429"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	79	"y"	"y"	"n"	NA	"norecurrence"	NA	NA	NA	NA	NA	NA	"suboptimal"	0	10	82	NA	"age_at_initial_pathologic_diagnosis: 79///anatomic_organ_subdivision: Right///bcr_patient_uuid: 4309ca23-1cf9-40a2-a01c-ccee90f958b2///days_to_birth: -29156///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2429///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: NA///chemo_therapy: NA///day_of_form_completion: NA///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: NA///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: NA///year_of_form_completion: NA///Extract.Name: TCGA-29-2429-01A-01T-1051-07///unique_patient_id: TCGA-29-2429"
"TCGA.29.2431"	"TCGA-29-2431-01A-01T-1051-07"	"TCGA-29-2431"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	59	"y"	"y"	"n"	960	"recurrence"	1285	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	14	86	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 996313ef-11e7-459d-ba5f-ac1a4d0de513///days_to_birth: -21832///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2431///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 660c77d7-5cc1-458b-940f-993ed928fa78///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1285///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 960///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-29-2431-01A-01T-1051-07///unique_patient_id: TCGA-29-2431"
"TCGA.29.2432"	"TCGA-29-2432-01A-01T-1051-07"	"TCGA-29-2432"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	"y"	"y"	"n"	360	"norecurrence"	653	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	0	12	88	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0e6c9433-289c-4744-a0c1-47ec67774047///days_to_birth: -22605///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2432///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5b747676-eca5-410c-8d08-36ff1266ba07///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 653///days_to_last_followup: 360///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 173///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-29-2432-01A-01T-1051-07///unique_patient_id: TCGA-29-2432"
"TCGA.29.2434"	"TCGA-29-2434-01A-01T-1051-07"	"TCGA-29-2434"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	52	"y"	"y"	"n"	349	"norecurrence"	349	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	90	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Left///bcr_patient_uuid: cb090048-9af1-489d-9ebe-7efaa3dc4e85///days_to_birth: -18996///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2434///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7f29f50c-d1c4-4c15-a139-611db85c9ea8///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 349///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-29-2434-01A-01T-1051-07///unique_patient_id: TCGA-29-2434"
"TCGA.29.2436"	"TCGA-29-2436-01A-01T-1051-07"	"TCGA-29-2436"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	36	"y"	"y"	"n"	297	"norecurrence"	297	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 36///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 295231ab-477b-4077-a368-db34f867102c///days_to_birth: -13345///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2436///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1d73fbe8-7e0f-4030-a6ac-73851d305020///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 297///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-29-2436-01A-01T-1051-07///unique_patient_id: TCGA-29-2436"
"TCGA.30.1714"	"TCGA-30-1714-01A-02T-0567-07"	"TCGA-30-1714"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	68	"y"	"y"	"n"	241	"recurrence"	1158	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	30	68	NA	"age_at_initial_pathologic_diagnosis: 68///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 09820a33-80b1-42d0-8366-a0ddaf94b122///days_to_birth: -25031///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1714///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 32baf547-650e-4412-8b72-977f2bfc79e6///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1158///days_to_last_followup: 1158///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 241///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1714-01A-02T-0567-07///unique_patient_id: TCGA-30-1714"
"TCGA.30.1718"	"TCGA-30-1718-01A-01T-0567-07"	"TCGA-30-1718"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	44	"y"	"y"	"n"	896	"recurrence"	1579	"deceased"	NA	NA	"locoregional"	NA	"optimal"	0	29	70	NA	"age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ad2939e6-b8b8-475a-90e2-6a369c3d3167///days_to_birth: -16400///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1718///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 634effee-a1bd-4dd7-a813-4f04f2c4a872///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1579///days_to_last_followup: 1579///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 896///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: DECT; Other CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1718-01A-01T-0567-07///unique_patient_id: TCGA-30-1718"
"TCGA.30.1853"	"TCGA-30-1853-01A-02T-0656-07"	"TCGA-30-1853"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	634	"recurrence"	1103	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	1	98	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5d603bba-62e6-48fb-b8fc-401109abcaee///days_to_birth: -21403///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1853///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 333dfd72-26d5-496a-bcc6-c256a5360b5c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 654///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1103///days_to_last_followup: 1103///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 634///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan and Other method-CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1853-01A-02T-0656-07///unique_patient_id: TCGA-30-1853"
"TCGA.30.1855"	"TCGA-30-1855-01A-01T-0585-07"	"TCGA-30-1855"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	NA	NA	NA	75	"norecurrence"	75	"deceased"	NA	NA	NA	NA	"optimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: NA///bcr_patient_uuid: 7d1e9451-7a6a-4086-af7f-3ed57505daf0///days_to_birth: -22393///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1855///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 87943368-20bb-43f9-8d5a-b63c57b9e63d///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 75///days_to_last_followup: 75///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1855-01A-01T-0585-07///unique_patient_id: TCGA-30-1855"
"TCGA.30.1856"	"TCGA-30-1856-01A-01T-0585-07"	"TCGA-30-1856"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	56	"y"	"y"	"n"	219	"recurrence"	477	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 91a6f311-c758-4e40-9abb-cc0f6584b9c9///days_to_birth: -20626///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1856///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6fe31f68-f93f-403c-9363-e526f881bc11///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 223///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 477///days_to_last_followup: 477///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 219///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1856-01A-01T-0585-07///unique_patient_id: TCGA-30-1856"
"TCGA.30.1857"	"TCGA-30-1857-01A-02T-0585-07"	"TCGA-30-1857"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	64	NA	NA	NA	8	"norecurrence"	8	"deceased"	NA	NA	NA	NA	NA	0	18	82	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Right///bcr_patient_uuid: 45baebac-32ae-4093-9eba-488b95c1a58d///days_to_birth: -23689///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1857///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1e076431-07c6-4bfb-a0e1-fbe4498b5035///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 8///days_to_last_followup: 8///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1857-01A-02T-0585-07///unique_patient_id: TCGA-30-1857"
"TCGA.30.1859"	"TCGA-30-1859-01A-01T-0656-07"	"TCGA-30-1859"	"tumor"	"ser"	"ov"	NA	"high"	NA	NA	NA	3	56	"y"	"y"	"n"	1462	"norecurrence"	1462	"deceased"	NA	NA	NA	"partialresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: dac8d825-dd47-47ed-a426-0ee75feb76f3///days_to_birth: -20498///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1859///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: NA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 653cdd67-0520-483f-9dcd-db752961bc6e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 210///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1462///days_to_last_followup: 1462///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1859-01A-01T-0656-07///unique_patient_id: TCGA-30-1859"
"TCGA.30.1860"	"TCGA-30-1860-01A-01T-0656-07"	"TCGA-30-1860"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	397	"recurrence"	1366	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	8	88	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 563853a2-9ac2-48be-adf3-1e547ee2b274///days_to_birth: -21406///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1860///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 1893088c-1c0b-4d3c-bf14-c89f641b604e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 974///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1366///days_to_last_followup: 1366///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 397///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan and CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1860-01A-01T-0656-07///unique_patient_id: TCGA-30-1860"
"TCGA.30.1861"	"TCGA-30-1861-01A-01T-0656-07"	"TCGA-30-1861"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	NA	NA	NA	NA	"norecurrence"	NA	NA	NA	NA	NA	NA	"optimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0724f800-e873-45d0-bc56-809d0ec4f6e9///days_to_birth: -27103///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1861///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: NA///chemo_therapy: NA///day_of_form_completion: NA///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: NA///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: NA///year_of_form_completion: NA///Extract.Name: TCGA-30-1861-01A-01T-0656-07///unique_patient_id: TCGA-30-1861"
"TCGA.30.1862"	"TCGA-30-1862-01A-02T-0656-07"	"TCGA-30-1862"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	65	NA	NA	NA	185	"norecurrence"	185	"deceased"	NA	NA	NA	NA	"suboptimal"	0	35	65	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: NA///bcr_patient_uuid: 58f5a54e-de50-4cca-afa1-cc331d8b3479///days_to_birth: -23895///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1862///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 98838264-1d26-43dc-a7f7-7d0b7a0e956b///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 185///days_to_last_followup: 185///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1862-01A-02T-0656-07///unique_patient_id: TCGA-30-1862"
"TCGA.30.1866"	"TCGA-30-1866-01A-02T-0656-07"	"TCGA-30-1866"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	61	"y"	"y"	"n"	284	"recurrence"	1114	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cbc7f427-5f7b-4267-ad56-055d8880a4cc///days_to_birth: -22562///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1866///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 105fdc97-99c0-4fb1-ae9d-4361199bbfc9///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 284///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1114///days_to_last_followup: 1114///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 284///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1866-01A-02T-0656-07///unique_patient_id: TCGA-30-1866"
"TCGA.30.1867"	"TCGA-30-1867-01A-01T-0656-07"	"TCGA-30-1867"	"tumor"	"ser"	"ov"	NA	NA	"late"	4	NA	NA	46	NA	NA	NA	36	"norecurrence"	36	"deceased"	NA	NA	NA	NA	NA	0	28	72	NA	"age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: NA///bcr_patient_uuid: f9824a6e-7a97-445c-8846-df8d8cddedaa///days_to_birth: -17159///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 1867///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b412d4a8-d468-4489-ad11-87d530725059///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 36///days_to_last_followup: 36///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1867-01A-01T-0656-07///unique_patient_id: TCGA-30-1867"
"TCGA.30.1869"	"TCGA-30-1869-01A-01T-0656-07"	"TCGA-30-1869"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	50	"y"	"y"	"n"	767	"recurrence"	1563	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	40	60	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 84f5876d-82b0-45ff-8f3d-a10653683454///days_to_birth: -18397///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1869///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: abee4203-c623-4b6e-8808-cd75ae936da3///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1563///days_to_last_followup: 1563///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 767///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan and Other method- increase CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1869-01A-01T-0656-07///unique_patient_id: TCGA-30-1869"
"TCGA.30.1880"	"TCGA-30-1880-01A-01T-0656-07"	"TCGA-30-1880"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	56	"y"	"y"	"n"	348	"recurrence"	1751	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	6	94	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: bc873b2a-35b7-4365-a2cc-e6a83063556e///days_to_birth: -20525///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1880///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 12029b34-6b0f-4cd6-bc27-ef536288b467///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1751///days_to_last_followup: 1751///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 348///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Ct Scan and - increased CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1880-01A-01T-0656-07///unique_patient_id: TCGA-30-1880"
"TCGA.30.1887"	"TCGA-30-1887-01A-01T-0656-07"	"TCGA-30-1887"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	67	"y"	"y"	"n"	738	"norecurrence"	738	"deceased"	NA	NA	NA	"partialresponse"	"optimal"	0	12	85	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f7e01929-733b-420a-ab2b-051dd4a992e5///days_to_birth: -24495///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 1887///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 74d29a4a-9838-4af5-9038-55466876772b///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 738///days_to_last_followup: 738///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1887-01A-01T-0656-07///unique_patient_id: TCGA-30-1887"
"TCGA.30.1891"	"TCGA-30-1891-01A-01T-0656-07"	"TCGA-30-1891"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	61	"y"	"y"	"n"	181	"recurrence"	914	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	20	68	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 4a2ca7b8-729d-4fab-a6f3-a5d1e5d1f4f3///days_to_birth: -22344///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1891///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8fdc5769-4e01-4a6e-b84d-79e1d6447711///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 536///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 914///days_to_last_followup: 914///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 181///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: PET Scan and Other method- increase CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1891-01A-01T-0656-07///unique_patient_id: TCGA-30-1891"
"TCGA.30.1892"	"TCGA-30-1892-01A-01T-0656-07"	"TCGA-30-1892"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	52	"y"	"y"	"n"	253	"recurrence"	1484	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	15	75	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Left///bcr_patient_uuid: a09f0626-002a-48fd-8b2d-c66b8285cf23///days_to_birth: -19255///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1892///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 0aa2e64a-fe67-47a7-a99b-0bc5d07725b0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1484///days_to_last_followup: 1484///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 253///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1892-01A-01T-0656-07///unique_patient_id: TCGA-30-1892"
"TCGA.31.1944"	"TCGA-31-1944-01A-01T-0656-07"	"TCGA-31-1944"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	47	"y"	"y"	"n"	678	"recurrence"	1386	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	24	70	NA	"age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6fee41dc-b8a9-4347-8085-b7e05f813ad0///days_to_birth: -17207///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1944///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d1397f20-f35b-48a1-8d55-fdf484d16766///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 701///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1386///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 678///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-31-1944-01A-01T-0656-07///unique_patient_id: TCGA-31-1944"
"TCGA.31.1946"	"TCGA-31-1946-01A-01T-0656-07"	"TCGA-31-1946"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	30	"y"	"y"	"n"	664	"recurrence"	918	"living"	NA	NA	"locoregional"	NA	"optimal"	0	26	70	NA	"age_at_initial_pathologic_diagnosis: 30///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: da274941-3edd-420b-9262-bbd959923c67///days_to_birth: -11145///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1946///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5a829c07-1749-4281-9d01-caab3b1caf7c///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 918///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 664///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Physical Examination///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-31-1946-01A-01T-0656-07///unique_patient_id: TCGA-31-1946"
"TCGA.31.1950"	"TCGA-31-1950-01A-01T-0656-07"	"TCGA-31-1950"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	76	"y"	"y"	"n"	349	"recurrence"	571	"living"	NA	NA	"locoregional"	"partialresponse"	"optimal"	0	50	46	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 4ca9c0e8-75a7-4665-9d88-6dd2bb44b1e1///days_to_birth: -28099///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1950///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 28f0e73c-c8c7-4bb4-9d20-f86f2d874e27///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 571///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 349///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-31-1950-01A-01T-0656-07///unique_patient_id: TCGA-31-1950"
"TCGA.31.1951"	"TCGA-31-1951-01A-01T-0656-07"	"TCGA-31-1951"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	658	"recurrence"	683	"living"	NA	NA	"locoregional"	NA	"optimal"	0	18	85	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Left///bcr_patient_uuid: b0839f46-8c82-4619-be3d-c857a1759463///days_to_birth: -21352///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1951///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b880add7-cdf8-492c-86f5-a1f8cbcdd513///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 683///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 658///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-31-1951-01A-01T-0656-07///unique_patient_id: TCGA-31-1951"
"TCGA.31.1953"	"TCGA-31-1953-01A-01T-0656-07"	"TCGA-31-1953"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	52	"y"	"y"	"n"	70	"recurrence"	204	"living"	NA	NA	"locoregional"	"progressivedisease"	NA	0	9	90	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 61feee94-3ac9-42fe-aaa3-dc6a3efe563c///days_to_birth: -19063///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1953///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0b48f22b-fc99-4647-bd44-0e2a250c6d91///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 204///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 70///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-31-1953-01A-01T-0656-07///unique_patient_id: TCGA-31-1953"
"TCGA.31.1955"	"TCGA-31-1955-01A-01T-0719-07"	"TCGA-31-1955"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	43	"y"	"y"	"n"	1293	"norecurrence"	1293	"living"	NA	NA	NA	NA	"optimal"	0	12	84	NA	"age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cce34351-1700-405b-818f-a598f63a33e8///days_to_birth: -15925///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1955///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7651c94b-9420-44da-afbc-a38c01e82d6d///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1293///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 918///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Physical Examination///progression_determined_by_notes: NA///radiation_therapy: YES///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-31-1955-01A-01T-0719-07///unique_patient_id: TCGA-31-1955"
"TCGA.31.1956"	"TCGA-31-1956-01A-01T-0719-07"	"TCGA-31-1956"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	60	"y"	"y"	"n"	1341	"norecurrence"	1341	"living"	NA	NA	NA	NA	NA	0	32	65	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Left///bcr_patient_uuid: e1158102-06f2-47bb-9fe0-49b57f070755///days_to_birth: -22100///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1956///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 97da6eb3-ae55-4f66-af96-3a0332182595///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 118///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1341///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-31-1956-01A-01T-0719-07///unique_patient_id: TCGA-31-1956"
"TCGA.31.1959"	"TCGA-31-1959-01A-01T-0656-07"	"TCGA-31-1959"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	49	"y"	"y"	"n"	66	"norecurrence"	66	"living"	NA	NA	NA	NA	NA	0	38	60	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 186d40cd-624c-4016-a497-b30c892d393c///days_to_birth: -18247///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 1959///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2550cdb2-11f6-4349-91e8-39780c044dbd///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 66///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-31-1959-01A-01T-0656-07///unique_patient_id: TCGA-31-1959"
"TCGA.36.1568"	"TCGA-36-1568-01A-01T-0541-07"	"TCGA-36-1568"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	52	"y"	"y"	"n"	547	"recurrence"	874	"living"	NA	NA	"locoregional"	"partialresponse"	NA	0	5	95	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: de548bdd-14ca-486b-bd16-a6fbdd5b50d2///days_to_birth: -19311///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1568///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8050daa1-0821-4b10-9f7e-13838a72c862///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 874///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 547///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abd/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NA///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1568-01A-01T-0541-07///unique_patient_id: TCGA-36-1568"
"TCGA.36.1569"	"TCGA-36-1569-01A-01T-0541-07"	"TCGA-36-1569"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	52	NA	NA	NA	884	"norecurrence"	884	"living"	NA	NA	NA	"partialresponse"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7d82ce56-32eb-4107-aa5c-c568764805c9///days_to_birth: -19151///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1569///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 770c209c-66ce-470e-a8fc-dabddcc580d7///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 884///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1569-01A-01T-0541-07///unique_patient_id: TCGA-36-1569"
"TCGA.36.1570"	"TCGA-36-1570-01A-01T-0541-07"	"TCGA-36-1570"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	49	"y"	"y"	"n"	655	"norecurrence"	655	"living"	NA	NA	NA	"partialresponse"	"suboptimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0f530b3e-5b6d-4892-9ebd-9138d76fdca7///days_to_birth: -17955///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1570///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 15fa99c0-2fe6-4a73-9c6b-612cf8d56d53///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 655///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 375///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Physical Examination///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1570-01A-01T-0541-07///unique_patient_id: TCGA-36-1570"
"TCGA.36.1571"	"TCGA-36-1571-01A-01T-0541-07"	"TCGA-36-1571"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	53	"y"	"y"	"n"	374	"recurrence"	695	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 12581634-eebb-4841-8498-71dc9d78c546///days_to_birth: -19608///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1571///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 00574d51-b04f-42c8-ba1a-f4d8af2e4ebd///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 695///days_to_last_followup: 695///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 374///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abd/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-36-1571-01A-01T-0541-07///unique_patient_id: TCGA-36-1571"
"TCGA.36.1574"	"TCGA-36-1574-01A-01T-0541-07"	"TCGA-36-1574"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	48	"y"	"y"	"n"	648	"recurrence"	686	"living"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: eeb9d147-608d-4692-8adf-2f601d23a8ff///days_to_birth: -17847///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1574///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a362d009-06b1-4ec1-a13b-762036f060a8///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 686///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 648///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1574-01A-01T-0541-07///unique_patient_id: TCGA-36-1574"
"TCGA.36.1575"	"TCGA-36-1575-01A-01T-0541-07"	"TCGA-36-1575"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	83	NA	NA	NA	260	"norecurrence"	260	"living"	NA	NA	NA	NA	"optimal"	8	8	82	NA	"age_at_initial_pathologic_diagnosis: 83///anatomic_organ_subdivision: NA///bcr_patient_uuid: 6ea9877f-eb8d-4ee9-af4c-32a78474d9a6///days_to_birth: -30591///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1575///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a467ed8b-fffc-416c-baec-1a137a98d03b///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 260///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1575-01A-01T-0541-07///unique_patient_id: TCGA-36-1575"
"TCGA.36.1576"	"TCGA-36-1576-01A-01T-0541-07"	"TCGA-36-1576"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	76	"y"	"y"	"n"	816	"recurrence"	914	"living"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	10	88	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: NA///bcr_patient_uuid: 3445c524-5a37-40b6-8614-956d76eed939///days_to_birth: -27778///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1576///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 606c8ee1-145a-4a52-85af-906e692faaba///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 914///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 816///eastern_cancer_oncology_group: 2///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abd/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1576-01A-01T-0541-07///unique_patient_id: TCGA-36-1576"
"TCGA.36.1577"	"TCGA-36-1577-01A-01T-0541-07"	"TCGA-36-1577"	"tumor"	"ser"	"ov"	NA	"low"	"early"	2	"c"	2	43	"y"	"y"	"n"	783	"norecurrence"	783	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	45	48	NA	"age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e294b940-2828-499c-be24-47ef6c2e9035///days_to_birth: -15803///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1577///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 210fbda1-7211-4d2b-9eea-f48f0d3f8567///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 783///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: YES///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1577-01A-01T-0541-07///unique_patient_id: TCGA-36-1577"
"TCGA.36.1578"	"TCGA-36-1578-01A-01T-0541-07"	"TCGA-36-1578"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	63	"y"	"y"	"n"	310	"recurrence"	847	"living"	NA	NA	"metastasis"	NA	"suboptimal"	0	8	90	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: NA///bcr_patient_uuid: f65f2e78-c001-4ef3-ae88-3e4f83c7aceb///days_to_birth: -23329///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1578///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 35caaae5-e969-4b89-bba6-dfc7859ae181///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 847///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 310///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abd/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1578-01A-01T-0541-07///unique_patient_id: TCGA-36-1578"
"TCGA.36.1580"	"TCGA-36-1580-01A-01T-0541-07"	"TCGA-36-1580"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	82	"y"	"n"	"n"	737	"norecurrence"	737	"deceased"	NA	NA	NA	NA	"suboptimal"	0	42	50	NA	"age_at_initial_pathologic_diagnosis: 82///anatomic_organ_subdivision: NA///bcr_patient_uuid: 533f5ff9-466c-4cdb-9c46-b841c2626775///days_to_birth: -29991///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1580///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0a7f42d0-c9d3-4d5c-8122-53760a34e6e1///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 737///days_to_last_followup: 737///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 440///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Physical Examination///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-36-1580-01A-01T-0541-07///unique_patient_id: TCGA-36-1580"
"TCGA.36.1581"	"TCGA-36-1581-01A-01T-0541-07"	"TCGA-36-1581"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	63	"y"	"y"	"n"	702	"recurrence"	751	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	2	94	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Left///bcr_patient_uuid: ef5e85cf-2d82-4d52-a02c-fed5c76e4cec///days_to_birth: -23272///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1581///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 434514f8-04e5-4ec5-a694-0216e535fd97///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 751///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 702///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abd/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1581-01A-01T-0541-07///unique_patient_id: TCGA-36-1581"
"TCGA.36.2529"	"TCGA-36-2529-01A-01T-1051-07"	"TCGA-36-2529"	"tumor"	"ser"	"other"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	567	"recurrence"	1066	"living"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	30	60	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 20ac688c-04c1-45a6-823a-6b523002ce92///days_to_birth: -26091///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C48.2///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2529///pretreatment_history: NO///race: NA///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: PERITONEUM (OVARY)///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8c9865eb-7ad9-47f8-bc03-649131604c68///chemo_therapy: YES///day_of_form_completion: 17///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1066///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 567///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2529-01A-01T-1051-07///unique_patient_id: TCGA-36-2529"
"TCGA.36.2530"	"TCGA-36-2530-01A-01T-1051-07"	"TCGA-36-2530"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	38	"y"	"y"	"n"	630	"recurrence"	1004	"living"	NA	NA	"locoregional_plus_metastatic"	"completeresponse"	"suboptimal"	0	6	89	NA	"age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 92a1a8f3-54f2-4983-bb14-dcb73658d897///days_to_birth: -13885///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2530///pretreatment_history: NO///race: ASIAN///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: eb2af194-4072-4aae-8504-3c74a9900431///chemo_therapy: YES///day_of_form_completion: 17///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1004///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 630///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abdomen/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Locoregional and Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2530-01A-01T-1051-07///unique_patient_id: TCGA-36-2530"
"TCGA.36.2532"	"TCGA-36-2532-01A-01T-1051-07"	"TCGA-36-2532"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	61	"y"	"y"	"n"	897	"norecurrence"	897	"living"	NA	NA	NA	NA	"optimal"	0	8	88	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 04abcf51-c52a-4e74-a5f4-4bc4fb444902///days_to_birth: -22333///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2532///pretreatment_history: NO///race: NA///residual_tumor: R0///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a4cbfcc9-9288-4209-8e36-b74c3b6692cc///chemo_therapy: YES///day_of_form_completion: 17///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 897///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2532-01A-01T-1051-07///unique_patient_id: TCGA-36-2532"
"TCGA.36.2533"	"TCGA-36-2533-01A-01T-1051-07"	"TCGA-36-2533"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	NA	NA	NA	NA	"norecurrence"	NA	NA	NA	NA	NA	NA	NA	0	22	70	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Right///bcr_patient_uuid: f7dece2a-d12c-4363-b8c3-2683c32d8271///days_to_birth: -20187///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2533///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: NA///chemo_therapy: NA///day_of_form_completion: NA///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: NA///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: NA///year_of_form_completion: NA///Extract.Name: TCGA-36-2533-01A-01T-1051-07///unique_patient_id: TCGA-36-2533"
"TCGA.36.2534"	"TCGA-36-2534-01A-01T-1051-07"	"TCGA-36-2534"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	72	"y"	"n"	"n"	NA	"recurrence"	906	"living"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	12	86	NA	"age_at_initial_pathologic_diagnosis: 72///anatomic_organ_subdivision: Right///bcr_patient_uuid: e08a619d-8a55-435d-8c41-a77a112ed889///days_to_birth: -26621///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2534///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ffa8c288-a2f2-4a74-8e66-b437588e8ba5///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 906///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 383///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Abdomen/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2534-01A-01T-1051-07///unique_patient_id: TCGA-36-2534"
"TCGA.36.2537"	"TCGA-36-2537-01A-01T-1051-07"	"TCGA-36-2537"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	39	"y"	"y"	"n"	NA	"recurrence"	788	"living"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	18	78	NA	"age_at_initial_pathologic_diagnosis: 39///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5075cdc1-1b7c-4e25-98ea-fb568bd35f2d///days_to_birth: -14594///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2537///pretreatment_history: NO///race: NA///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 16ec4be7-a32c-4b9e-bae5-30c468066390///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 788///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 431///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 2///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Abdomen/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2537-01A-01T-1051-07///unique_patient_id: TCGA-36-2537"
"TCGA.36.2538"	"TCGA-36-2538-01A-01T-1051-07"	"TCGA-36-2538"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	37	"y"	"y"	"n"	523	"recurrence"	763	"living"	NA	NA	"locoregional_plus_metastatic"	"completeresponse"	"suboptimal"	0	22	72	NA	"age_at_initial_pathologic_diagnosis: 37///anatomic_organ_subdivision: Right///bcr_patient_uuid: 3ea880f4-7a78-4cb7-bfe4-54b3c30a812e///days_to_birth: -13681///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2538///pretreatment_history: NO///race: NA///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 89084cd7-3421-4d79-be7e-f24a2bdf54c6///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 763///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 523///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Abdomen/Pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Locoregional and Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2538-01A-01T-1051-07///unique_patient_id: TCGA-36-2538"
"TCGA.36.2540"	"TCGA-36-2540-01A-01T-1051-07"	"TCGA-36-2540"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	26	"y"	"y"	"n"	665	"recurrence"	724	"living"	NA	NA	"locoregional_plus_metastatic"	"completeresponse"	"suboptimal"	10	8	87	NA	"age_at_initial_pathologic_diagnosis: 26///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 30c7efdd-5a86-4418-a33c-a5d27fe56e42///days_to_birth: -9760///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G1///patient_id: 2540///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e4383d0b-9cc4-4fb5-a4a1-312928dd2e34///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 724///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 665///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Locoregional and Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2540-01A-01T-1051-07///unique_patient_id: TCGA-36-2540"
"TCGA.36.2542"	"TCGA-36-2542-01A-01T-1051-07"	"TCGA-36-2542"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	59	"y"	"y"	"n"	657	"norecurrence"	657	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	15	82	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7aadc24b-3de2-478f-b9e5-aca44424f514///days_to_birth: -21902///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2542///pretreatment_history: NO///race: ASIAN///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a439d861-b6a1-45a9-a2d7-f3cd9c2603e0///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 657///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2542-01A-01T-1051-07///unique_patient_id: TCGA-36-2542"
"TCGA.36.2543"	"TCGA-36-2543-01A-01T-1051-07"	"TCGA-36-2543"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	85	NA	NA	NA	68	"norecurrence"	68	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	9	8	79	NA	"age_at_initial_pathologic_diagnosis: 85///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 73b63d07-0c1d-4bf2-bf11-b183e090e200///days_to_birth: -31210///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2543///pretreatment_history: NO///race: NA///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 39b21e93-385a-47bc-b804-7db98b08fde2///chemo_therapy: NO///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 68///days_to_last_followup: 68///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 27///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 3///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-36-2543-01A-01T-1051-07///unique_patient_id: TCGA-36-2543"
"TCGA.36.2544"	"TCGA-36-2544-01A-01T-1051-07"	"TCGA-36-2544"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	58	"y"	"y"	"n"	NA	"recurrence"	638	"living"	NA	NA	"metastasis"	"partialresponse"	"suboptimal"	0	10	84	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: da56dfbe-35ae-4bd7-9a11-d9bbb02b1833///days_to_birth: -21383///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2544///pretreatment_history: NO///race: NA///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6cf6fd0d-3d0c-496a-a035-dfc94ed68911///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 638///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 325///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2544-01A-01T-1051-07///unique_patient_id: TCGA-36-2544"
"TCGA.36.2545"	"TCGA-36-2545-01A-01T-1051-07"	"TCGA-36-2545"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	42	"y"	"y"	"n"	557	"norecurrence"	557	"living"	NA	NA	NA	NA	"optimal"	0	14	78	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f3cd0ca3-8e5d-481b-b28c-619a4123dcd0///days_to_birth: -15444///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2545///pretreatment_history: NO///race: NA///residual_tumor: R0///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9d76fdcd-128d-4287-8eb5-694eef3b5754///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 557///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2545-01A-01T-1051-07///unique_patient_id: TCGA-36-2545"
"TCGA.36.2547"	"TCGA-36-2547-01A-01T-1051-07"	"TCGA-36-2547"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	64	"y"	"y"	"n"	624	"norecurrence"	624	"living"	NA	NA	NA	NA	"optimal"	0	22	72	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Left///bcr_patient_uuid: 5e447cbc-9bc9-4e1a-9b43-06cf619e5aa9///days_to_birth: -23706///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2547///pretreatment_history: NO///race: NA///residual_tumor: R0///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2debace6-a790-48a8-a169-ca0f12294b4c///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 624///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2547-01A-01T-1051-07///unique_patient_id: TCGA-36-2547"
"TCGA.36.2548"	"TCGA-36-2548-01A-01T-1051-07"	"TCGA-36-2548"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	395	"recurrence"	431	"living"	NA	NA	"metastasis"	NA	"suboptimal"	0	20	74	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Right///bcr_patient_uuid: 3250e604-d12a-4922-aaca-6f0cae095842///days_to_birth: -20897///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Other method, specify:///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2548///pretreatment_history: NO///race: NA///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: e62733f2-7722-4da0-9627-f34bce5e5c29///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 431///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 395///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2548-01A-01T-1051-07///unique_patient_id: TCGA-36-2548"
"TCGA.36.2549"	"TCGA-36-2549-01A-01T-1051-07"	"TCGA-36-2549"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	54	"y"	"y"	"n"	184	"norecurrence"	184	"living"	NA	NA	NA	NA	"optimal"	4	12	82	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9815ab87-454d-4dfc-8b3d-4b35af32d764///days_to_birth: -20075///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2549///pretreatment_history: NO///race: NA///residual_tumor: R0///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6c2295e6-1597-4bc3-b5a4-18a051398009///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 184///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2549-01A-01T-1051-07///unique_patient_id: TCGA-36-2549"
"TCGA.36.2551"	"TCGA-36-2551-01A-01T-1051-07"	"TCGA-36-2551"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	338	"recurrence"	491	"living"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	8	12	80	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9f096022-e3ec-4f63-8c52-03ef24c018f3///days_to_birth: -21045///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2551///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 87bc498f-d002-429f-a48a-47c19dff4fae///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 491///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 338///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2551-01A-01T-1051-07///unique_patient_id: TCGA-36-2551"
"TCGA.36.2552"	"TCGA-36-2552-01A-01T-1051-07"	"TCGA-36-2552"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	64	"y"	"y"	"n"	349	"norecurrence"	349	"living"	NA	NA	NA	NA	"optimal"	0	25	70	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2d8b42fb-b12c-454e-a5a5-22c91913386f///days_to_birth: -23379///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2552///pretreatment_history: NO///race: NA///residual_tumor: R0///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f0f073e9-431f-4e1b-bcf4-92efb3848872///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 349///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-36-2552-01A-01T-1051-07///unique_patient_id: TCGA-36-2552"
"TCGA.42.2582"	"TCGA-42-2582-01A-01T-1051-07"	"TCGA-42-2582"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	49	"y"	"y"	"n"	616	"recurrence"	792	"living"	NA	NA	"metastasis"	"stabledisease"	"optimal"	0	0	100	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7922df77-f09a-488c-a1be-58646ceb9b3e///days_to_birth: -17960///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2582///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 42///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 50a689bd-b234-4bbe-a9ae-c0cfadb1a842///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 616///days_to_death: NA///days_to_last_followup: 792///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 616///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2011///Extract.Name: TCGA-42-2582-01A-01T-1051-07///unique_patient_id: TCGA-42-2582"
"TCGA.42.2587"	"TCGA-42-2587-01A-01T-1051-07"	"TCGA-42-2587"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	75	"y"	"y"	"n"	722	"norecurrence"	722	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	0	0	98	NA	"age_at_initial_pathologic_diagnosis: 75///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: eef62876-7d17-496a-8971-2c7008d77014///days_to_birth: -27509///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2587///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 42///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 897a2b59-77f9-472a-b8a4-d2c9db024b60///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 722///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2011///Extract.Name: TCGA-42-2587-01A-01T-1051-07///unique_patient_id: TCGA-42-2587"
"TCGA.42.2588"	"TCGA-42-2588-01A-01T-1051-07"	"TCGA-42-2588"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	61	"y"	"y"	"n"	NA	"norecurrence"	880	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	8	0	92	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 654d02ab-05b4-4863-99d9-04d087ff91b4///days_to_birth: -22377///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2588///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 42///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 32c5dbaa-fb36-4b5b-9cd2-387c31275f16///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 880///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 267///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2012///Extract.Name: TCGA-42-2588-01A-01T-1051-07///unique_patient_id: TCGA-42-2588"
"TCGA.42.2589"	"TCGA-42-2589-01A-01T-1051-07"	"TCGA-42-2589"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	54	"y"	"y"	"n"	230	"norecurrence"	230	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	25	73	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: dfb7dc5d-92f4-4a3a-9667-db38efcc9fdb///days_to_birth: -19852///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2589///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 42///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 99416484-a8e7-4141-8120-c9be36ef04db///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 230///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-42-2589-01A-01T-1051-07///unique_patient_id: TCGA-42-2589"
"TCGA.42.2590"	"TCGA-42-2590-01A-01T-1051-07"	"TCGA-42-2590"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	57	"y"	"n"	"n"	NA	"norecurrence"	317	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	0	12	78	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2724109f-7d5a-402c-a915-741e43c6f7f9///days_to_birth: -20964///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2590///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 42///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 180b4b5e-1924-4e63-a66b-e8fbafcdbe3d///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 317///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 226///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2011///Extract.Name: TCGA-42-2590-01A-01T-1051-07///unique_patient_id: TCGA-42-2590"
"TCGA.42.2591"	"TCGA-42-2591-01A-01T-1051-07"	"TCGA-42-2591"	"tumor"	"ser"	"ov"	NA	NA	"late"	3	"c"	NA	57	"y"	"y"	"n"	681	"norecurrence"	681	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	15	75	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0750ebcc-348a-4ea9-9dd2-6274d5e6eeaa///days_to_birth: -20845///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: GX///patient_id: 2591///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 42///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1eb2b34d-438c-47f9-b92f-1c9f3f888fc9///chemo_therapy: YES///day_of_form_completion: 22///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 681///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2011///Extract.Name: TCGA-42-2591-01A-01T-1051-07///unique_patient_id: TCGA-42-2591"
"TCGA.57.1582"	"TCGA-57-1582-01A-01T-0541-07"	"TCGA-57-1582"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	50	"y"	"n"	"n"	731	"norecurrence"	731	"deceased"	NA	NA	NA	"progressivedisease"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Left///bcr_patient_uuid: 4ea50685-3b63-440a-b037-597ef2529e7d///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1582///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d6ebac21-c97c-456d-b42e-726017a129d6///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 731///days_to_last_followup: 731///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-57-1582-01A-01T-0541-07///unique_patient_id: TCGA-57-1582"
"TCGA.57.1583"	"TCGA-57-1583-01A-01T-0541-07"	"TCGA-57-1583"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	346	"norecurrence"	346	"deceased"	NA	NA	NA	NA	"optimal"	0	10	94	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Left///bcr_patient_uuid: 76cc2d21-eebc-4f09-9bc7-dbf7af0aafa8///days_to_birth: -21154///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1583///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 226da9f5-f0ba-4f11-9c5e-1e1c53456ce7///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 346///days_to_last_followup: 346///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-57-1583-01A-01T-0541-07///unique_patient_id: TCGA-57-1583"
"TCGA.57.1584"	"TCGA-57-1584-01A-01T-0541-07"	"TCGA-57-1584"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	47	"y"	"y"	"n"	530	"recurrence"	643	"living"	NA	NA	"metastasis"	NA	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ed21615c-0de3-421c-9e8d-8996026c4431///days_to_birth: -17257///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1584///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: aca7dfdd-2755-43e1-a775-1687dee80c72///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 532///days_to_death: NA///days_to_last_followup: 643///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 530///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT of abdomen and pelvis with contrast///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-57-1584-01A-01T-0541-07///unique_patient_id: TCGA-57-1584"
"TCGA.57.1585"	"TCGA-57-1585-01A-01T-0541-07"	"TCGA-57-1585"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	53	"norecurrence"	53	"deceased"	NA	NA	NA	"progressivedisease"	"suboptimal"	0	12	82	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5ed14506-f69a-4da8-9965-72d3270b9f72///days_to_birth: -20850///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1585///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 80632215-5601-43af-ad21-18fba962496e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 53///days_to_last_followup: 53///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-57-1585-01A-01T-0541-07///unique_patient_id: TCGA-57-1585"
"TCGA.57.1586"	"TCGA-57-1586-01A-02T-0567-07"	"TCGA-57-1586"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	66	"y"	"y"	"n"	259	"recurrence"	679	"living"	NA	NA	"locoregional"	NA	"suboptimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 66///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 48e66676-dbed-48a4-9a7f-a6d247b15c17///days_to_birth: -24317///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1586///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 63a6f203-f1b7-48b2-bb80-5d6fd277e34c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 679///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 259///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-57-1586-01A-02T-0567-07///unique_patient_id: TCGA-57-1586"
"TCGA.57.1992"	"TCGA-57-1992-01A-01T-0656-07"	"TCGA-57-1992"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	62	NA	NA	NA	881	"norecurrence"	881	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	32	68	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: Left///bcr_patient_uuid: 419a486f-7fa5-4fbd-9e98-2f8f4c6d5081///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1992///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f99aac95-b604-411a-9a3b-1fbf4662054f///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 881///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-57-1992-01A-01T-0656-07///unique_patient_id: TCGA-57-1992"
"TCGA.57.1993"	"TCGA-57-1993-01A-01T-0656-07"	"TCGA-57-1993"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	56	"y"	"y"	"n"	762	"norecurrence"	762	"living"	NA	NA	NA	NA	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 15fc17cd-d073-4f81-a4a2-2db3cb9d7069///days_to_birth: -20485///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1993///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c5c65b87-f672-4576-8cc3-10552aea8459///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 762///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-57-1993-01A-01T-0656-07///unique_patient_id: TCGA-57-1993"
"TCGA.57.1994"	"TCGA-57-1994-01A-01T-0656-07"	"TCGA-57-1994"	"tumor"	"ser"	"ov"	NA	NA	NA	NA	NA	NA	63	NA	NA	NA	761	"norecurrence"	761	"living"	NA	NA	NA	NA	NA	0	8	85	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: NA///bcr_patient_uuid: 602e2934-223a-44db-8c33-06eb05d72f94///days_to_birth: -23061///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: NA///patient_id: 1994///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: NA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0c4a4165-8e20-496f-b731-9666c8c63d86///chemo_therapy: NO///day_of_form_completion: 10///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 761///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2011///Extract.Name: TCGA-57-1994-01A-01T-0656-07///unique_patient_id: TCGA-57-1994"
"TCGA.59.2348"	"TCGA-59-2348-01A-01T-0712-07"	"TCGA-59-2348"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	59	NA	NA	NA	5480	"norecurrence"	5480	"living"	NA	NA	NA	"completeresponse"	NA	0	10	85	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 20cf00ea-d7da-42bb-bce7-f005f0b952eb///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2348///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1994///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 46960c42-55ef-44c0-8839-18409aac5337///chemo_therapy: NA///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 5480///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-59-2348-01A-01T-0712-07///unique_patient_id: TCGA-59-2348"
"TCGA.59.2349"	"TCGA-59-2349-01A-01T-0712-07"	"TCGA-59-2349"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	71	NA	NA	NA	2437	"norecurrence"	2437	"deceased"	NA	NA	NA	"completeresponse"	"optimal"	1	4	95	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Left///bcr_patient_uuid: 2222b629-02ab-4ead-997f-09d91c6f7cf4///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2349///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1994///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a70c772a-bc64-4db5-82aa-f4a429a8ee3f///chemo_therapy: NA///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2437///days_to_last_followup: 2437///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-59-2349-01A-01T-0712-07///unique_patient_id: TCGA-59-2349"
"TCGA.59.2350"	"TCGA-59-2350-01A-01T-0712-07"	"TCGA-59-2350"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	44	NA	NA	NA	NA	"recurrence"	679	"deceased"	NA	NA	"locoregional"	"partialresponse"	"optimal"	1	19	77	NA	"age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e978a457-92ff-4eab-b759-ec6e74d973e8///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2350///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3623594b-c07c-40e0-9eba-0a95a662d146///chemo_therapy: NA///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: 211///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 679///days_to_last_followup: 679///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 211///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-59-2350-01A-01T-0712-07///unique_patient_id: TCGA-59-2350"
"TCGA.59.2351"	"TCGA-59-2351-01A-01T-0712-07"	"TCGA-59-2351"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	NA	NA	NA	NA	"recurrence"	3532	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	1	19	79	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 16829472-5666-4fba-9bf9-360ec1689aa0///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2351///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 714f1bfd-54f3-4a05-bbc7-3bc9bc5ace8e///chemo_therapy: NA///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: 2154///days_to_additional_surgery_metastatic_procedure: 2154///days_to_death: NA///days_to_last_followup: 3532///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 2139///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; site of tumor first recurrence is also Metastasis///radiation_therapy: NA///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NA///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-59-2351-01A-01T-0712-07///unique_patient_id: TCGA-59-2351"
"TCGA.59.2352"	"TCGA-59-2352-01A-01T-0712-07"	"TCGA-59-2352"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	78	NA	NA	NA	NA	"norecurrence"	NA	NA	NA	NA	NA	NA	NA	0	10	87	NA	"age_at_initial_pathologic_diagnosis: 78///anatomic_organ_subdivision: Right///bcr_patient_uuid: 758e6b52-062e-4ca0-84d1-ea38477414ac///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2352///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: NA///chemo_therapy: NA///day_of_form_completion: NA///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: NA///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: NA///year_of_form_completion: NA///Extract.Name: TCGA-59-2352-01A-01T-0712-07///unique_patient_id: TCGA-59-2352"
"TCGA.59.2354"	"TCGA-59-2354-01A-01T-0712-07"	"TCGA-59-2354"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	64	"y"	"n"	"n"	1046	"norecurrence"	1046	"deceased"	NA	NA	NA	"stabledisease"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Left///bcr_patient_uuid: d7925dfc-18ce-46ab-a47b-9d06eacc96d0///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2354///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 43712126-05c8-4734-8834-ceeb5a6f0ffe///chemo_therapy: YES///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1046///days_to_last_followup: 1046///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 461///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Other method- CA 125///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-59-2354-01A-01T-0712-07///unique_patient_id: TCGA-59-2354"
"TCGA.59.2355"	"TCGA-59-2355-01A-01T-0712-07"	"TCGA-59-2355"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	58	"y"	"y"	"n"	65	"norecurrence"	65	"deceased"	NA	NA	NA	NA	"suboptimal"	0	18	72	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Right///bcr_patient_uuid: 708eec28-2348-4e15-b98c-8c6f9d057b1e///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2355///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 395e39dd-fe65-4c7c-ae0d-6065c0217d5f///chemo_therapy: YES///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 65///days_to_last_followup: 65///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-59-2355-01A-01T-0712-07///unique_patient_id: TCGA-59-2355"
"TCGA.59.2363"	"TCGA-59-2363-01A-01T-0712-07"	"TCGA-59-2363"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	40	"n"	"y"	"n"	164	"norecurrence"	164	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	10	87	NA	"age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f4d95c8e-fb84-46ca-acc0-827015cc9d0a///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2363///pretreatment_history: NO///race: ASIAN///residual_tumor: R0///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b9fa6c71-a686-47cc-8b85-ba5cca27a399///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 164///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-59-2363-01A-01T-0712-07///unique_patient_id: TCGA-59-2363"
"TCGA.59.2372"	"TCGA-59-2372-01A-01T-1051-07"	"TCGA-59-2372"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	74	"y"	"y"	"n"	1362	"norecurrence"	1362	"deceased"	NA	NA	NA	NA	"optimal"	0	0	99	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5d8abed4-62b3-4e17-a8ce-9f6028e97103///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 2372///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 775d5554-2b75-4382-9f09-177790839905///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1362///days_to_last_followup: 1362///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-59-2372-01A-01T-1051-07///unique_patient_id: TCGA-59-2372"
"TCGA.61.1721"	"TCGA-61-1721-01A-01T-0656-07"	"TCGA-61-1721"	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	1	38	"y"	"y"	"n"	338	"norecurrence"	338	"living"	NA	NA	NA	"completeresponse"	NA	0	0	85	NA	"age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1c0318d9-0472-4840-add4-46bb9f914a30///days_to_birth: -13894///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G1///patient_id: 1721///pretreatment_history: YES///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 902be45d-0481-4e42-8dc7-10a185ca8ade///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 338///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1721-01A-01T-0656-07///unique_patient_id: TCGA-61-1721"
"TCGA.61.1722"	"TCGA-61-1722-01A-01T-0585-07"	"TCGA-61-1722"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"b"	3	89	"n"	"n"	"n"	NA	"recurrence"	245	"living"	NA	NA	"locoregional"	"stabledisease"	"optimal"	0	22	72	NA	"age_at_initial_pathologic_diagnosis: 89///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 47feba88-1ec9-4904-b0e2-3718f294badb///days_to_birth: -32853///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1722///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2633c1c8-3dd9-4dfa-93cd-be433aa18856///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 245///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1722-01A-01T-0585-07///unique_patient_id: TCGA-61-1722"
"TCGA.61.1724"	"TCGA-61-1724-01A-01T-0656-07"	"TCGA-61-1724"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	47	"y"	"n"	"n"	NA	"recurrence"	637	"deceased"	NA	NA	"locoregional"	"progressivedisease"	"optimal"	0	2	90	NA	"age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2ae65a06-df0f-4de1-a536-537cae0cc260///days_to_birth: -17168///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1724///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 81734ce6-1983-4b83-a2ac-394d263fefb0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 186///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 637///days_to_last_followup: 637///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Abd///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1724-01A-01T-0656-07///unique_patient_id: TCGA-61-1724"
"TCGA.61.1725"	"TCGA-61-1725-01A-01T-0585-07"	"TCGA-61-1725"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	40	"y"	"y"	"n"	843	"recurrence"	955	"living"	NA	NA	"metastasis"	"stabledisease"	"suboptimal"	0	0	85	NA	"age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a6eb0cd0-fe57-41b0-8593-776208684293///days_to_birth: -14782///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1725///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4795b469-2ea1-4e65-bb8f-5b401b6632d5///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 955///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 843///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1725-01A-01T-0585-07///unique_patient_id: TCGA-61-1725"
"TCGA.61.1727"	"TCGA-61-1727-01A-01T-0585-07"	"TCGA-61-1727"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	74	"y"	"n"	"n"	564	"norecurrence"	564	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	0	96	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Right///bcr_patient_uuid: 99407c1d-40b5-4ded-ba29-1e40dfd65be4///days_to_birth: -27202///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1727///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4604d1b5-1dbc-456f-9c29-2deabd74636e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 564///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1727-01A-01T-0585-07///unique_patient_id: TCGA-61-1727"
"TCGA.61.1728"	"TCGA-61-1728-01A-01T-0656-07"	"TCGA-61-1728"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	59	"y"	"y"	"n"	533	"recurrence"	848	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	0	88	NA	"age_at_initial_pathologic_diagnosis: 59///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 07fbdb3c-8337-4319-8255-f2363f8a031e///days_to_birth: -21582///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1728///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 16d97d30-b99b-4b12-9913-cf03f002008d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 533///days_to_death: NA///days_to_last_followup: 848///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 533///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1728-01A-01T-0656-07///unique_patient_id: TCGA-61-1728"
"TCGA.61.1730"	"TCGA-61-1730-01A-01T-0585-07"	"TCGA-61-1730"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	78	NA	NA	NA	132	"norecurrence"	132	"deceased"	NA	NA	NA	NA	"optimal"	0	0	90	NA	"age_at_initial_pathologic_diagnosis: 78///anatomic_organ_subdivision: Left///bcr_patient_uuid: 107bd8af-13e6-4c6a-9bdc-83c08eaaff90///days_to_birth: -28507///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1730///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 92566454-18d4-4cca-a334-0485b15866f2///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 132///days_to_last_followup: 132///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1730-01A-01T-0585-07///unique_patient_id: TCGA-61-1730"
"TCGA.61.1733"	"TCGA-61-1733-01A-01T-0585-07"	"TCGA-61-1733"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"y"	"y"	"n"	174	"recurrence"	966	"living"	NA	NA	"metastasis"	"stabledisease"	"optimal"	0	0	96	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 04ecaf38-0232-4dcd-9242-308a22cc1331///days_to_birth: -26180///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1733///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: a342a16c-6eba-4ab9-9688-f1b9f952ac7f///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 174///days_to_death: NA///days_to_last_followup: 966///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 174///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1733-01A-01T-0585-07///unique_patient_id: TCGA-61-1733"
"TCGA.61.1734"	"TCGA-61-1734-01B-01T-0841-07"	"TCGA-61-1734"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	52	"y"	"y"	"n"	866	"norecurrence"	866	"living"	NA	NA	NA	"completeresponse"	NA	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b5e64bdb-24f1-400d-aaf7-8fda8ab6fd3c///days_to_birth: -19026///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1734///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2abe1e0f-edaa-4908-b0b4-55626b3eb663///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 866///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1734-01B-01T-0841-07///unique_patient_id: TCGA-61-1734"
"TCGA.61.1736"	"TCGA-61-1736-01B-01T-0695-07"	"TCGA-61-1736"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	45	"y"	"y"	"n"	764	"recurrence"	1484	"deceased"	NA	NA	"locoregional"	"completeresponse"	NA	0	34	65	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0a2d29de-869a-4dc8-ad11-6ee0d0a3a895///days_to_birth: -16612///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1736///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: dbee91e2-9410-4570-9c69-8e43beb8887d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 812///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1484///days_to_last_followup: 1484///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 764///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1736-01B-01T-0695-07///unique_patient_id: TCGA-61-1736"
"TCGA.61.1737"	"TCGA-61-1737-01A-01T-0585-07"	"TCGA-61-1737"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	42	"y"	"y"	"n"	1364	"norecurrence"	1364	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	0	92	NA	"age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0aa020cb-69d2-4235-a609-c279a133d8bb///days_to_birth: -15514///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1737///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 36c9e79e-9559-4eb1-bc79-7274be460b42///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1364///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1737-01A-01T-0585-07///unique_patient_id: TCGA-61-1737"
"TCGA.61.1738"	"TCGA-61-1738-01A-01T-0585-07"	"TCGA-61-1738"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	"y"	"y"	"n"	276	"recurrence"	1089	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"optimal"	0	0	96	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Right///bcr_patient_uuid: 72c40fba-f502-489b-ad87-843f52655894///days_to_birth: -21965///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1738///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8a114a36-f83c-41c5-9e9b-3f3e303592ca///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 907///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1089///days_to_last_followup: 1089///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 276///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1738-01A-01T-0585-07///unique_patient_id: TCGA-61-1738"
"TCGA.61.1740"	"TCGA-61-1740-01A-01T-0585-07"	"TCGA-61-1740"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	"n"	"n"	"n"	NA	"recurrence"	74	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"suboptimal"	0	0	98	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Right///bcr_patient_uuid: 005a6517-2e5a-4ea3-ab36-531522723607///days_to_birth: -26168///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1740///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0e3413d9-8c58-4ac6-a310-028165e36dcd///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 74///days_to_last_followup: 74///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 3///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1740-01A-01T-0585-07///unique_patient_id: TCGA-61-1740"
"TCGA.61.1741"	"TCGA-61-1741-01A-02T-0585-07"	"TCGA-61-1741"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	76	"y"	"y"	"n"	487	"recurrence"	1024	"deceased"	NA	NA	"metastasis"	"completeresponse"	"suboptimal"	0	0	90	NA	"age_at_initial_pathologic_diagnosis: 76///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 16ced1b8-64d5-4498-82df-4d37bfe5b310///days_to_birth: -27762///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1741///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6c399b77-3d5e-4eb6-ae9a-f4857b8b5dab///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1024///days_to_last_followup: 1024///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 487///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1741-01A-02T-0585-07///unique_patient_id: TCGA-61-1741"
"TCGA.61.1743"	"TCGA-61-1743-01A-01T-0656-07"	"TCGA-61-1743"	"tumor"	"ser"	"ov"	NA	"low"	"early"	2	"c"	2	53	"y"	"y"	"n"	809	"recurrence"	1329	"deceased"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	0	95	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a3e26259-732b-49fb-bc95-2f0ec7a0494e///days_to_birth: -19365///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1743///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NA///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b213f402-12f7-443a-bce1-f344086505fb///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 829///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1329///days_to_last_followup: 1329///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 809///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1743-01A-01T-0656-07///unique_patient_id: TCGA-61-1743"
"TCGA.61.1895"	"TCGA-61-1895-01A-01T-0585-07"	"TCGA-61-1895"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	52	"y"	"n"	"n"	43	"norecurrence"	43	"living"	NA	NA	NA	"stabledisease"	"optimal"	2	8	85	NA	"age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0dd95368-0713-45f0-84f4-c91af9cbba74///days_to_birth: -19060///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1895///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c1f746b4-ff13-496d-a9f5-5ffabca2bff5///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 43///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1895-01A-01T-0585-07///unique_patient_id: TCGA-61-1895"
"TCGA.61.1899"	"TCGA-61-1899-01A-01T-0585-07"	"TCGA-61-1899"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	81	"y"	"y"	"n"	256	"norecurrence"	256	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 81///anatomic_organ_subdivision: Left///bcr_patient_uuid: 35b1bb47-b32b-4acd-8e5e-fe6bd56c0289///days_to_birth: -29692///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1899///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7eb2e429-e0c5-4482-9210-7a48a331c602///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 256///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1899-01A-01T-0585-07///unique_patient_id: TCGA-61-1899"
"TCGA.61.1900"	"TCGA-61-1900-01A-01T-0585-07"	"TCGA-61-1900"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	51	"y"	"y"	"n"	176	"norecurrence"	176	"living"	NA	NA	NA	"stabledisease"	"optimal"	0	8	88	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ef653772-e5d2-46ec-8610-f81d75d7353c///days_to_birth: -18963///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1900///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8b7bebba-673b-4d44-b33d-6a5d7409982f///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 176///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1900-01A-01T-0585-07///unique_patient_id: TCGA-61-1900"
"TCGA.61.1901"	"TCGA-61-1901-01A-01T-0585-07"	"TCGA-61-1901"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	65	"y"	"n"	"n"	NA	"recurrence"	347	"deceased"	NA	NA	"metastasis"	"stabledisease"	NA	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7a75d318-b301-4f77-a97f-4d6784d27216///days_to_birth: -24042///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1901///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ba0241ae-e66a-4fa9-8fb4-310aca8c7c68///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 347///days_to_last_followup: 347///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 329///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: MRI of the brain///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1901-01A-01T-0585-07///unique_patient_id: TCGA-61-1901"
"TCGA.61.1903"	"TCGA-61-1903-01A-01T-0585-07"	"TCGA-61-1903"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"b"	3	55	"y"	"y"	"n"	396	"norecurrence"	396	"living"	NA	NA	NA	"completeresponse"	NA	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b3df9c0a-420c-4cc2-a3e0-56df1ed7e997///days_to_birth: -20380///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1903///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 28eb5a27-818e-40de-8c31-7bc1d2bdb26a///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 396///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1903-01A-01T-0585-07///unique_patient_id: TCGA-61-1903"
"TCGA.61.1904"	"TCGA-61-1904-01A-01T-0585-07"	"TCGA-61-1904"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	60	"y"	"n"	"n"	276	"norecurrence"	276	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2cdd5154-ee5c-4d67-b2eb-947dfaa56be2///days_to_birth: -22009///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1904///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: babf7376-e2bc-4165-acda-25c8f38e15ca///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 276///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1904-01A-01T-0585-07///unique_patient_id: TCGA-61-1904"
"TCGA.61.1906"	"TCGA-61-1906-01A-01T-0656-07"	"TCGA-61-1906"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	55	"y"	"y"	"n"	236	"recurrence"	1038	"deceased"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	12	88	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f553e953-6464-421f-8933-26ca82cb79d3///days_to_birth: -20377///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1906///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a3385a59-9fd2-4e64-b6c4-6d6169bf5042///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1038///days_to_last_followup: 1038///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 236///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1906-01A-01T-0656-07///unique_patient_id: TCGA-61-1906"
"TCGA.61.1907"	"TCGA-61-1907-01A-01T-0585-07"	"TCGA-61-1907"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"n"	"n"	952	"norecurrence"	952	"living"	NA	NA	NA	"stabledisease"	"suboptimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7ab3765f-910a-41c9-86cc-08534d2a4e4b///days_to_birth: -23204///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1907///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 62747011-66cb-4750-a1b1-5614de54b2e5///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 952///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 743///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1907-01A-01T-0585-07///unique_patient_id: TCGA-61-1907"
"TCGA.61.1910"	"TCGA-61-1910-01A-01T-0585-07"	"TCGA-61-1910"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	56	"y"	"y"	"n"	1126	"norecurrence"	1126	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 75f2d97a-b96c-403f-8055-5c5c8083e856///days_to_birth: -20779///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1910///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ef3544b8-339a-4e76-a50b-3d8c27dfb9de///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1126///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1910-01A-01T-0585-07///unique_patient_id: TCGA-61-1910"
"TCGA.61.1913"	"TCGA-61-1913-01A-01T-0585-07"	"TCGA-61-1913"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	48	"y"	"n"	"n"	1488	"norecurrence"	1488	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Right///bcr_patient_uuid: 8516d4f2-0b98-4847-99c6-4d7269fa4af2///days_to_birth: -17574///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1913///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 13bbd5c0-51bc-4d78-800b-adad5eaa8d38///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1488///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1913-01A-01T-0585-07///unique_patient_id: TCGA-61-1913"
"TCGA.61.1914"	"TCGA-61-1914-01A-01T-0585-07"	"TCGA-61-1914"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"y"	"n"	1673	"recurrence"	1721	"living"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	10	87	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8e1b8811-1eb2-4337-852c-c19eaa0ee418///days_to_birth: -23850///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1914///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: bf92b598-521f-46b7-a2e9-92a747d5177f///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: 1701///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1721///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1673///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker- CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1914-01A-01T-0585-07///unique_patient_id: TCGA-61-1914"
"TCGA.61.1915"	"TCGA-61-1915-01A-01T-0585-07"	"TCGA-61-1915"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	50	"y"	"y"	"n"	2060	"norecurrence"	2060	"living"	NA	NA	NA	"completeresponse"	NA	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0adadf17-c4b6-48b0-a326-21450de3e144///days_to_birth: -18424///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1915///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b7206aa3-0932-424c-b730-59730aa0c46c///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2060///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1915-01A-01T-0585-07///unique_patient_id: TCGA-61-1915"
"TCGA.61.1916"	"TCGA-61-1916-01A-01T-0811-07"	"TCGA-61-1916"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	53	"y"	"y"	"n"	326	"recurrence"	475	"deceased"	NA	NA	"metastasis"	NA	"optimal"	0	10	80	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b25b3379-df8f-4900-9bce-0f8df50f549b///days_to_birth: -19463///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1916///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: bdb38e81-b854-4e27-b784-47790d09af9d///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 367///days_to_death: 475///days_to_last_followup: 475///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 326///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-61-1916-01A-01T-0811-07///unique_patient_id: TCGA-61-1916"
"TCGA.61.1917"	"TCGA-61-1917-01A-01T-0656-07"	"TCGA-61-1917"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	60	"y"	"y"	"n"	1321	"norecurrence"	1321	"deceased"	NA	NA	NA	"completeresponse"	NA	0	10	82	NA	"age_at_initial_pathologic_diagnosis: 60///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 87cdf9a8-0579-4d3e-b4df-0f8eef63d7f4///days_to_birth: -21972///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1917///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a316538e-69fd-4b85-86e5-e43c4aeab4e4///chemo_therapy: YES///day_of_form_completion: 30///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1321///days_to_last_followup: 1321///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1917-01A-01T-0656-07///unique_patient_id: TCGA-61-1917"
"TCGA.61.1918"	"TCGA-61-1918-01A-01T-0656-07"	"TCGA-61-1918"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	45	"y"	"y"	"n"	413	"recurrence"	479	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	12	75	NA	"age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3491d67a-4f83-4f67-8085-bbb9fe942be5///days_to_birth: -16689///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1918///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f5f189d5-ceda-430f-996d-dbd6cdbb24a2///chemo_therapy: YES///day_of_form_completion: 30///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 479///days_to_last_followup: 479///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 413///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan and CA 125 elevation///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1918-01A-01T-0656-07///unique_patient_id: TCGA-61-1918"
"TCGA.61.1919"	"TCGA-61-1919-01A-01T-0656-07"	"TCGA-61-1919"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	58	NA	NA	NA	439	"recurrence"	1161	"deceased"	NA	NA	"metastasis"	"completeresponse"	NA	0	20	72	NA	"age_at_initial_pathologic_diagnosis: 58///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ce871097-a6e9-4139-897e-642ee24ee123///days_to_birth: -21199///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1919///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 32f30aa0-9c9e-4a94-8b29-558fb4a1029f///chemo_therapy: YES///day_of_form_completion: 30///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 438///days_to_death: 1161///days_to_last_followup: 1161///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 439///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1919-01A-01T-0656-07///unique_patient_id: TCGA-61-1919"
"TCGA.61.1995"	"TCGA-61-1995-01A-01T-0671-07"	"TCGA-61-1995"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	43	"y"	"y"	"n"	60	"norecurrence"	60	"living"	NA	NA	NA	"stabledisease"	"optimal"	9	9	71	NA	"age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 931738a7-4b5b-46dc-b69f-72600862d8af///days_to_birth: -16016///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1995///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 23cec1cb-18f5-4261-bb98-4a4260f7306c///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 60///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1995-01A-01T-0671-07///unique_patient_id: TCGA-61-1995"
"TCGA.61.1998"	"TCGA-61-1998-01A-01T-0841-07"	"TCGA-61-1998"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	48	"y"	"y"	"n"	168	"norecurrence"	168	"living"	NA	NA	NA	NA	"optimal"	15	56	19	NA	"age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 565d06a1-3640-4274-8fb3-8cad7e578876///days_to_birth: -17855///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1998///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0d0da8b8-e9f8-4dbb-9a7f-ff76d2dc734f///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 168///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1998-01A-01T-0841-07///unique_patient_id: TCGA-61-1998"
"TCGA.61.2000"	"TCGA-61-2000-01A-01T-0695-07"	"TCGA-61-2000"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	67	"y"	"y"	"n"	339	"recurrence"	441	"living"	NA	NA	"locoregional"	"stabledisease"	"optimal"	9	8	72	NA	"age_at_initial_pathologic_diagnosis: 67///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 29949b65-2913-4c86-bbd7-b85c5df6f15e///days_to_birth: -24723///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2000///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e1ec40cf-3f01-42e9-859f-d16e3aaff23e///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: 381///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 441///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 339///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2000-01A-01T-0695-07///unique_patient_id: TCGA-61-2000"
"TCGA.61.2002"	"TCGA-61-2002-01A-01T-0695-07"	"TCGA-61-2002"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	46	"y"	"y"	"n"	547	"norecurrence"	547	"living"	NA	NA	NA	"progressivedisease"	"suboptimal"	9	6	78	NA	"age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 85bb4987-51e7-40fe-ad59-2aa56754eca9///days_to_birth: -17115///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2002///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7707c515-3224-4835-89c6-76f1f0d0e875///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 547///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2002-01A-01T-0695-07///unique_patient_id: TCGA-61-2002"
"TCGA.61.2003"	"TCGA-61-2003-01A-01T-0841-07"	"TCGA-61-2003"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	53	"y"	"y"	"n"	121	"norecurrence"	121	"living"	NA	NA	NA	"progressivedisease"	"optimal"	7	5	85	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 33dc48d8-2e01-482b-944c-ac10da727ec9///days_to_birth: -19605///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 2003///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b31360a4-1e89-4989-a36b-11f5e8817b5d///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 121///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2003-01A-01T-0841-07///unique_patient_id: TCGA-61-2003"
"TCGA.61.2009"	"TCGA-61-2009-01A-01T-0695-07"	"TCGA-61-2009"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	65	"y"	"y"	"n"	101	"recurrence"	1212	"living"	NA	NA	"locoregional"	"completeresponse"	"suboptimal"	0	8	90	NA	"age_at_initial_pathologic_diagnosis: 65///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ae914f23-87b9-4169-a7f7-a3483078c902///days_to_birth: -23772///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2009///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fc604495-213e-4fd9-bf0b-968863d4f36d///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: 819///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1212///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 101///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: PET CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2009-01A-01T-0695-07///unique_patient_id: TCGA-61-2009"
"TCGA.61.2012"	"TCGA-61-2012-01A-01T-0841-07"	"TCGA-61-2012"	"tumor"	"ser"	"ov"	NA	"low"	"early"	2	"c"	2	81	"y"	"y"	"n"	NA	"recurrence"	932	"living"	NA	NA	"metastasis"	NA	NA	0	10	80	NA	"age_at_initial_pathologic_diagnosis: 81///anatomic_organ_subdivision: Left///bcr_patient_uuid: 20c6be4d-7baf-4ea0-93e2-a5212f2e9b9c///days_to_birth: -29830///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 2012///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c66877b2-6de0-46a6-8a98-f8808fc13af9///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 932///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: YES///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2012-01A-01T-0841-07///unique_patient_id: TCGA-61-2012"
"TCGA.61.2016"	"TCGA-61-2016-01A-01T-0695-07"	"TCGA-61-2016"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	NA	NA	NA	36	"norecurrence"	36	"deceased"	NA	NA	NA	"progressivedisease"	"optimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 512de609-757b-42be-8b30-c414f71af422///days_to_birth: -18788///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2016///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 991e4692-11e2-4ff7-9ca7-f07af311826f///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 36///days_to_last_followup: 36///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2016-01A-01T-0695-07///unique_patient_id: TCGA-61-2016"
"TCGA.61.2017"	"TCGA-61-2017-01A-01T-0841-07"	"TCGA-61-2017"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	64	"y"	"y"	"n"	1006	"recurrence"	1398	"living"	NA	NA	"locoregional"	"completeresponse"	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 64///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f0ca8205-0754-4bd8-a6a8-31901040c5e7///days_to_birth: -23508///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G1///patient_id: 2017///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a1de5eb8-5151-4daa-aa00-cae596d21fa0///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: 1033///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1398///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1006///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2017-01A-01T-0841-07///unique_patient_id: TCGA-61-2017"
"TCGA.61.2018"	"TCGA-61-2018-01A-01T-0671-07"	"TCGA-61-2018"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	62	"y"	"y"	"n"	1381	"norecurrence"	1381	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 13d6c31a-6899-4119-a5c2-90adcb5bd20c///days_to_birth: -22929///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2018///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: af1c06af-cd9a-4a86-9d96-ad8d83e3b9ff///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1381///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2018-01A-01T-0671-07///unique_patient_id: TCGA-61-2018"
"TCGA.61.2087"	"TCGA-61-2087-01A-01T-0671-07"	"TCGA-61-2087"	"tumor"	"ser"	"ov"	NA	"high"	"early"	1	"c"	3	49	"y"	"y"	"n"	146	"norecurrence"	146	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Left///bcr_patient_uuid: be03bfec-5bb6-4cab-9dd2-bee590bd45f1///days_to_birth: -18182///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2087///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: bc37cd71-1aa4-4e1e-9286-b1a9a766f05e///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 146///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2087-01A-01T-0671-07///unique_patient_id: TCGA-61-2087"
"TCGA.61.2088"	"TCGA-61-2088-01A-01T-0671-07"	"TCGA-61-2088"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	51	"y"	"n"	"n"	145	"norecurrence"	145	"living"	NA	NA	NA	NA	"optimal"	0	5	94	NA	"age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 242943fe-1fa0-4a12-8f7e-9c6c4af1194d///days_to_birth: -18769///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2088///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 90f9f7a2-99d8-496e-9276-a94390ef4587///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 145///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2088-01A-01T-0671-07///unique_patient_id: TCGA-61-2088"
"TCGA.61.2092"	"TCGA-61-2092-01A-01T-0841-07"	"TCGA-61-2092"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	57	"y"	"y"	"n"	1573	"norecurrence"	1573	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	8	92	NA	"age_at_initial_pathologic_diagnosis: 57///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c183d3fb-2eee-44f8-890e-b9bf907141e6///days_to_birth: -21071///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2092///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fbfa4e68-8edf-44d8-84cb-ced0ddad76bd///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1573///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2092-01A-01T-0841-07///unique_patient_id: TCGA-61-2092"
"TCGA.61.2094"	"TCGA-61-2094-01A-01T-0671-07"	"TCGA-61-2094"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"y"	"n"	2182	"norecurrence"	2182	"living"	NA	NA	NA	"completeresponse"	NA	0	12	85	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b31d85cc-d2e2-4bd1-9986-d6bbe30e657f///days_to_birth: -23272///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2094///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d6ca83f9-d13e-48c8-9739-0ddfe7467b49///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2182///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2094-01A-01T-0671-07///unique_patient_id: TCGA-61-2094"
"TCGA.61.2095"	"TCGA-61-2095-01A-01T-0671-07"	"TCGA-61-2095"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	54	"y"	"y"	"n"	445	"recurrence"	1875	"deceased"	NA	NA	"metastasis"	"completeresponse"	"optimal"	0	38	60	NA	"age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 778ce436-a825-4689-81c1-b7c965404163///days_to_birth: -19797///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2095///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: b64c63f4-4421-42fe-b4f4-fe30be2673cb///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 452///days_to_death: 1875///days_to_last_followup: 1875///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 445///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: YES///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2095-01A-01T-0671-07///unique_patient_id: TCGA-61-2095"
"TCGA.61.2096"	"TCGA-61-2096-01A-01T-0671-07"	"TCGA-61-2096"	"tumor"	"ser"	"ov"	NA	"low"	"early"	1	"c"	2	56	"y"	"y"	"n"	421	"recurrence"	1776	"living"	NA	NA	"metastasis"	"progressivedisease"	"optimal"	0	50	50	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Right///bcr_patient_uuid: 6beaa1cb-a9f1-4127-898c-7aff2273788e///days_to_birth: -20662///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2096///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fe500f96-37c9-445e-9e91-ca55df7e2783///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1776///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 421///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2096-01A-01T-0671-07///unique_patient_id: TCGA-61-2096"
"TCGA.61.2097"	"TCGA-61-2097-01A-02T-0841-07"	"TCGA-61-2097"	"tumor"	"ser"	"ov"	NA	"low"	"early"	2	"c"	2	71	"y"	"y"	"n"	1844	"norecurrence"	1844	"living"	NA	NA	NA	"completeresponse"	"optimal"	0	20	80	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 47681e4b-01e8-4779-b966-ce57aff4b712///days_to_birth: -25961///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 2097///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 351a21ef-4b26-45db-93f0-92941df09685///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1844///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: YES///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2097-01A-02T-0841-07///unique_patient_id: TCGA-61-2097"
"TCGA.61.2098"	"TCGA-61-2098-01A-01T-0671-07"	"TCGA-61-2098"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	62	"y"	"y"	"n"	1992	"norecurrence"	1992	"living"	NA	NA	NA	"completeresponse"	"suboptimal"	0	25	75	NA	"age_at_initial_pathologic_diagnosis: 62///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: eb7c3b35-7a5e-4621-b31f-9775c51f9a23///days_to_birth: -22876///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2098///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0ed0fcad-6f61-425a-9057-ea887d6128ce///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1992///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2098-01A-01T-0671-07///unique_patient_id: TCGA-61-2098"
"TCGA.61.2101"	"TCGA-61-2101-01A-01T-0671-07"	"TCGA-61-2101"	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	55	"y"	"y"	"n"	1688	"norecurrence"	1688	"deceased"	NA	NA	NA	"partialresponse"	"suboptimal"	0	10	90	NA	"age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5d1a54fe-e0df-4c17-b623-b649a136dc82///days_to_birth: -20287///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2101///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d25c7ceb-de04-4a5b-87e1-8c217938de7d///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1688///days_to_last_followup: 1688///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 100///month_of_form_completion: 12///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2101-01A-01T-0671-07///unique_patient_id: TCGA-61-2101"
"TCGA.61.2102"	"TCGA-61-2102-01A-01T-0671-07"	"TCGA-61-2102"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	74	"y"	"y"	"n"	197	"norecurrence"	197	"deceased"	NA	NA	NA	NA	NA	55	42	32	NA	"age_at_initial_pathologic_diagnosis: 74///anatomic_organ_subdivision: Right///bcr_patient_uuid: 7a08efd0-f984-430e-a8eb-1881047214b6///days_to_birth: -27255///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2102///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0b2aa437-7686-4d29-ac07-bc166237edbf///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 197///days_to_last_followup: 197///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2102-01A-01T-0671-07///unique_patient_id: TCGA-61-2102"
"TCGA.61.2104"	"TCGA-61-2104-01A-01T-0671-07"	"TCGA-61-2104"	"tumor"	"ser"	"ov"	NA	"low"	"early"	2	"c"	2	53	"y"	"y"	"n"	1680	"recurrence"	2337	"living"	NA	NA	"metastasis"	"completeresponse"	"optimal"	14	8	72	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 05263959-c4f5-4540-b6d2-d8c8a128861f///days_to_birth: -19432///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2104///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 02ac5e72-78e8-458e-9966-f78a3fb86f69///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1680///days_to_death: NA///days_to_last_followup: 2337///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1680///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: PET Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2104-01A-01T-0671-07///unique_patient_id: TCGA-61-2104"
"TCGA.61.2109"	"TCGA-61-2109-01A-01T-0671-07"	"TCGA-61-2109"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	40	"y"	"y"	"n"	465	"recurrence"	629	"deceased"	NA	NA	"metastasis"	NA	"suboptimal"	9	2	82	NA	"age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: dc5a6ce7-01e5-408d-812e-e3e0ddc1cde5///days_to_birth: -14899///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2109///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 716014bf-2f9f-4dc8-81fe-c2baa9c4303c///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 629///days_to_last_followup: 629///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 465///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2109-01A-01T-0671-07///unique_patient_id: TCGA-61-2109"
"TCGA.61.2110"	"TCGA-61-2110-01A-01T-0671-07"	"TCGA-61-2110"	"tumor"	"ser"	"ov"	NA	NA	"late"	3	"c"	NA	56	"y"	"y"	"n"	213	"recurrence"	1354	"deceased"	NA	NA	"metastasis"	"progressivedisease"	"optimal"	35	4	55	NA	"age_at_initial_pathologic_diagnosis: 56///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 88180134-710f-46ea-9b06-5e5d860d6d9f///days_to_birth: -20718///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: NA///patient_id: 2110///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 47c8d668-e766-409d-b4bd-eb05a7befb17///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 213///days_to_death: 1354///days_to_last_followup: 1354///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 213///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2110-01A-01T-0671-07///unique_patient_id: TCGA-61-2110"
"TCGA.61.2111"	"TCGA-61-2111-01A-01T-0671-07"	"TCGA-61-2111"	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	61	"y"	"y"	"n"	2205	"recurrence"	3824	"living"	NA	NA	"metastasis"	"completeresponse"	NA	2	4	82	NA	"age_at_initial_pathologic_diagnosis: 61///anatomic_organ_subdivision: Left///bcr_patient_uuid: 91a17d40-c8cb-4cce-b306-966382a8fe4a///days_to_birth: -22517///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2111///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 273e554f-1bb2-4549-a9b8-c642b76e2458///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 2232///days_to_death: NA///days_to_last_followup: 3824///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 2205///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Core biopsy///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2111-01A-01T-0671-07///unique_patient_id: TCGA-61-2111"
"TCGA.61.2113"	"TCGA-61-2113-01A-01T-0671-07"	"TCGA-61-2113"	"tumor"	"ser"	"ov"	NA	"high"	"early"	2	"c"	3	53	"y"	"y"	"n"	676	"norecurrence"	676	"deceased"	NA	NA	NA	NA	NA	0	30	70	NA	"age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Right///bcr_patient_uuid: 71faa2c1-0d5b-4dcc-bdf9-f2405f29907c///days_to_birth: -19722///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2113///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 58e8e9bc-2bf0-47e6-a806-3a51341022fb///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 676///days_to_last_followup: 676///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 291///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2113-01A-01T-0671-07///unique_patient_id: TCGA-61-2113"
"TCGA.61.2612"	"TCGA-61-2612-01A-01T-1142-07"	"TCGA-61-2612"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	63	"y"	"y"	"n"	179	"recurrence"	193	"deceased"	NA	NA	"locoregional"	"stabledisease"	"optimal"	0	32	58	NA	"age_at_initial_pathologic_diagnosis: 63///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c040df8a-9d6d-43bd-911a-17a7b4e1ec74///days_to_birth: -23074///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2612///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9d18705d-71b9-44c3-9737-de3fe27e89e1///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: 189///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 193///days_to_last_followup: 193///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 179///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 9///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-61-2612-01A-01T-1142-07///unique_patient_id: TCGA-61-2612"
"TCGA.61.2613"	"TCGA-61-2613-01A-01T-1142-07"	"TCGA-61-2613"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	73	"y"	"y"	"n"	358	"recurrence"	945	"deceased"	NA	NA	"locoregional"	"stabledisease"	"suboptimal"	0	50	45	NA	"age_at_initial_pathologic_diagnosis: 73///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c88502e9-0bc6-47c3-adc4-d98b63c7797b///days_to_birth: -26779///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2613///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 656e7ee7-60c1-407e-abad-3db1ca8f547c///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 945///days_to_last_followup: 945///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 358///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 9///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-61-2613-01A-01T-1142-07///unique_patient_id: TCGA-61-2613"
"TCGA.61.2614"	"TCGA-61-2614-01A-01T-1142-07"	"TCGA-61-2614"	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	71	NA	NA	NA	38	"recurrence"	261	"deceased"	NA	NA	"locoregional"	"stabledisease"	"optimal"	0	40	55	NA	"age_at_initial_pathologic_diagnosis: 71///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 09643c0d-efdb-46b4-94df-018bd6134a88///days_to_birth: -26142///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2614///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6f9863a6-5596-41d2-8532-fbac794ef1c6///chemo_therapy: NO///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: 38///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 261///days_to_last_followup: 261///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 38///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 9///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-61-2614-01A-01T-1142-07///unique_patient_id: TCGA-61-2614"
